var title_f36_54_37728="Assess pain cogn impaired";
var content_f36_54_37728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Algorithm for the assessment of pain in elderly persons with severe cognitive impairment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 539px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiner, D, Herr, K, Rudy, T, eds. Persistent Pain in Older Adults: An Interdisciplinary Guide for Treatment, 2002; p. 34. Copyright &copy;2002 Debra Weiner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37728=[""].join("\n");
var outline_f36_54_37728=null;
var title_f36_54_37729="Rust ring";
var content_f36_54_37729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rust ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows a typical rust ring, likely caused by a metallic foreign body. Removal can be attempted with a small burr drill.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin J Knoop, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37729=[""].join("\n");
var outline_f36_54_37729=null;
var title_f36_54_37730="Vitiligo - hands";
var content_f36_54_37730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple depigmented macules and patches are present on the hands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37730=[""].join("\n");
var outline_f36_54_37730=null;
var title_f36_54_37731="Multiple vitamins (injectable): Patient drug information";
var content_f36_54_37731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Multiple vitamins (injectable): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/52/26434?source=see_link\">",
"     see \"Multiple vitamins (injectable): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Infuvite&reg; Adult;",
"     </li>",
"     <li>",
"      Infuvite&reg; Pediatric;",
"     </li>",
"     <li>",
"      M.V.I. Adult&trade;;",
"     </li>",
"     <li>",
"      M.V.I.&reg;-12 ;",
"     </li>",
"     <li>",
"      M.V.I&reg; Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vitamins are needed for growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12155 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37731=[""].join("\n");
var outline_f36_54_37731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234608\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013394\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013393\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013397\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013398\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013400\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013396\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013401\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013402\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/52/26434?source=related_link\">",
"      Multiple vitamins (injectable): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_54_37732="Oprelvekin: Pediatric drug information";
var content_f36_54_37732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oprelvekin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?33/58/34724?source=see_link\">",
"    see \"Oprelvekin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/19/26933?source=see_link\">",
"    see \"Oprelvekin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neumega&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2738290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Biological Response Modulator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Thrombopoietic Growth Factor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2738300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/58/34724?source=see_link\">",
"      see \"Oprelvekin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     First dose should not be administered until 6-24 hours after the end of chemotherapy. Discontinue the drug at least 48 hours before beginning the next cycle of chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 25-50 mcg/kg once daily for 27 days was shown to be efficacious with decreased toxicities as compared to higher doses in one study with 47 pediatric patients (Cairo, 2005); dosing should continue until postnadir platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer states that, until efficacy/toxicity parameters are established, the use of oprelvekin in pediatric patients (particularly those &lt;12 years of age) should be restricted to use in controlled clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 50 mcg/kg once daily for 10-21 days (until postnadir platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal failure:",
"     </b>",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 25 mcg/kg once daily for 10-21 days (until postnadir platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neumega&reg;: 5 mg [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2738361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Reconstitute to a final concentration of 5 mg/mL with SWI; direct diluent down side of vial, gently swirl, do not shake. Administer subcutaneously in either the abdomen, thigh, hip, or upper arm (if not self-injected).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2738297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vials under refrigeration between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light; do not freeze. Use reconstituted oprelvekin within 3 hours of reconstitution; store reconstituted solution at either 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or room temperature (&le;25&deg;C/70&deg;F). Do not freeze reconstituted solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2738291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oprelvekin may be confused with aldesleukin, Proleukin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Neumega&reg; may be confused with Neulasta&reg;, Neupogen&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F203882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial arrhythmia, cardiomegaly, edema, palpitation, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, fever, headache, insomnia, neutropenic fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, mucositis, nausea/vomiting, oral moniliasis, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (dilutional)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, periostitis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctival injection/redness/swelling, papilledema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, rhinitis, pharyngitis, pleural effusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, amblyopia, anaphylaxis/anaphylactoid reactions, blindness, blurred vision, capillary leak syndrome, cardiac arrest, chest pain, dehydration, dysarthria, exfoliative dermatitis, eye hemorrhage, facial edema, fibrinogen increased, fluid overload, HF, hypoalbuminemia, hypocalcemia, hypokalemia, hypotension, injection site reactions (dermatitis, pain, discoloration), loss of consciousness, mental status changes, optic neuropathy, paresthesia, pericardial effusion, peripheral edema, pneumonia, pulmonary edema, renal failure, shock, skin discoloration, stroke, urticaria, ventricular arrhythmia, visual acuity changes, visual field defect, von Willebrand factor concentration increased, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2738293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oprelvekin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2738367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oprelvekin may cause serious fluid retention resulting in peripheral edema, facial edema, dyspnea on exertion, pulmonary edema, capillary leak syndrome, atrial arrhythmias, and exacerbation of pre-existing pleural effusions. Use cautiously in patients with conditions where expansion of plasma volume should be avoided (eg, left ventricular dysfunction, CHF, hypertension). Use caution in patients with cardiac arrhythmias or conduction defects (ventricular arrhythmias generally occurring within 2-7 days of initiation of treatment have been reported postmarketing); use with caution in patients with respiratory disease; history of thromboembolic problems or stroke, and hepatic or renal dysfunction; modify dosage in patients with severe renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2738294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment has been associated with severe hypersensitivity reactions including anaphylaxis [U.S. Boxed Warning]; may occur with the first or with subsequent doses; permanently discontinue oprelvekin in any patient developing an allergic reaction.",
"     </b>",
"     Not indicated following myeloablative chemotherapy as effectiveness was not significant vs placebo and toxicity (edema, conjunctival bleeding, hypotension, and tachycardia) was increased vs placebo in these patients. Severe hypokalemia and/or sudden death have been reported in patients receiving chronic diuretic therapy, ifosfamide, and oprelvekin. Moderate decreases in hemoglobin, hematocrit, and RBC without a decrease in red cell mass have been observed; this is predominately related to an increase in plasma volume (dilutional anemia) from renal sodium and water retention. Onset of dilutional anemia is within 3-5 days of oprelvekin therapy and is reversible over approximately 7 days following discontinuation of oprelvekin. Stroke has been reported in patients who develop atrial fibrillation/flutter while receiving oprelvekin. Animal studies were predictive of an effect of oprelvekin on developing bone in children; thickening of femoral and tibial growth plates was noted. Per the manufacturer, oprelvekin should not be used in children, particularly those &lt;12 years of age, except as part of a controlled clinical trial; some adverse events occurred more frequently in children, such as tachycardia (84%), conjunctival injection (57%), cardiomegaly (21%), and periosteal changes (11%).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dose-limiting papilledema, more frequently associated with use in children (16% vs 2% in adults), has occurred (usually following repeated cycles); use with caution in patients with pre-existing papilledema or with tumors involving the central nervous system; may worsen pre-existing papilledema. Patients experiencing oprelvekin-related papilledema may be at risk for visual acuity changes, including blurred vision or blindness.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3277319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated adverse fetal effects. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefits outweigh the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2738362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor electrolytes and fluid balance during therapy; obtain a CBC at regular intervals during therapy; monitor platelet counts until adequate recovery has occurred; renal function (at baseline)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2738298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oprelvekin stimulates multiple stages of megakaryocytopoiesis and thrombopoiesis, resulting in proliferation of megakaryocyte progenitors and megakaryocyte maturation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2738368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 5-9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 14-19 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Up to 7 days after discontinuation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2738299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 112-152 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &gt;80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Uncertain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Terminal: 6.9-8.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3.2  &plusmn; 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (primarily as metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Adults: 2.2-2.7 mL/min/kg; clearance decreases with age and is about 1.2-1.6 times faster in children than in adults",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2738364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/19/26933?source=see_link\">",
"      see \"Oprelvekin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any swelling in the arms or legs (peripheral edema), shortness of breath (congestive failure, anemia), irregular heartbeat, headaches, or hypersensitivity reactions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams VR and Brenner TL, &ldquo;Oprelvekin (Neumega&reg;),&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 1999, 5(3):117-24.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cairo MS, Davenport V, Bessmertny O, et al, \"Phase I/II Dose Escalation Study of Recombinant Human Interleukin-11 Following Ifosfamide, Carboplatin and Etoposide in Children, Adolescents and Young Adults With Solid Tumours or Lymphoma: A Clinical, Haematological and Biological Study,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 128(1):49-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37732/abstract-text/15606549/pubmed\" id=\"15606549\" target=\"_blank\">",
"        15606549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Du X and Williams DA, &ldquo;Interleukin-11: Review of Molecular, Cell Biology, and Clinical Use,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1997, 89(11):3897-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37732/abstract-text/9166826/pubmed\" id=\"9166826\" target=\"_blank\">",
"        9166826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon MS, &ldquo;Thrombopoietic Activity of Recombinant Human Interleukin 11 in Cancer Patients Receiving Chemotherapy,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1996, 38 (Suppl):96-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37732/abstract-text/8765426/pubmed\" id=\"8765426\" target=\"_blank\">",
"        8765426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milman E, Berdon WE, Garvin JH, et al, \"Periostitis Secondary to Interleukin-11 (Oprelvekin, Neumega&reg;). Treatment for Thrombocytopenia in Pediatric Patients,\"",
"      <i>",
"       Pediatr Radiol",
"      </i>",
"      , 2003, 33(7):450-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37732/abstract-text/12728286/pubmed\" id=\"12728286\" target=\"_blank\">",
"        12728286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tepler I, Elias L, Smith JW 2d, et al, &ldquo;A Randomized Placebo-Controlled Trial of Recombinant Human Interleukin-11 in Cancer Patients With Severe Thrombocytopenia Due to Chemotherapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1996, 87(9):3607-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37732/abstract-text/8611684/pubmed\" id=\"8611684\" target=\"_blank\">",
"        8611684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teramura M, Kobayashi S, Yoshinaga K, et al, &ldquo;Effect of Interleukin 11 on Normal and Pathological Thrombopoiesis,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1996, 38 (Suppl):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37732/abstract-text/8765427/pubmed\" id=\"8765427\" target=\"_blank\">",
"        8765427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12946 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37732=[""].join("\n");
var outline_f36_54_37732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709182\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203860\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738290\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738300\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203844\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203828\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738361\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738297\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738291\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203884\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203882\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738293\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738367\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738294\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299793\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203837\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203840\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3277319\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738362\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738298\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738368\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738299\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738364\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/58/34724?source=related_link\">",
"      Oprelvekin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/19/26933?source=related_link\">",
"      Oprelvekin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_54_37733="T cell receptor genetics";
var content_f36_54_37733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   T cell receptor genetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37733/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37733/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37733/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37733/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37733/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37733/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/54/37733/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics of the T cell receptor (TCR) and the process of assembly of mature TCR genes from gene segments during T cell development in the thymus are discussed here. T cell development and the cellular immune response are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .) A web site devoted to immunogenetics can be found at",
"    <span class=\"nowrap\">",
"     www.imgt.org/",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     T CELL RECEPTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of TCRs (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority (95 percent or more) of peripheral blood T cells bear a heterodimeric receptor made of two chains called alpha and beta (",
"      <a class=\"graphic graphic_figure graphicRef56665 \" href=\"mobipreview.htm?12/58/13229\">",
"       figure 1",
"      </a>",
"      ). This form of the TCR is also called TCR2.",
"     </li>",
"     <li>",
"      The minority of circulating T cells bear a different type of TCR made up of two chains, called gamma and delta (TCR1). T cells bearing TCR1 constitute only 3 to 5 percent of the total population in the circulation, although they may predominate in some tissues (eg, intestinal mucosa).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with immunoglobulins (Ig), each TCR chain is encoded by multiple rearranging gene segments. The rearrangement process leads to diversification of the assembled genes through differences in the manner in which gene segments are joined in each cell undergoing its own unique rearrangement events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=see_link\">",
"     \"Structure of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to Ig molecules, TCR proteins contain variable, diverse, joining, and constant regions. The variable regions are divided into framework and hypervariable regions, as are antibody V regions. The hypervariable portions of both B and T cell receptor variable regions are also called complementarity determining regions (CDRs). X-ray crystallography studies show that the amino acids encoded by the CDR1 and CDR2 in TCR alpha and beta variable region gene segments often interact with peptide-MHC. These portions of the TCR may be the focus of evolutionary selective pressure for MHC binding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/2\">",
"     2",
"    </a>",
"    ]. TCRs also exhibit allotypic and idiotypic determinants associated with constant and variable regions, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     T CELL RECEPTOR GENE ORGANIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chromosomal locations of the TCR genes are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef76049 \" href=\"mobipreview.htm?0/29/475\">",
"     table 1",
"    </a>",
"    ). The alpha locus, analogous to immunoglobulin (Ig) light chains, contains three gene clusters, Valpha, Jalpha, and Calpha (",
"    <a class=\"graphic graphic_figure graphicRef75615 \" href=\"mobipreview.htm?3/18/3373\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TCR beta chain is encoded by four gene segments, similar to the Ig heavy chain. Figure 3 shows the organization of the beta chain gene clusters, Vbeta, and a tandem of Dbeta1-Jbeta1-Cbeta1, and Dbeta2-Jbeta2-Cbeta2 (",
"    <a class=\"graphic graphic_figure graphicRef55731 \" href=\"mobipreview.htm?36/62/37868\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/4,6-9\">",
"     4,6-9",
"    </a>",
"    ]. TCR alpha genes, like gamma genes are composed of three rearranging segments (",
"    <a class=\"graphic graphic_figure graphicRef78099 \" href=\"mobipreview.htm?19/56/20365\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like beta chains, delta chains are made up of four gene segments (",
"    <a class=\"graphic graphic_figure graphicRef64384 \" href=\"mobipreview.htm?16/12/16589\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Note that the delta locus is positioned between Valpha and Jalpha. Thus, a chromosome that has rearranged the alpha locus no longer contains DNA encoding the delta chain.",
"   </p>",
"   <p>",
"    Sequence analysis of large numbers of Valpha and Vdelta genes from ethnically diverse individuals reveals significant allelic variation (single nucleotide polymorphisms, or SNPs) in many of these genes. These sequences define haplotypes that can be used to infer divergence among ethnic groups and possibly also patterns of evolutionary selection that may have implications for immune protection and other disease associations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     T CELL RECEPTOR GENE REARRANGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The orderly progression of TCR gene segment rearrangement is regulated in a complex manner by chromatin structure determining accessibility to gene segments and signal sequences, as well as a variety of promoters, enhancers, and other associated DNA sequences that recruit a variety of transcription and binding factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T cell receptor genes rearrange via the same mechanisms and according to the same rules as Ig genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    ). The 3' flanking region of Vbeta genes contain heptamer and nonamer recombination signal sequences separated by a 23 base pair (bp) spacer. Dbeta genes are also flanked by nonamer and heptamer sequences with 12 bp spacers on either side, while Jbeta genes have flanking sequences with 23 bp spacers on the 5' side. These signal sequences also flank the alpha, gamma, and delta TCR gene segments.",
"   </p>",
"   <p>",
"    There are constraints on the joining of gene segments that act in conjunction with the",
"    <span class=\"nowrap\">",
"     12/23",
"    </span>",
"    base-pair rule, but that are not determined by the number of nucleotides in the spacers alone. Undefined sequence features within or near the",
"    <span class=\"nowrap\">",
"     signal/spacer",
"    </span>",
"    units also act to determine which segments may or may not join together. This level of regulation is called \"beyond",
"    <span class=\"nowrap\">",
"     12/23\"",
"    </span>",
"    <span class=\"nowrap\">",
"     (B12/23)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The organization and rearrangement of Ig and TCR genes also have important differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TCR gene loci tend to have fewer V region segments and a greater number of J segments.",
"     </li>",
"     <li>",
"      Junctional diversity with the addition of N regions at gene segment junctions and with utilization of D genes in multiple reading frames plays a greater role in generating diversity in the TCR repertoire.",
"     </li>",
"     <li>",
"      TCR genes do not undergo somatic hypermutation following initial rearrangement; expressed TCR genes are very stable during T cell development.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several instances have been described where Vgamma gene segments are productively rearranged with Jbeta and Cbeta segments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/22\">",
"     22",
"    </a>",
"    ]. These rearrangements produce functional, expressed genes with all of the molecular characteristics that one would expect from rearrangement and joining directed by the signal sequences and mechanisms discussed above. The rearrangements require an inversion involving a large part of chromosome 7 to bring these loci into a relationship permitting gene recombination (",
"    <a class=\"graphic graphic_table graphicRef76049 \" href=\"mobipreview.htm?0/29/475\">",
"     table 1",
"    </a>",
"    ). Lymphocytes containing this type of rearrangement represent approximately",
"    <span class=\"nowrap\">",
"     1/12,500",
"    </span>",
"    of peripheral blood lymphocytes in healthy individuals.",
"   </p>",
"   <p>",
"    T cells expressing TCR1 do not express TCR2, and vice-versa. However, beta genes may rearrange incompletely in TCR1 positive cells, while gamma genes may rearrange normally in TCR2 positive cells, but without ensuing gamma transcription. As one may suspect, TCR gene expression is controlled by DNA sequences and sequence-specific regulatory proteins similar to those governing Ig gene expression. Regulation occurs via both positive (increase transcription) and negative (suppressive) mechanisms. The regulation of TCR gene expression is beyond the scope of this discussion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TCR gene rearrangement does not occur prior to cell entry into the thymus. The gamma and delta genes are the first to be expressed during fetal thymic T cell development. The beta genes are next expressed in the fetus; the alpha genes are expressed last. Subsequently, TCR1- and TCR2-bearing cells develop contemporaneously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ALLELIC EXCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described elsewhere, B cells express a single Ig specificity; its antibodies contain only one type of heavy or light chain. The regulation of Ig gene rearrangement during B cell development dictates that only one (of two) Ig heavy chain locus, and only one light chain locus will ever contain a functional rearranged gene. The other will be either inexpressible due to unsuccessful rearrangement or will be incompletely rearranged. Thus, only one Ig heavy or light chain allele is expressed. This is referred to as allelic exclusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T cells also exhibit allelic exclusion, but it is achieved differently from that in B cells. In T cells bearing TCR2 (alpha-beta), the beta genes rearrange first. Following a productive beta gene rearrangement, the beta protein is expressed on the cell surface in association with the pre-T alpha chain (pTalpha, the product of a single gene that is not made up of rearranging gene segments). A signal received through pTalpha-beta suppresses further beta gene rearrangement, and is required for the initiation of alpha gene rearrangement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to Ig light chains, the productive rearrangement of one alpha locus and expression of a mature TCR alpha-beta heterodimer does not stop alpha gene rearrangement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/25\">",
"     25",
"    </a>",
"    ]; it is possible to have one cell with two productively rearranged alpha genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/25\">",
"     25",
"    </a>",
"    ]. In some instances, since one alpha chain is incapable of forming a heterodimer with the expressed beta, only one heterodimer appears on the cell surface. In this way, there is phenotypic allelic exclusion even if there is not genotypic exclusion.",
"   </p>",
"   <p>",
"    However, T cells expressing two different alpha chains in complete heterodimeric receptors have been described. The differences in allelic exclusion between T cells and B cells must reflect the different constraints placed on these cell types by the selective processes that maintain self-tolerance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     T CELL RECEPTOR EXCISION CIRCLES (TRECS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The germline DNA that is in between two segments that are being joined (eg, Vbeta and Jbeta) is excised and covalently closed to form a stable DNA loop during the process of gene segment rearrangement. This loop is known as a T cell receptor excision circle (TREC) and is maintained as a non-replicating episomal DNA fragment in the T cell nucleus. TRECs are found only in T cells still within the thymus, or those that have left recently (recent thymic emigrants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/26\">",
"     26",
"    </a>",
"    ]. The TREC content is diluted as T cells expand in the periphery, since TRECs are not replicated. TREC levels, determined by PCR or other molecular methods, are used as a measure of thymic output or function in a variety of disease states, including primary and secondary immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RECEPTOR EDITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;One series of gene rearrangements (of either Ig or TCR genes, either productive or non-productive) may leave many upstream V genes and downstream D or J genes that may be used in a subsequent rearrangement event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/27\">",
"     27",
"    </a>",
"    ]. This process is known as receptor editing.",
"   </p>",
"   <p>",
"    Because of the large number of Jalpha genes, the alpha locus may commonly undergo many nested rearrangements during T cell development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/28\">",
"     28",
"    </a>",
"    ]. Murine studies suggest that even after exit from the thymus, some T cells may undergo receptor editing rearrangement at the beta locus (ie, replacement of the beta chain) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This may occur to change an autoreactive TCR specificity and maintain tolerance. Whether or not this contributes significantly to the T cell repertoire or maintenance of tolerance in mice or humans is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REPERTOIRE DIVERSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of gene rearrangement described above ultimately yield a large repertoire of distinct TCR specificities. The predominant type of T cell in the human periphery, cells expressing TCR2",
"    <span class=\"nowrap\">",
"     (alpha/beta),",
"    </span>",
"    contains approximately 10(7) to 10(8) different molecular types of TCRs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/31\">",
"     31",
"    </a>",
"    ]. These include cells having low affinity for their targets as well as cells with high affinity. The affinity of the TCR for its peptide-MHC target determines the consequences of interaction: activation, anergy, memory cell formation, etc. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37733/abstract/32\">",
"     32",
"    </a>",
"    ]. The determinants of what constitutes an adequate repertoire for effective antimicrobial immunity have not yet been determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two types of T cell receptors (TCRs). The majority (95 percent or more) of peripheral blood T cells bear a heterodimeric receptor made of two chains called alpha and beta, also called TCR2 (",
"      <a class=\"graphic graphic_figure graphicRef56665 \" href=\"mobipreview.htm?12/58/13229\">",
"       figure 1",
"      </a>",
"      ). The minority of circulating T cells bear a different type of TCR made up of two chains, called gamma and delta (TCR1). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'T cell receptor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T cell receptor genes rearrange via the same mechanisms and according to the same rules as Ig genes, with a few important differences. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'T cell receptor gene rearrangement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Germline DNA excised during TCR gene rearrangements forms stable DNA loops that are maintained as non-replicating episomal DNA fragments in the T cell nucleus known as T cell receptor excision circles (TRECs). TRECs can be used as a measure of thymic output or function. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'T cell receptor excision circles (TRECS)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/1\">",
"      Giudicelli V, Chaume D, Lefranc MP. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 2005; 33:D256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/2\">",
"      Marrack P, Rubtsova K, Scott-Browne J, Kappler JW. T cell receptor specificity for major histocompatibility complex proteins. Curr Opin Immunol 2008; 20:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/3\">",
"      Koop BF, Rowen L, Wang K, et al. The human T-cell receptor TCRAC/TCRDC (C alpha/C delta) region: organization, sequence, and evolution of 97.6 kb of DNA. Genomics 1994; 19:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/4\">",
"      Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/5\">",
"      Yoshikai Y, Clark SP, Taylor S, et al. Organization and sequences of the variable, joining and constant region genes of the human T-cell receptor alpha-chain. Nature 1985; 316:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/6\">",
"      Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996; 272:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/7\">",
"      Tunnacliffe A, Rabbitts TH. Sequence of the D beta 2-J beta 2 region of the human T-cell receptor beta-chain locus. Nucleic Acids Res 1985; 13:6651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/8\">",
"      Wei S, Charmley P, Robinson MA, Concannon P. The extent of the human germline T-cell receptor V beta gene segment repertoire. Immunogenetics 1994; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/9\">",
"      Leiden JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 1993; 11:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/10\">",
"      LeFranc MP, Forster A, Baer R, et al. Diversity and rearrangement of the human T cell rearranging gamma genes: nine germ-line variable genes belonging to two subgroups. Cell 1986; 45:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/11\">",
"      Buresi C, Ghanem N, Huck S, et al. Exon duplication and triplication in the human T-cell receptor gamma constant region genes and RFLP in French, Lebanese, Tunisian, and black African populations. Immunogenetics 1989; 29:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/12\">",
"      Zhang XM, Cathala G, Soua Z, et al. The human T-cell receptor gamma variable pseudogene V10 is a distinctive marker of human speciation. Immunogenetics 1996; 43:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/13\">",
"      Huck S, Lefranc MP. Rearrangements to the JP1, JP and JP2 segments in the human T-cell rearranging gamma gene (TRG gamma) locus. FEBS Lett 1987; 224:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/14\">",
"      Huck S, Dariavach P, Lefranc MP. Variable region genes in the human T-cell rearranging gamma (TRG) locus: V-J junction and homology with the mouse genes. EMBO J 1988; 7:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/15\">",
"      Satyanarayana K, Hata S, Devlin P, et al. Genomic organization of the human T-cell antigen-receptor alpha/delta locus. Proc Natl Acad Sci U S A 1988; 85:8166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/16\">",
"      Loh EY, Cwirla S, Serafini AT, et al. Human T-cell-receptor delta chain: genomic organization, diversity, and expression in populations of cells. Proc Natl Acad Sci U S A 1988; 85:9714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/17\">",
"      Takihara Y, Tkachuk D, Michalopoulos E, et al. Sequence and organization of the diversity, joining, and constant region genes of the human T-cell delta-chain locus. Proc Natl Acad Sci U S A 1988; 85:6097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/18\">",
"      Mackelprang R, Livingston RJ, Eberle MA, et al. Sequence diversity, natural selection and linkage disequilibrium in the human T cell receptor alpha/delta locus. Hum Genet 2006; 119:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/19\">",
"      Krangel MS. Mechanics of T cell receptor gene rearrangement. Curr Opin Immunol 2009; 21:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/20\">",
"      Krangel MS, Hernandez-Munain C, Lauzurica P, et al. Developmental regulation of V(D)J recombination at the TCR alpha/delta locus. Immunol Rev 1998; 165:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/21\">",
"      Tillman RE, Wooley AL, Hughes MM, et al. Regulation of T-cell receptor beta-chain gene assembly by recombination signals: the beyond 12/23 restriction. Immunol Rev 2004; 200:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/22\">",
"      Lipkowitz S, Stern MH, Kirsch IR. Hybrid T cell receptor genes formed by interlocus recombination in normal and ataxia-telangiectasis lymphocytes. J Exp Med 1990; 172:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/23\">",
"      Fehling HJ, Krotkova A, Saint-Ruf C, von Boehmer H. Crucial role of the pre-T-cell receptor alpha gene in development of alpha beta but not gamma delta T cells. Nature 1995; 375:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/24\">",
"      O'Shea CC, Thornell AP, Rosewell IR, et al. Exit of the pre-TCR from the ER/cis-Golgi is necessary for signaling differentiation, proliferation, and allelic exclusion in immature thymocytes. Immunity 1997; 7:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/25\">",
"      Padovan E, Casorati G, Dellabona P, et al. Expression of two T cell receptor alpha chains: dual receptor T cells. Science 1993; 262:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/26\">",
"      Dion ML, S&eacute;kaly RP, Cheynier R. Estimating thymic function through quantification of T-cell receptor excision circles. Methods Mol Biol 2007; 380:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/27\">",
"      Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/28\">",
"      Petrie HT, Livak F, Schatz DG, et al. Multiple rearrangements in T cell receptor alpha chain genes maximize the production of useful thymocytes. J Exp Med 1993; 178:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/29\">",
"      McMahan CJ, Fink PJ. RAG reexpression and DNA recombination at T cell receptor loci in peripheral CD4+ T cells. Immunity 1998; 9:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/30\">",
"      Lantelme E, Orlando L, Porcedda P, et al. An in vitro model of T cell receptor revision in mature human CD8+ T cells. Mol Immunol 2008; 45:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/31\">",
"      Arstila TP, Casrouge A, Baron V, et al. A direct estimate of the human alphabeta T cell receptor diversity. Science 1999; 286:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37733/abstract/32\">",
"      Turner SJ, La Gruta NL, Kedzierska K, et al. Functional implications of T cell receptor diversity. Curr Opin Immunol 2009; 21:286.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3978 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37733=[""].join("\n");
var outline_f36_54_37733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      T CELL RECEPTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      T CELL RECEPTOR GENE ORGANIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      T CELL RECEPTOR GENE REARRANGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALLELIC EXCLUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      T CELL RECEPTOR EXCISION CIRCLES (TRECS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RECEPTOR EDITING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REPERTOIRE DIVERSITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3978\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3978|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/58/13229\" title=\"figure 1\">",
"      T-cell antigen receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/18/3373\" title=\"figure 2\">",
"      Human TCR alpha chain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/62/37868\" title=\"figure 3\">",
"      Human TCR beta chain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/56/20365\" title=\"figure 4\">",
"      Human TCR gamma chain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/12/16589\" title=\"figure 5\">",
"      Human TCR delta chain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3978|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/29/475\" title=\"table 1\">",
"      Chromosomal locat TCR gene",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_54_37734="Pentamidine: Pediatric drug information";
var content_f36_54_37734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentamidine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"    see \"Pentamidine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/2/39973?source=see_link\">",
"    see \"Pentamidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nebupent&reg;;",
"     </li>",
"     <li>",
"      Pentam&reg; 300",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"      see \"Pentamidine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"      (PCP), prophylaxis (primary and secondary):",
"     </b>",
"     Limited data available:",
"     <b>",
"      Note:",
"     </b>",
"     For patients intolerant to sulfamethoxazole and trimethoprim.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HIV-exposed/-positive patients: Children &ge;5 years and Adolescents: Inhalation: 300 mg/dose monthly via Respirgard&reg; II nebulizer (CDC, 2009; CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oncology patients: Children &ge;2 years and Adolescents: I.V.: 4 mg/kg/dose once a month (Kim, 2008; Prasad, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      PCP, treatment (moderate-severe disease):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     For patients who cannot tolerate or who fail to respond to 5-7 days of sulfamethoxazole and trimethoprim.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Infants &ge;5 months, Children, and Adolescents: I.M., I.V.: 4 mg/kg/dose once daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     HIV-exposed/-positive patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children: I.V.: 4 mg/kg/dose once daily; if clinical improvement after 7-10 days of therapy, may change to an oral regimen to complete a 21-day course (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents: I.V.: 4 mg/kg/dose once daily for 21 days; some experts recommend a dose reduction to 3 mg/kg/dose for toxicity (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Non-HIV-exposed/-positive patients: I.V.: 3-4 mg/kg/dose once daily for 21 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Trypanosomiasis; treatment (non-CNS disease):",
"     </b>",
"     I.M.: 4 mg/kg/dose once daily for 7 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cutaneous leishmaniasis; treatment:",
"     </b>",
"     I.M., I.V.: 2-3 mg/kg/dose once daily or every 2 days for 4-7 doses (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      PCP:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis (primary and secondary): Inhalation: 300 mg/dose every 4 weeks via Respirgard&reg; II nebulizer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment (moderate-severe disease):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: I.M., I.V.: 4 mg/kg/dose once daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CDC recommendation: I.V.: 3-4 mg/kg/dose once daily for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AIDS",
"     <i>",
"      Info",
"     </i>",
"     guidelines (HIV-infected/-exposed): I.V.: 4 mg/kg/dose once daily; 3 mg/kg/dose may be used by some clinicians due to toxicities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     The FDA-approved labeling recommends that caution should be used in patients with renal impairment; however, no specific dosage adjustment guidelines are provided. The following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 4 mg/kg/dose every 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     and peritoneal dialysis: Administer 4 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 4 mg/kg/dose every 48 hours, after dialysis on dialysis days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis: 4 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy:  No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 4 mg/kg/dose every 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis: Administer 4 mg/kg/dose every 48 hours and 750 mg after each dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis: 4 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy:  No adjustment required",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as isethionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentam&reg; 300: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, for nebulization, as isethionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nebupent&reg;: 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral inhalation: Reconstitute powder for nebulization with 6 mL SWI. Safe and effective administration via nebulization in children is dependent on patients wearing an appropriately sized pediatric face mask. Deliver via Respirgard&reg; II nebulizer until nebulizer is emptied (30-45 minutes). Use appropriate precautions to minimize exposure to healthcare personnel; refer to individual institutional policy. The manufacturer recommends the use of freshly prepared solutions for inhalation. Do not mix with other nebulizer solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Reconstitute vial with 3 mL SWI to a final concentration of 100 mg/mL; administer deep I.M.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Reconstitute with 3-5 mL SWI or D",
"     <sub>",
"      5",
"     </sub>",
"     W; the manufacturer recommends further dilution in D",
"     <sub>",
"      5",
"     </sub>",
"     W; however, stability with further dilution in NS has also been documented. Administer by slow I.V. infusion over a period of at least 60-120 minutes at a final concentration for administration not to exceed 6 mg/mL; rapid I.V. administration can cause severe hypotension. Avoid extravasation; assess catheter position before and during infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F207979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS (do not use NS for initial reconstitution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diltiazem, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, fluconazole, foscarnet, linezolid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light; do not reconstitute with NS because precipitation will occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol: The manufacturer recommends the use of freshly prepared solutions for inhalation; once reconstituted, the solution is stable for up to 48 hours in the vial at room temperature; protect from light. Do",
"     <b>",
"      not",
"     </b>",
"     mix with other nebulizer solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: After reconstitution with SWI, solution is stable for 48 hours in the vial at room temperature if protected from light. Store at 22&deg;C to 30&deg;C (72&deg;F to 86&deg;F) to avoid crystallization. Solutions for infusion (1-2.5 mg/mL) in D",
"     <sub>",
"      5",
"     </sub>",
"     W are stable for at least 24 hours at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol: Prevention of pneumonia caused by",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     (formerly",
"     <i>",
"      carinii",
"     </i>",
"     ) (PCP) (FDA approved  in ages &ge;17 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of pneumonia caused by",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     (formerly",
"     <i>",
"      carinii",
"     </i>",
"     ) (PCP) (FDA approved  in ages &gt;4 months and adults).",
"     <b>",
"      Note:",
"     </b>",
"     The CDC recommends pentamidine for patients who cannot tolerate or who fail to respond to sulfamethoxazole and trimethoprim; has also been used in the treatment of African trypanosomiasis, cutaneous leishmaniasis, and amebic meningoencephalitis.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F207978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Aerosol:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness/lightheadedness, fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Gastrointestinal: Appetite decreased, nausea, oral candida, taste alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis, chest pain, cough, dyspnea, pharyngitis, sinusitis, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes infection, infection, influenza, night sweats",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Confusion/hallucinations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Gastrointestinal: Nausea/anorexia, taste alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Local reactions at I.M. injection site (includes sterile abscess, necrosis, pain, induration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Azotemia, BUN increased, creatinine increased, renal function impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes infection, infection, influenza, night sweats",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Aerosol or injection:",
"     </b>",
"     Rare but important or life-threatening: Abdominal pain, allergic reaction, anaphylaxis, anxiety, arthralgia, asthma, blepharitis, blurred vision, bronchitis, bronchospasm, cardiac arrhythmia, central venous line related sepsis, cerebrovascular accident, chest tightness, chills, clotting time prolonged, CMV infection, colitis, confusion, congestion (chest, nasal), conjunctivitis, cough, cryptococcal meningitis, cyanosis, defibrination, depression, dermatitis, desquamation, diabetes mellitus, diabetic ketoacidosis, diarrhea, dizziness, drowsiness, dyspepsia, dyspnea, emotional lability, eosinophilia, erythema, esophagitis, extrapulmonary pneumocystosis, extravasation (tissue ulceration, necrosis, and/or sloughing), facial edema, flank pain, gait unsteady, gagging, gingivitis, headache, hearing loss, hematochezia, hematuria, hemoptysis, hepatic dysfunction, hepatitis, hepatomegaly, histoplasmosis, hyperglycemia, hyperkalemia, hypersalivation, hypertension, hyperventilation, hypesthesia, hypocalcemia, hypomagnesemia, incontinence, insomnia, laryngitis, laryngospasm, leg edema, melena, memory loss, nephritis, nervousness, neuralgia, neuropathy, neutropenia, night sweats, palpitation, pancreatitis, pancytopenia, paranoia, paresthesia, peripheral neuropathy, phlebitis, pleuritis, pneumonitis (eosinophilic or interstitial), pneumothorax, pruritus, rales, renal dysfunction, renal failure, rhinitis, seizure, splenomegaly, Stevens-Johnson syndrome, ST segment abnormal, syncope, syndrome of inappropriate antidiuretic hormone (SIADH), tachycardia, tachypnea, temperature abnormal, torsade de pointes, tremor, vasodilation, vasculitis, ventricular tachycardia, vertigo, vomiting, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentamidine isethionate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in hepatic impairment; has not been studied. Use with caution in patients with diabetes mellitus; hyper-/hypoglycemia and pancreatic islet cell necrosis with hyperinsulinemia has been reported; symptoms may occur months after therapy; monitor blood glucose daily on therapy and periodically thereafter. Use with caution in patients with pre-existing cardiovascular disease; hyper-/hypotension, and arrhythmia, including QT prolongation and  ventricular tachycardia (eg, torsade de pointes) have been reported; avoid use in patients with diagnosed or suspected congenital long QT syndrome, avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval. Use caution in patients with hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with current evidence and/or prior history of hematologic disorders; anemia, leukopenia, and/or thrombocytopenia have been reported; concurrent use with other bone marrow suppressants may increase the risk for myelotoxicity.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Sudden, severe hypotension (including some fatalities) has been observed, even after a single dose; may occur with either I.V. or I.M. administration, although more common with rapid I.V. administration; monitor blood pressure (during and after infusion); patient should be lying down during administration and emergency equipment should be available. Extravasations which have proceeded to ulceration, tissue necrosis, and/or sloughing at the injection site have been reported; closely monitor I.V. site. Stevens-Johnson syndrome (SJS) has been reported; use with caution in patients with SJS. Nephrotoxicity (eg, increased creatinine, azotemia, renal failure) frequently occurs with parenteral therapy (~30% of patients); concurrent use with other nephrotoxic drugs (eg, aminoglycosides, amphotericin B, cisplatin, foscarnet, vancomycin) may increase risk for nephrotoxicity; use with caution in renal impairment; consider dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Aerosolized pentamidine may induce bronchospasm or cough, especially in patients with asthma (inhaled bronchodilator therapy prior to pentamidine may control symptoms).  Acute pancreatitis has been reported in patients receiving aerosolized pentamidine; use with caution in patients with a history of pancreatic disease or elevated amylase/lipase levels; acute pancreatitis (with fatality) has been reported. Discontinue inhalational pentamidine if signs/symptoms of acute pancreatitis occur. Acute PCP may develop despite aerosolized pentamidine prophylaxis; although rare, extrapulmonary",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     disease may occur and has been associated with aerosolized pentamidine; if symptoms of infection occur a thorough evaluation should be conducted. Healthcare personnel who administer aerosolized pentamidine inhalation therapy should be aware of the possibility of secondary exposure to tuberculosis or other infections from patients with undiagnosed pulmonary disease; use appropriate precautions to minimize exposure to healthcare personnel.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F207967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7305395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies were not conducted by the manufacturer; therefore, pentamidine is classified pregnancy category C. In postmarketing studies, pentamidine was embryocidal but not teratogenic when administered to animals. Pentamidine crosses the human placenta. Administration via the aerosolized route may minimize maternal serum concentrations. Concern regarding occupational exposure of pregnant healthcare workers has been discussed in the literature. Pregnant healthcare workers should avoid aerolized exposure if possible. If avoidance is not possible, they should wear a mask and gloves and ensure proper ventilation. Pentamidine may be used in pregnancy for prophylaxis or treatment of PCP if the patient is unable to take first line medications.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, renal function tests (daily), blood glucose (daily), serum potassium and calcium, CBC with differential and platelet count, ECG, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with RNA/DNA, phospholipids and protein synthesis through inhibition of oxidative phosphorylation and/or interference with incorporation of nucleotides and nucleic acids into RNA and DNA in protozoa",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Well absorbed; Aerosol: Limited systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Binds to tissues and plasma protein; high concentrations are found in the liver, kidney, adrenals, spleen, lungs and pancreas; poor penetration into CNS; following oral inhalation, high concentrations are found in bronchoalveolar fluid; V",
"     <sub>",
"      dss",
"     </sub>",
"     : I.V.: 821 &plusmn; 535 L; I.M.: 2724 &plusmn; 1066 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: I.V.: 5-8 hours; I.M.: 7-11 hours; half-life may be prolonged in patients with severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: I.V.: &le;12% in urine as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not appreciably removed by hemodialysis or peritoneal dialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/2/39973?source=see_link\">",
"      see \"Pentamidine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalant medication must be prepared and used with a nebulizer exactly as directed and as often as prescribed. Frequent blood tests and blood pressure checks may be required while using this medication. PCP pneumonia may still occur despite use of this medication. Maintain adequate hydration unless instructed to restrict fluid intake. Avoid excessive alcohol (may exacerbate adverse effects). If diabetic, monitor glucose levels closely and frequently. May cause hypotension, metallic taste, nausea, vomiting, or anorexia. Report chest pain or irregular heartbeat; unusual confusion or hallucinations; rash; or unusual wheezing, coughing, or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 97, 177.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Amebic Meningoencephalitis, Primary and Granulomatous.&rdquo; Available at:",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/AmebicMeningoencephalitis.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/AmebicMeningoencephalitis.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37734/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-194. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Leishmania.&rdquo; Available at:",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Leishmania.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Leishmania.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;",
"      <i>",
"       Pneumocystis jiroveci",
"      </i>",
"      (formerly",
"      <i>",
"       carinii",
"      </i>",
"      ) Pneumonia (PCP).&rdquo; Available at:",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Trypanosomiasis.&rdquo; Available at:",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Trypanosomiasis.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Trypanosomiasis.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim SY, Dabb AA, Glenn DJ, et al, \"Intravenous Pentamidine Is Effective as Second Line Pneumocystis Pneumonia Prophylaxis in Pediatric Oncology Patients,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(4):779-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37734/abstract-text/17635000/pubmed\" id=\"17635000\" target=\"_blank\">",
"        17635000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prasad P, Nania JJ, and Shankar SM, \"Pneumocystis Pneumonia in Children Receiving Chemotherapy,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(4):896-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/54/37734/abstract-text/17458875/pubmed\" id=\"17458875\" target=\"_blank\">",
"        17458875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12690 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.10.40.236-8B04AB009B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37734=[""].join("\n");
var outline_f36_54_37734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207948\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049322\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049314\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207928\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207913\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049325\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207979\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049317\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049324\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207978\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049328\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049313\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049312\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207967\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207922\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207924\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7305395\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049321\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049311\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049327\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049319\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=related_link\">",
"      Pentamidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/2/39973?source=related_link\">",
"      Pentamidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_54_37735="M mode aortic stenosis";
var content_f36_54_37735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram and carotid pulse (CP) tracings show aortic stenosis of various severity. Panel A: mild aortic stenosis. There is increased density in region of aortic valve (AV) but preservation of the rapid movement of one leaflet. The carotid pulse tracing shows an upstroke time of 17 msec and an ejection time of 35 msec. Panel B: Critical aortic stenosis. There are dense echoes through the leaflets, which are uninterupted by leaflet motion. The carotid upstroke time is prolonged to 25 msec.",
"    <div class=\"footnotes\">",
"     Ao: aortic root; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37735=[""].join("\n");
var outline_f36_54_37735=null;
var title_f36_54_37736="Cervical adenocarcinoma in situ";
var content_f36_54_37736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical adenocarcinoma in situ",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37736/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37736/contributors\">",
"     Marcela G del Carmen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37736/contributors\">",
"     John O Schorge, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37736/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37736/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/54/37736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H181231650\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinoma in situ of the uterine cervix is a premalignant glandular condition. Adenocarcinoma in situ is the only known precursor to cervical adenocarcinoma, and appropriate management can prevent the occurrence of invasive disease in many cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/1\">",
"     1",
"    </a>",
"    ]. The usual interval between clinically detectable adenocarcinoma in situ and early invasion appears to be at least five years, suggesting ample opportunity for screening and intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glandular neoplasia of the uterine cervix is less common than squamous neoplasia, comprising one quarter of all annual cervical cancers diagnoses in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/4\">",
"     4",
"    </a>",
"    ]. Over the past few decades, however, the incidence of adenocarcinoma in situ and invasive adenocarcinoma has increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of cervical adenocarcinoma in situ are reviewed here. Related topics are discussed separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glandular cells on cervical cytology (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Invasive adenocarcinoma of the cervix (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=see_link\">",
"       \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6938?source=see_link\">",
"       \"Invasive cervical adenocarcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11311344\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average age of women at diagnosis of cervical adenocarcinoma in situ (AIS) is 36.9 years, based upon a meta-analysis that included 33 studies with 1278 patients with a diagnosis of AIS on cervical cone biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Surveillance, Epidemiology and End Results (SEER) United States national cancer database reported that, from 1995 to 2000, the incidences of AIS among white and black women, respectively, in the United States were 1.25 and 0.31 per 100,000 woman-years, respectively; data regarding other racial or ethnic groups were not included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of both AIS and adenocarcinoma of the cervix have increased over the past several decades, particularly among young women. From 1976 to 1995, SEER data shows a sharp increase particularly in white women, who had a sixfold rise from 0.21 to 1.25 per 100,000 woman-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/5\">",
"     5",
"    </a>",
"    ]. Several factors have probably contributed to this increase, including: increased rates and efficacy of screening, changes in the Bethesda cervical cytology classification system that have better clarified glandular findings, and increased exposure to factors that cause or promote glandular neoplasia (high risk human papillomavirus [HPV], oral contraceptives) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link&amp;anchor=H15#H15\">",
"     \"Cervical cytology: Interpretation of results\", section on 'Glandular cell abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIS and adenocarcinoma are less common than squamous cell cervical cancer (SCC) and its precursors. SEER data from 2001 to 2004 showed that among cervical cancer cases, 25 percent were adenocarcinoma and 70 percent SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk factors for AIS are the same as for invasive cervical adenocarcinoma, most notably HPV infection, particularly with subtypes 16 or 18; prolonged infection with high risk HPV subtypes is also a risk factor for squamous cervical neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Some data suggest that oral contraceptive use is associated with an increased risk of AIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/8\">",
"     8",
"    </a>",
"    ]. Risk factors for cervical adenocarcinoma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6938?source=see_link&amp;anchor=H175461#H175461\">",
"     \"Invasive cervical adenocarcinoma\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181231657\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytologically, the atypical glandular cells resemble those of cervical invasive adenocarcinoma, but histologically no invasion is present.",
"   </p>",
"   <p>",
"    Adenocarcinoma in situ (AIS) of the cervix is characterized histologically by endocervical glands that exhibit a crowded, cribriform pattern and are lined with atypical columnar epithelial cells (",
"    <a class=\"graphic graphic_picture graphicRef52908 \" href=\"mobipreview.htm?23/0/23560\">",
"     picture 1",
"    </a>",
"    ). The predominant histologic type is endocervical, although pagetoid AIS has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pattern of AIS lesions vary, making diagnosis of the full extent of disease difficult in some cases. Lesions usually originate at the transformation zone with contiguous extension proximally within the endocervical canal. Ten to 15 percent of patients with AIS have multifocal disease (&ldquo;skip&rdquo; lesions) with foci of AIS that are separated by at least 2 mm of normal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/14\">",
"     14",
"    </a>",
"    ]. AIS lesions may also be located high in the endocervical canal and involve the deeper portions of the endocervical clefts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181231664\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinoma in situ (AIS) of the cervix is nearly always asymptomatic and is generally not visible upon gross examination. It is typically detected due to an abnormal finding on cervical cytology.",
"   </p>",
"   <p>",
"    Rarely, women with AIS present with cervical bleeding, which is usually described by the patient as vaginal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The cervix can only be identified as the site of bleeding with pelvic examination. A postcoital pattern of bleeding has traditionally been associated with cervical neoplasia, although it appears that fewer than 1 in 2000 women with postcoital bleeding have cervical cancer. Women with cervical bleeding should be evaluated with cervical cytology. If the results are negative, the patient should be evaluated for other etiologies (eg, benign cervical lesion, cervicitis). Abnormal cytology results should be evaluated as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8054?source=see_link&amp;anchor=H3#H3\">",
"     \"Postcoital bleeding in women\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Follow-up of abnormal cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H852913\">",
"    <span class=\"h2\">",
"     Cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIS is typically detected upon evaluation of abnormal findings on cervical cytology, as noted above. Either glandular or squamous cytologic abnormalities may precede a diagnosis of AIS. Retrospective studies have reported the following results of the cervical cytology specimen just prior to diagnosis of AIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glandular (50 to 69 percent)",
"     </li>",
"     <li>",
"      Squamous (26 to 31 percent) &ndash; among squamous findings, most were high grade squamous intraepithelial lesions (76 to 79 percent)",
"     </li>",
"     <li>",
"      Mixed squamous and glandular (15 percent)",
"     </li>",
"     <li>",
"      Negative (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among women with atypical glandular cells on cervical cytology, 3 to 4 percent have AIS and 2 percent have cervical adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link&amp;anchor=H16564920#H16564920\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\", section on 'Risk of premalignant or malignant disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7455202\">",
"    <span class=\"h2\">",
"     Pelvic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who present with abnormal cervical cytology, a focussed pelvic examination is performed. The examination should include a speculum examination with visual inspection of the cervix. This examination will typically be negative in women with AIS, since AIS is a microscopic condition. If present, a grossly visible lesion should be biopsied to exclude malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link&amp;anchor=H10#H10\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'Biopsy of visible lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=see_link\">",
"     \"Congenital cervical anomalies and benign cervical lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women who present with genital tract bleeding, a complete pelvic examination should be performed to determine the source of the bleeding and other relevant findings (eg, uterine size and mobility). The evaluation of women with genital tract bleeding is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851887\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinoma in situ (AIS) of the uterine cervix is a histologic diagnosis made with a cervical biopsy, which may include one or more of the following biopsy techniques: colposcopy-directed biopsy, endocervical curettage, or cone biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7454927\">",
"    <span class=\"h2\">",
"     Colposcopy, biopsy, and endocervical curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal findings on cervical cytology should be evaluated further with colposcopy. Exceptions to this are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Follow-up of abnormal cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Colposcopy is performed with biopsy of areas suspicious for neoplasia. AIS has no colposcopic features that differentiate it from other cervical lesions. We also perform endocervical curettage (ECC) in all women with a cytologic finding glandular abnormalities (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"mobipreview.htm?18/51/19261\">",
"     table 1",
"    </a>",
"    ) or a high grade squamous intraepithelial lesion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link&amp;anchor=H9#H9\">",
"     \"Colposcopy\", section on 'Examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link&amp;anchor=H11#H11\">",
"     \"Colposcopy\", section on 'Endocervical curettage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with some glandular cytologic abnormalities, if biopsy and ECC are negative, further evaluation with conization may be warranted.",
"   </p>",
"   <p>",
"    Women with squamous cytologic abnormalities with a negative biopsy and ECC should be evaluated as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7455288\">",
"    <span class=\"h2\">",
"     Conization",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIS is usually multifocal and is also often high in the endocervical canal; thus, we perform conization for women with suspected disease who have negative biopsy and ECC results. These include women with the following findings (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link&amp;anchor=H10#H10\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\", section on 'Negative or low-grade findings on initial evaluation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytology with AIS (or adenocarcinoma) and a negative biopsy and ECC",
"     </li>",
"     <li>",
"      Cytology with atypical glandular cells (AGC), classified as favor neoplasia, and a negative biopsy, ECC, and endometrial biopsy",
"     </li>",
"     <li>",
"      Cytology with persistent AGC, classified as endocervical or not otherwise specified, and negative results after biopsy, ECC, and endometrial biopsy have each been performed more than once",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with abnormal cervical cytology who have a negative conization are followed as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link&amp;anchor=H10#H10\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\", section on 'Negative or low-grade findings on initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of women with AIS on conization is described below. (See",
"    <a class=\"local\" href=\"#H181231671\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Women with a squamous lesion alone or coexistent with AIS on conization are managed as appropriate. (See",
"    <a class=\"local\" href=\"#H7455411\">",
"     'Evaluation of coexistent squamous neoplasia'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    The choice of conization technique is discussed below. (See",
"    <a class=\"local\" href=\"#H853541\">",
"     'Conization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H852102\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cervical adenocarcinoma in situ (AIS) includes other etiologies of abnormal cervical cytology. These include other types of glandular and squamous preinvasive and invasive disease. The type of cervical neoplasia is determined through cervical biopsy, as described above. (See",
"    <a class=\"local\" href=\"#H7454927\">",
"     'Colposcopy, biopsy, and endocervical curettage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, some women with atypical glandular cells on cervical cytology are found to have endometrial carcinoma or, rarely, cancer at other sites (ovaries, colon). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical bleeding is a rare presentation of AIS, as noted above. However, abnormal genital tract bleeding is common clinical complaint. The differential diagnosis and evaluation of women with genital tract bleeding, and cervical bleeding in particular, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35113?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of causes of genital tract bleeding in women\", section on 'Cervical bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H853442\">",
"    <span class=\"h1\">",
"     POSTDIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cervical adenocarcinoma in situ (AIS) diagnosed with colposcopic-directed biopsy or endocervical curettage (ECC) require cervical conization. The role of conization in these patients is to confirm the diagnosis, assess the extent of disease, exclude invasive disease, and exclude a coexistent squamous lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H853541\">",
"    <span class=\"h2\">",
"     Conization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conization may be performed using one of several techniques, including: cold knife conization (CKC), loop electrosurgical excision procedure (LEEP) or laser conization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that conization technique impacts outcomes. In our practice, we prefer CKC rather than LEEP, since CKC yields a specimen that has margins that are more easily interpretable than a LEEP specimen for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CKC specimens typically have an increased depth and width [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LEEP specimens have significant thermal artifact at the edges, which may obscure assessment of the margins.",
"     </li>",
"     <li>",
"      CKC specimens are usually in one piece, while LEEP specimens are often in several pieces. A single piece specimen can be marked at the 12 o&rsquo;clock position, allowing the pathologist to report the anatomic location of a positive margin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many women with AIS patients will undergo LEEP due to clinician preference, or more commonly, because there was no preoperative suspicion of glandular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. These patients are managed the same way as those who underwent CKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laser conization also results in thermal artifact, similar to LEEP, but the size of the specimen can be comparable to CKC. Use of laser conization is limited by need for specialized training and equipment.",
"   </p>",
"   <p>",
"    Some surgeons perform endocervical curettage (ECC) at the time of conization. Data conflict regarding whether performing this provides additional information regarding the likelihood of residual disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In our practice, we perform ECC above the cone, since it does not add to operative risk and potentially provides additional reassurance (if negative) or indicates the need for another excision (if positive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some women with AIS on colposcopically-directed biopsy will not have AIS in the cone specimen. Nevertheless, these women have a histologic diagnosis of AIS and we manage them in the same manner as other patients with a cone with negative margins.",
"   </p>",
"   <p>",
"    The management of women with AIS on conization is described below. (See",
"    <a class=\"local\" href=\"#H181231671\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients whose conization specimen shows a squamous lesion alone or coexistent with AIS, we follow them as appropriate for the squamous finding. (See",
"    <a class=\"local\" href=\"#H7455411\">",
"     'Evaluation of coexistent squamous neoplasia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7455411\">",
"    <span class=\"h2\">",
"     Evaluation of coexistent squamous neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with AIS are found to have a coexisting squamous lesion (55 percent in a meta-analysis of 33 studies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6,28,29\">",
"     6,28,29",
"    </a>",
"    ]. Squamous cervical intraepithelial neoplasia or carcinoma should be further evaluated and managed as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181231671\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of women with adenocarcinoma in situ (AIS) of the cervix is challenging. Because of the pattern of disease distribution of AIS (multifocal, high in the endocervical canal, inside endocervical clefts), negative margins on a cone biopsy specimen or a negative endocervical curettage do not necessarily ensure that the lesion has been completely excised. This also makes it difficult to detecting",
"    <span class=\"nowrap\">",
"     persistent/recurrent",
"    </span>",
"    disease or adenocarcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15587586\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is the standard treatment for AIS; the alternative is conization followed by surveillance. Unfortunately, women treated with conization alone have a high risk of residual AIS or adenocarcinoma, while the incidence of adenocarcinoma after hysterectomy is limited to rare case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The risk of residual disease is particularly high for women with a positive conization margin.",
"   </p>",
"   <p>",
"    The best available data regarding the risk of residual AIS or adenocarcinoma following conization are from a meta-analysis of 33 observational studies including 1278 patients who were followed for an average of three years (range one to five years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6\">",
"     6",
"    </a>",
"    ]. Among 60 patients who underwent subsequent conization or hysterectomy, the rates of residual AIS and adenocarcinoma were: initial conization margin positive (AIS: 52.8 percent; adenocarcinoma: 6.3 percent [17 of 266]) and initial conization negative (20.3 percent; 1.5 percent [4 of 341]). Adenocarcinoma was diagnosed in an additional eight women (six with positive margins; two with negative margins) who were managed conservatively. The clinical importance of residual AIS is that it is likely to develop into invasive disease. However, progression may take five or more years and long-term data are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surveillance of women with AIS has not been proven effective in preventing progression to invasive disease or increasing survival for women with adenocarcinoma. The multifocal nature of AIS greatly limits the ability of testing with cervical cytology, colposcopy, biopsy, and endocervical sampling to detect residual disease or adenocarcinoma.",
"   </p>",
"   <p>",
"    Given these considerations, for women with cervical AIS who do not wish to preserve fertility, we recommend hysterectomy rather than cervical conization alone for women with positive conization margins. For those with negative conization margins there are few data. The risk of adenocarcinoma in these patients is approximately 1.8 percent, based upon low quality data, while the risk of serious morbidity of extrafascial abdominal hysterectomy is 4 to 6 percent (",
"    <a class=\"graphic graphic_table graphicRef79688 \" href=\"mobipreview.htm?7/48/7948\">",
"     table 2",
"    </a>",
"    ). We suggest hysterectomy for these patients. Conization followed by surveillance is an option for women who value avoiding the potential morbidity of hysterectomy more than avoidance of an approximately one percent risk of cervical adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=see_link&amp;anchor=H1745544#H1745544\">",
"     \"Abdominal hysterectomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women who wish to preserve fertility, conization followed by surveillance is a reasonable option",
"    <strong>",
"     only",
"    </strong>",
"    for women who have a negative conization margin (including a negative endocervical curettage) and who are willing to accept a higher risk of cervical adenocarcinoma. We recommend hysterectomy for women with a positive conization margin following two or more conizations.",
"   </p>",
"   <p>",
"    These recommendations are consistent with guidelines from the American Society for Colposcopy and Cervical Pathology, United States National Comprehensive Cancer Network, and American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the complexity of managing AIS, treatment by a gynecologic oncologist generally preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3010837\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3011609\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with AIS are treated with a total extrafascial hysterectomy. Ovaries may be conserved. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    If a laparoscopic approach is used, morcellation should be avoided. An intact specimen is important for evaluation of margins, particularly given the likelihood of skip lesions in AIS.",
"   </p>",
"   <p>",
"    Prior to hysterectomy, for women who had positive margins on conization, we suggest a repeat conization procedure to exclude invasive disease. This avoids the possibility of performing only an extrafascial hysterectomy in the setting of an occult invasive cancer that should be staged and treated with a more radical surgical procedure. We repeat the conization procedure approximately six weeks prior to hysterectomy to allow for resolution of inflammation in and around the cervix.",
"   </p>",
"   <p>",
"    Women in whom adenocarcinoma is discovered at time of hysterectomy should be managed as appropriate. Further surgical staging and treatment with radical parametrectomy and lymph node dissection may be required. In addition, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6938?source=see_link\">",
"     \"Invasive cervical adenocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1701574\">",
"    <span class=\"h3\">",
"     Post-hysterectomy follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following hysterectomy for AIS, the optimal surveillance strategy has not been established and clinical practice is variable. Assuming the hysterectomy specimen did not show invasive cancer, we use the following protocol:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal cytology and high risk human papillomavirus (HPV) testing of the vaginal fornix at 6 and 12 months after hysterectomy",
"     </li>",
"     <li>",
"      If normal, once a year indefinitely",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If vaginal cytology results are abnormal, we evaluate with vaginal colposcopy. If colposcopy and biopsy are positive for high grade dysplasia (glandular or squamous), the patient is treated either with an ablative procedure (eg, carbon dioxide laser or ultrasonic surgical aspiration) or excision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link&amp;anchor=H16#H16\">",
"     \"Colposcopy\", section on 'Vaginal colposcopy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    If HPV testing is positive and vaginal cytology negative, the HPV test and cytology are repeated at the next surveillance visit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3011617\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are rare reports of cervical adenocarcinoma in women treated for AIS with hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These most likely represent adenocarcinoma that was not recognized at the time of hysterectomy, although in both of these cases the hysterectomy specimen showed AIS without evidence of invasive disease with negative margins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3010845\">",
"    <span class=\"h2\">",
"     Fertility preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIS is a disease that affects many women of reproductive age, since the mean age at diagnosis is the late thirties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, many women with AIS desire to preserve fertility. Women who are candidates for conization followed by surveillance are those who have the lowest risk of developing adenocarcinoma, those with a negative conization margin (including a negative endocervical curettage [ECC]). Women treated conservatively for AIS require close surveillance for cervical adenocarcinoma. &nbsp;",
"   </p>",
"   <p>",
"    Oophorectomy is not required at time of hysterectomy for AIS. Women of reproductive age who have undergone hysterectomy and conserved their ovaries may be candidates for in vitro fertilization using a gestational carrier. (See",
"    <a class=\"local\" href=\"#H3011609\">",
"     'Procedure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367110\">",
"    <span class=\"h3\">",
"     Conization margin status",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3011634\">",
"    <span class=\"h4\">",
"     Negative margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a negative conization have a risk of residual AIS or adenocarcinoma of 20 and 1 percent, respectively, based upon data from hysterectomy or repeat conization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6\">",
"     6",
"    </a>",
"    ]. The risk of invasive disease is low, but is still higher than hysterectomy, after which there are only rare cases of adenocarcinoma. For women with these findings who desire fertility preservation, we offer management with conization followed by surveillance. Patients considering conservative management should be counseled about the",
"    <span class=\"nowrap\">",
"     persistent/recurrent",
"    </span>",
"    AIS or adenocarcinoma.",
"   </p>",
"   <p>",
"    ECC is performed by some surgeons at the time of conization. We consider the ECC results to be part of the margin status (ie, a positive ECC is a positive margin). (See",
"    <a class=\"local\" href=\"#H853541\">",
"     'Conization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6840447\">",
"    <span class=\"h4\">",
"     Positive margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a positive conization margin who desire to preserve fertility should be evaluated with a repeat conization. We repeat the conization procedure approximately six weeks after the first conization, to allow for sufficient healing and resolution of inflammation of the cervix. If the repeat conization margin is negative, we offer surveillance.",
"   </p>",
"   <p>",
"    Women typically do not undergo more than two conization procedures. A third conization is sometimes technically feasible, but the risk of operative complications and preterm delivery in subsequent pregnancy increases with repeat procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=see_link&amp;anchor=H12#H12\">",
"     \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\", section on 'Number of procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=see_link&amp;anchor=H8#H8\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\", section on 'Complications'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    We recommend hysterectomy for women with a positive conization margin following two or more conizations. Women with a finding of adenocarcinoma on a repeat conization are treated, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6938?source=see_link\">",
"     \"Invasive cervical adenocarcinoma\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3011642\">",
"    <span class=\"h3\">",
"     Post-conization follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up is required for women with AIS who do not undergo hysterectomy. Post-conization follow-up consists of cervical cytology and testing for high risk HPV subtypes.",
"   </p>",
"   <p>",
"    There are no data to establish the optimal surveillance schedule for women treated for AIS with conization alone. The following protocol is advised by the American Society for Colposcopy and Cervical Pathology, United States National Comprehensive Cancer Network, and American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical cytology (with or without ECC) and high risk HPV testing every six months. Colposcopy may also be performed, but it is often difficult to see the entire transformation zone and proves unsatisfactory.",
"     </li>",
"     <li>",
"      When both cervical cytology and HPV testing have been consistently negative for two years, the surveillance interval may be extended to 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If either cytology or HPV testing are abnormal during follow-up, the patient should be evaluated with colposcopy and ECC. Women with adequate and negative colposcopy and a negative ECC may resume the surveillance protocol described above. Patients with recurrent AIS or high grade squamous dysplasia on colposcopic-guided biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ECC should undergo repeat cervical conization or hysterectomy.",
"   </p>",
"   <p>",
"    After completion of childbearing, we suggest that women with AIS who were treated with conization alone undergo hysterectomy. Hysterectomy reduces the risk of adenocarcinoma almost entirely compared with a 1 to 5 percent risk following conization alone, as discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6\">",
"     6",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H181231671\">",
"     'Management'",
"    </a>",
"    above). However, there are no data that have evaluated continued surveillance versus deferred hysterectomy in this patient population.",
"   </p>",
"   <p>",
"    Women who have chosen fertility preservation are likely to have undergone testing every 6 to 12 months in the interval between AIS diagnosis and the end of childbearing. The period of time from diagnosis to completion of childbearing is at least one year, but may be as long as ten years or longer. Most studies of conservative management of AIS have followed patients for less than five years. Also, there are no data to guide treatment decisions based upon the results of interim testing. As an example, the largest series of women who chose treatment of AIS with conization to preserve fertility included only 101 women and had a follow-up period of an average of four years (range four months to 12 years); there were no cases of adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/36\">",
"     36",
"    </a>",
"    ]. Two of five women who ultimately underwent hysterectomy had residual AIS in the hysterectomy specimen and had also had a positive conization margin, but no data were given about whether surveillance findings were the indication for hysterectomy. Given the limited data, continued surveillance is a reasonable choice for women who have had consistently normal testing, particularly for five or more years, following conization. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1702364\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1702372\">",
"    <span class=\"h4\">",
"     AIS or adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing persistent or recurrent AIS or invasive adenocarcinoma following conservative management varies by conization margin status. There is a lack of high quality data regarding the outcomes of conservative management of AIS. A meta-analysis of 33 observational studies described above found a risk of adenocarcinoma of 1.5 percent for women with a negative margin on initial conization and 5.0 percent in those with a positive margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H181231671\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1702380\">",
"    <span class=\"h4\">",
"     Reproductive outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility and obstetric outcomes for women managed conservatively for AIS are the same as for other women who have had a conization procedure. This has not been well studied specifically in women with AIS, but in one of the largest series (n = 101), 35 women achieved a total of 49 pregnancies during a mean follow-up of 52 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/21\">",
"     21",
"    </a>",
"    ]. There were 35 term deliveries (76 percent), two preterm births secondary to preterm premature rupture of membranes, eight spontaneous first trimester miscarriages, three elective pregnancy terminations, and one ectopic pregnancy.",
"   </p>",
"   <p>",
"    Reproductive outcomes following treatment of cervical intraepithelial neoplasia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181231706\">",
"    <span class=\"h1\">",
"     PREGNANT WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIS is rarely diagnosed during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37736/abstract/36\">",
"     36",
"    </a>",
"    ]. Endocervical curettage and conization are generally discouraged in pregnant women, but may be performed if invasive disease is suspected. Evaluation and management of cervical cancer during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=see_link\">",
"     \"Cervical cancer in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181231713\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenocarcinoma in situ (AIS) of the uterine cervix is a premalignant glandular condition and is the only known precursor to cervical adenocarcinoma. (See",
"      <a class=\"local\" href=\"#H181231650\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The average age of women at diagnosis of AIS is 36.9 years. Over the past few decades, the incidence of AIS and invasive adenocarcinoma has increased. From 1995 to 2000, the incidences of AIS among white and black women in the United States, respectively, were 1.25 and 0.31 per 100,000 woman-years. (See",
"      <a class=\"local\" href=\"#H11311344\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AIS is nearly always asymptomatic and is not visible upon gross visual examination. It is typically detected with evaluation of an abnormal finding on cervical cytology. Either glandular or squamous cytologic abnormalities may precede a histologic diagnosis of AIS. (See",
"      <a class=\"local\" href=\"#H181231664\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pattern of AIS lesions vary, making diagnosis of the full extent of disease difficult in some cases. Lesions usually originate at the cervical transformation zone and extend proximally within the endocervical canal. Most lesions are contiguous, but 10 to 15 percent of patients with AIS have multifocal disease (&ldquo;skip&rdquo; lesions). AIS lesions may also be located high in the endocervical canal and involve the deeper portions of the endocervical clefts. (See",
"      <a class=\"local\" href=\"#H181231657\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AIS is a histologic diagnosis made with cervical biopsy. Women with known or suspected AIS require cervical conization to make confirm the diagnosis, assess the extent of disease, exclude invasive disease, and exclude a coexistent squamous lesion. In our practice, we prefer cold knife conization since it yields a specimen that has margins that are more easily interpretable than a loop electrosurgical excision procedure. (See",
"      <a class=\"local\" href=\"#H853541\">",
"       'Conization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with AIS who do not wish to preserve fertility, for those with positive conization margins we recommend hysterectomy rather than cervical conization alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For those with negative conization margins, we suggest hysterectomy rather than conization alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Conization followed by surveillance is an option for women who value avoiding the potential morbidity of hysterectomy more than avoidance of an approximately one percent risk of cervical adenocarcinoma. (See",
"      <a class=\"local\" href=\"#H181231671\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with cervical AIS who wish to preserve fertility and are willing to accept a higher risk of cervical adenocarcinoma (see",
"      <a class=\"local\" href=\"#H3010845\">",
"       'Fertility preservation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conization followed by surveillance is a reasonable option for women with a negative conization margin (including a negative endocervical curettage).",
"     </li>",
"     <li>",
"      Women with a positive conization margin should be evaluated with a repeat conization. We recommend hysterectomy rather than surveillance for women with a positive conization margin following two or more conizations (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      We suggest that women with AIS who opted for fertility preservation undergo hysterectomy after completion of childbearing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Continued surveillance is a reasonable option for women who have had consistently normal testing, particularly for five or more years, following conization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outcomes of conservative management of AIS vary by conization margin status. The rates of recurrent or persistent AIS and adenocarcinoma, respectively, in women with negative margins on initial conization are 20 and 1 percent and with positive margins are 53 and 5 percent. Long-term follow-up with cervical cytology and high risk HPV testing is required for women who do not undergo hysterectomy. (See",
"      <a class=\"local\" href=\"#H6840447\">",
"       'Positive margin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1702372\">",
"       'AIS or adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/1\">",
"      Dunton CJ. Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am 2008; 35:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/2\">",
"      Lee KR, Flynn CE. Early invasive adenocarcinoma of the cervix. Cancer 2000; 89:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/3\">",
"      Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 1999; 75:55.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/csr/1975_2004/results_merged/sect_05_cervix_uteri.pdf (Accessed on August 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/5\">",
"      Wang SS, Sherman ME, Hildesheim A, et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004; 100:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/6\">",
"      Salani R, Puri I, Bristow RE. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol 2009; 200:182.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/7\">",
"      Quint KD, de Koning MN, van Doorn LJ, et al. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol 2010; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/8\">",
"      Madeleine MM, Daling JR, Schwartz SM, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/9\">",
"      Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/10\">",
"      Vizcaino AP, Moreno V, Bosch FX, et al. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998; 75:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/11\">",
"      Dahlstr&ouml;m LA, Ylitalo N, Sundstr&ouml;m K, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010; 127:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/12\">",
"      Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006; 94:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/13\">",
"      Mahdi H, Thrall M, Agoff N, Doherty M. Pagetoid adenocarcinoma in situ of the cervix with pagetoid spread into the vagina. Obstet Gynecol 2011; 118:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/14\">",
"      Ost&ouml;r AG, Duncan A, Quinn M, Rome R. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol 2000; 79:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/15\">",
"      Terada T. Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. Arch Gynecol Obstet 2010; 281:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/16\">",
"      Tob&oacute;n H, Dave H. Adenocarcinoma in situ of the cervix. Clinicopathologic observations of 11 cases. Int J Gynecol Pathol 1988; 7:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/17\">",
"      Shin CH, Schorge JO, Lee KR, Sheets EE. Cytologic and biopsy findings leading to conization in adenocarcinoma in situ of the cervix. Obstet Gynecol 2002; 100:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/18\">",
"      Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study. Acta Cytol 2004; 48:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/19\">",
"      Geier CS, Wilson M, Creasman W. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol 2001; 184:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/20\">",
"      Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/21\">",
"      Bull-Phelps SL, Garner EI, Walsh CS, et al. Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. Gynecol Oncol 2007; 107:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/22\">",
"      Girardi F, Heydarfadai M, Koroschetz F, et al. Cold-knife conization versus loop excision: histopathologic and clinical results of a randomized trial. Gynecol Oncol 1994; 55:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/23\">",
"      Mathevet P, Dargent D, Roy M, Beau G. A randomized prospective study comparing three techniques of conization: cold knife, laser, and LEEP. Gynecol Oncol 1994; 54:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/24\">",
"      Bryson P, Stulberg R, Shepherd L, et al. Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS? Gynecol Oncol 2004; 93:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/25\">",
"      Lea JS, Shin CH, Sheets EE, et al. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol 2002; 87:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/26\">",
"      Denehy TR, Gregori CA, Breen JL. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol 1997; 90:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/27\">",
"      Srisomboon J, Kietpeerakool C, Suprasert P, et al. Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy. Asian Pac J Cancer Prev 2007; 8:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/28\">",
"      Shin CH, Schorge JO, Lee KR, Sheets EE. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol 2000; 79:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/29\">",
"      Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol 2002; 86:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/30\">",
"      Krivak TC, Retherford B, Voskuil S, et al. Recurrent invasive adenocarcinoma after hysterectomy for cervical adenocarcinoma in situ. Gynecol Oncol 2000; 77:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/31\">",
"      Miller B, Dunn J, Dalrymple J, Krivak TC. Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ. Gynecol Oncol 2005; 99:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/32\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/33\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol 2008; 112:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/34\">",
"      Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/35\">",
"      Partridge EE, Abu-Rustum N, Campos S, et al. Cervical cancer screening. J Natl Compr Canc Netw 2008; 6:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37736/abstract/36\">",
"      Lacour RA, Garner EI, Molpus KL, et al. Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol 2005; 192:1449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3218 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-75F91836D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37736=[""].join("\n");
var outline_f36_54_37736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H181231713\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181231650\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11311344\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181231657\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181231664\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H852913\">",
"      Cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7455202\">",
"      Pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H851887\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7454927\">",
"      Colposcopy, biopsy, and endocervical curettage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7455288\">",
"      Conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H852102\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H853442\">",
"      POSTDIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H853541\">",
"      Conization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7455411\">",
"      Evaluation of coexistent squamous neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181231671\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15587586\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3010837\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3011609\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1701574\">",
"      - Post-hysterectomy follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3011617\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3010845\">",
"      Fertility preservation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H367110\">",
"      - Conization margin status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3011634\">",
"      Negative margin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6840447\">",
"      Positive margin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3011642\">",
"      - Post-conization follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1702364\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1702372\">",
"      AIS or adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1702380\">",
"      Reproductive outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181231706\">",
"      PREGNANT WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181231713\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3218|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/0/23560\" title=\"picture 1\">",
"      Cervical AIS histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3218|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/51/19261\" title=\"table 1\">",
"      Bethesda class cervix cytol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/48/7948\" title=\"table 2\">",
"      Abdominal hyst complication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=related_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=related_link\">",
"      Cervical intraepithelial neoplasia: Reproductive effects of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6938?source=related_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8054?source=related_link\">",
"      Postcoital bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_54_37737="Overview of electrosurgery";
var content_f36_54_37737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of electrosurgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Jon Ivar Einarsson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Jon Gould, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37737/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/54/37737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrosurgery refers to the cutting and coagulation of tissue using high-frequency electrical current [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/1\">",
"     1",
"    </a>",
"    ]. Physicians using this technique must be knowledgeable about prevention and management of potential complications of electrosurgical procedures. In addition, they should understand the mechanism of action and how to troubleshoot equipment. Education on the principles of electrosurgery is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/2\">",
"     2",
"    </a>",
"    ], as electrosurgical complications are relatively common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical current is created by the movement of electrons; voltage is the force that causes this movement. There are two types of electrical current: direct current (DC), where the electrons always flow in the same direction (eg, simple battery), and alternating current (AC), where the current changes direction periodically (eg, electrical wall outlet). Each time an AC current reverses direction is considered one cycle; frequency refers to the number of cycles in one second and is measured in hertz (Hz).",
"   </p>",
"   <p>",
"    Electrosurgical units (ESU) used in operating rooms convert standard electrical frequencies from the wall outlet, which are 50 to 60 Hz, to much higher frequencies, 500,000 to 3,000,000 Hz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/1\">",
"     1",
"    </a>",
"    ]. This is important to minimize nerve and muscle stimulation, which occurs at electrical currents below 10,000 Hz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible effects of applying current to tissue are fulguration,",
"    <span class=\"nowrap\">",
"     desiccation/coagulation,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     vaporization/ablation",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef62221 \" href=\"mobipreview.htm?16/14/16610\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Monopolar versus bipolar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrosurgery can be performed using either a monopolar or a bipolar instrument. The main difference between these two modalities is that in monopolar surgery, the current goes through the patient to complete the current cycle, while in bipolar surgery, the current only goes through the tissue between the two electrodes of the instrument.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monopolar surgery &ndash; In monopolar surgery, electrical current created in the ESU passes through a single electrode to the tissue, causing the desired tissue effect (eg, fulguration, desiccation, or vaporization) (",
"      <a class=\"graphic graphic_figure graphicRef56659 \" href=\"mobipreview.htm?12/51/13119\">",
"       figure 2",
"      </a>",
"      ). The tissue effect occurs almost exclusively near the electrode, since the density of electrons diminishes rapidly as the distance from the electrode increases.",
"      <br/>",
"      <br/>",
"      To complete the cycle, however, the current needs to exit the patient, and will invariably choose the path of least resistance in seeking to return to an electron reservoir, such as the ground. Currently, most operating rooms use an isolated-generator system with a dispersive electrode pad that is attached to the patient in relative proximity to the surgical site. This creates a set path for the current to exit the patient. The large surface area of the dispersion pad results in low current density at the attachment site, thereby minimizing the risk of skin burns. However, if the dispersion pad becomes loose with only partial skin attachment, the current density increases with the potential risk of skin burns.",
"      <br/>",
"      <br/>",
"      For maximum safety, the pad should be applied to well-perfused, dry, hairless skin over a large muscle and away from bone metal. Variables such as keloids, metal, hair, and poor perfusion distal to a tourniquet increase impedance, which can result in burns. Some ESUs have sensors that measure pad-to-skin contact and current density; these instruments sound an alarm and shut off the current if contact is poor.",
"      <br/>",
"      <br/>",
"      Older ground referenced systems had the potential for the current to take alternative routes to exit the patient, such as through an intravenous fluid pole lying up against the patient's arm and causing a burn at this site. Other contact points may include EKG leads, towel clips, stirrups, and temperature probes.",
"     </li>",
"     <li>",
"      Bipolar surgery &ndash; In bipolar surgery, the electrical current created in the ESU is confined to the tissue between the two electrodes of the surgical instrument. The electrodes may be tines of forceps, blades of scissors, or graspers. A separate return electrode (ie, dispersion pad) for the current to exit is not needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cutting and coagulation currents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgeon chooses the output setting for the ESU (",
"    <a class=\"graphic graphic_figure graphicRef51380 \" href=\"mobipreview.htm?33/30/34276\">",
"     figure 3",
"    </a>",
"    ). The main settings are 'cutting' and 'coagulation':",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutting mode &ndash; In the cutting mode, the ESU generates a continuous (or unmodulated), low-voltage current, concentrating the energy on a small area (high current density). The cutting mode results in more rapid tissue heating than the coagulation mode. If tissue is heated rapidly, the oscillation of the AC current causes intense vibration and heat within the cells, which leads them to explode and form smoke (plume). This is called vaporization, and is the mechanism whereby tissue is cut [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/5\">",
"       5",
"      </a>",
"      ]. To cut tissue, the tip of the electrode is held very near to the tissue, but not in direct contact, to concentrate current at the tip.",
"     </li>",
"     <li>",
"      Coagulation mode &ndash; In the coagulation mode, the ESU generates an interrupted (or modulated), high-voltage current, dispersed over a large surface area (low current density). As an example, the current may flow about 6 percent of the time and be off 94 percent of the time, and these proportions can be adjusted. The modulated current allows the tissue to cool slightly, so tissue heating is slower than with the cutting mode. This results in coagulation, which is a dehydration effect (loss of cellular fluid and protein denaturation) rather than vaporization. Dehydration is not as effective as vaporization for cutting tissue, but is ideal for sealing blood vessels. However, the modulated current requires a high power setting (higher voltage) to achieve dehydration, which causes more tissue damage and more thermal spread, increasing the risk of potential complications. For this reason, most authorities recommend that the cut setting be used most of the time, and reserve the coagulation setting for select circumstances, such as in a vascular environment where coagulation is important, and when dealing with tissue with poor conductivity, such as fatty tissue and dry tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/5\">",
"       5",
"      </a>",
"      ]. In these situations, the higher voltage on the coagulation setting provides better tissue penetration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, several \"blend\" options are available, combining various proportions of the two main modalities. These blends allow the enhancement of the ability of cutting currents to coagulate small bleeders during dissection, and coagulation currents to dissect tissue during hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Desiccation, vaporization, and fulguration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As electrical current comes in contact with tissue, heat is created because of the inherent resistance of tissue. Heat causes desiccation, vaporization, or fulguration, depending upon the ESU setting and the amount of contact between the tissue and surgical instrument.",
"   </p>",
"   <p>",
"    Desiccation can be produced using either the cutting or coagulation mode. It is produced by direct contact of the instrument and the tissue. Slow, superficial tissue heating results in protein denaturation, which causes the tissue to appear white. At higher temperatures, both dehydration and protein denaturation occur, resulting in desiccation. Tissue that is completely desiccated has very high resistance and does not conduct electrical current. Thus, loss of conductivity on the ESU's flow meter is an indication of complete desiccation, which is useful information during tubal sterilization or ablation of endometriosis implants. Continued application of heat with no or minimal tissue penetration results in superficial carbonization (char).",
"   </p>",
"   <p>",
"    Vaporization and fulguration are noncontact methods of electrosurgery. To cut tissue, the tip of the electrode is held at the tissue surface; the high heat generated by the current vaporizes tissue immediately adjacent to the tip of the electrode without the need to press the electrode against the tissue. Since the cells \"explode,\" no char is produced.",
"   </p>",
"   <p>",
"    The electrode is held a bit further away when fulgurating tissue; in this situation, electrical current (sparks) jumps or arcs between the electrode tip and the nearby tissue, which causes it to char. Fulguration is used to control bleeding over a wide area. Fulguration is a particularly useful technique to control diffuse bleeding from raw surfaces of solid vascular organs, such as the liver bed, following cholecystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Time, power, tissue, and electrode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shape and size of electrode, the time it is in contact with tissue (dwell time), the type of tissue, and the power setting of the ESU are other variables that impact electrosurgical results. The power output of the ESU is usually displayed in Watts (Watt = voltage times current). Generally, a surgeon should use the lowest possible power setting to effectively complete a procedure. A common initial setting for cutting and coagulation is 40 Watts, although there is wide individual surgeon preference and some surgeons have reported excellent results using a much higher initial setting for cutting (70 to 90 Watts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thermal spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Application of electrosurgery with different electrosurgical devices results in varying degrees of thermal spread. Thermal spread can cause tissue necrosis at the site of application, which may result in delayed healing and postoperative recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/7\">",
"     7",
"    </a>",
"    ]. Thermal spread can also cause injury to adjacent organs, eg, ureter, bladder, or bowel. It is therefore important for surgeons to understand the potential thermal spread from specific electrosurgical devices.",
"   </p>",
"   <p>",
"    One comparative study used monopolar and bipolar electrocautery, the Harmonic&reg; Scalpel and LigaSure on porcine muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/8\">",
"     8",
"    </a>",
"    ]. The degree of lateral thermal spread varied with instrument type, power setting and application time. Monopolar diathermy resulted in the highest temperatures and the greatest degree of thermal spread in tissues.",
"   </p>",
"   <p>",
"    The expected thermal spread from several devices that are commonly used in surgery are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditional bipolar device &ndash; 2 to 22 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ultrasonic cutting and coagulation device &ndash; 0 to 3 mm with the Harmonic Scalpel&reg; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/9,10,12,13\">",
"       9,10,12,13",
"      </a>",
"      ]; however, this is dependent on application time and setting, and thermal spread of up to 25 mm being reported in an animal model (with continuous ultrasonic dissection for 10 to 15 seconds at the highest level) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vessel sealing devices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      1.1 mm for the EnSeal&trade; Tissue Sealing and Hemostasis System [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      1.8 mm with the 10 mm LigaSure&trade; device to 4.4 mm with the 5 mm LigaSure&trade; device [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      6.3 mm with the Gyrus Plasma Trissector&trade;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One comparative study found less thermal spread with the EnSeal&reg; Tissue Sealing and Hemostasis System compared with the Gyrus Plasma Trissector&trade;, LigaSure&trade;, and SonoSurg&reg; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/15\">",
"     15",
"    </a>",
"    ]. However, another study found that the Harmonic Scalpel&reg; was associated with less thermal spread than EnSeal&reg; Tissue Sealing and Hemostasis System, LigaSure&trade;, or Gyrus Plasma Trissector&trade; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-quality comparative studies are needed to evaluate the relative thermal damage caused by each device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Smoke plume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The smoke plume generated by electrosurgical destruction of tissue contains potentially toxic substances. In high concentrations, these substances can irritate the eyes and respiratory tract of any individuals in the operating room, and can even transmit viruses. For this reason, smoke should be captured and evacuated using suction and smoke evacuation devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that the surgeon be aware of the principles discussed above, as different clinical situations require different usage of electrosurgical instruments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monopolar electrosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either the cutting (low voltage) or coagulation (high voltage) mode may be used to achieve the desired tissue effect. The cut mode is preferred when thermal spread is undesirable, such as in close proximity to the ureter, bowel or other vital structures. It might also be prudent to use the cut mode during desiccation of a deep endometriosis lesion since the electrical current penetrates deeper into the tissue during the cut mode. Due to higher voltage, the coagulation mode achieves better penetration through high-resistance areas, such as fatty tissue and scar tissue, and is also more applicable when fulgurating a large surface area with superficial bleeders, as might be encountered following ovarian cystectomy or laparoscopic cholecystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bipolar electrosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar electrosurgery is generally performed at low voltage (cutting mode) since tissue impedance is relatively low due to the proximity of the two electrodes. For this reason, these instruments are less effective for cutting tissue since adequate vaporization is difficult to achieve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/18\">",
"     18",
"    </a>",
"    ]. Attempts to cut tissue can result in excessive dehydration, rather than vaporization, causing the tissue to char and stick to the surgical instrument. One way to avoid this and to obtain better tissue penetration of energy is to apply the energy in a pulsatile fashion and to let go of the tissue just before stopping the flow of current.",
"   </p>",
"   <p>",
"    Bipolar electrosurgery is ideal when dealing with vascular areas or 3 to 7 mm blood vessels, such as the uterine artery. Effective hemostasis can be achieved by coapting and thermally welding the blood vessels. In contrast, monopolar energy disperses the electrical current in the intravascular fluid, causing inadequate tissue damage at the vessel lumen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/19\">",
"     19",
"    </a>",
"    ]. This creates a potentially dangerous situation, since the surgeon might think the vessel is sealed judging from its outer appearance, only to encounter brisk bleeding once the vessel is cut.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laparoscopic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrosurgery is commonly used during laparoscopic procedures. The instruments are longer and are passed through a trocar that can be made from metal, plastic, or both (hybrid). Monopolar electrosurgical instruments have an insulating layer, which is designed to protect the patient from inadvertent injury. The insulating layer is not foolproof, however, and electrosurgery during laparoscopy has certain inherent electrosurgical complications associated with it, most notably capacitive coupling (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/20\">",
"     20",
"    </a>",
"    ]. When electrosurgery is used near bowel, the surgeon should be aware of the potential for bowel injury which can present in a delayed manner. The use of electrosurgical devices in laparoscopic surgery is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14984?source=see_link\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hysteroscopic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of electrosurgery during hysteroscopic procedures had been limited to monopolar electrosurgery due to the conductive nature of normal saline. With the development of nonconductive distension media, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , and glycine, bipolar electrosurgery could be used for hysteroscopic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Further improvements in technology have enabled use of bipolar electrosurgery with normal saline as a distension medium instead of a hypotonic nonconductive media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/22\">",
"     22",
"    </a>",
"    ]. The advantage of using bipolar instruments with normal saline is the reduced risk of hyponatremia and other consequences of intravascular dilution as a result of the hypotonic distension media. The main disadvantages of using bipolar instruments are increased cost and possibly longer procedure times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Severe complications have also been reported to occur during bipolar hysteroscopic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrosurgery-related complications are relatively common, occurring in 2 to 5 per 1000 procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The complication rate appears to be related to surgical experience, reaching a plateau after approximately 60 procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most serious complications is injury to the small or large bowel, which can have fatal consequences, especially if undetected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Symptoms of bowel perforation secondary to thermal injury usually appear 4 to 10 days postoperatively, depending upon the severity of the coagulation necrosis. These injuries have distinct histopathological findings, which distinguish them from other causes of bowel perforation.",
"   </p>",
"   <p>",
"    As discussed above, a higher power setting (higher voltage) causes more tissue damage and more thermal spread, increasing the risk of potential complications. Surgeons need to keep this in mind when working close to structures, such as the bowel or ureter, which are prone to serious complications if subjected to thermal injury. Whitening of tissue surrounding the tip of the electrosurgical instrument suggests thermal spread. Looking at the bubbles that form during heating of tissue can help guide the application of energy. These bubbles represent water vapor; thus, the tissue is dry (desiccated) when the bubbles disappear, so it is time to stop the application of electrosurgical energy.",
"   </p>",
"   <p>",
"    Severe burns can occur if the dispersive electrode pad becomes partially detached from the patient as a result of increased current density on the smaller surface area of the skin. This problem can be averted with the use of a return electrode monitoring system (see below).",
"   </p>",
"   <p>",
"    Patients with electrical implants require special precautions, especially when using monopolar devices. Although many of these implants are designed to be shielded from electrical currents in the environment, it is prudent to use bipolar devices and check the function of the electrical implants during and after surgery.",
"   </p>",
"   <p>",
"    The surgeon may become a recipient of electrical current through",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    surgical gloves if they have a hole, or by capacitive coupling.",
"   </p>",
"   <p>",
"    Certain electrosurgical complications are more prevalent during laparoscopic surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct coupling &ndash; Direct coupling results from inadvertent contact of two noninsulated instruments (such as a metal trocar and a metal grasper). Electrical current flows from the primary to the secondary instrument, which acts as a second conductor. This can lead to severe injury if the second conductor is in contact with bowel or other sensitive structures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/1\">",
"       1",
"      </a>",
"      ]. In laparoscopic cholecystectomy, monopolar electrosurgical energy is associated with delayed, remote common bile duct injuries due to direct coupling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Capacitive coupling &ndash; Capacitive coupling is another threat during laparoscopic surgery, and has also been reported to occur during hysteroscopic monopolar surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/30\">",
"       30",
"      </a>",
"      ]. A capacitor is defined as two nearby conductors separated by a nonconducting medium. A prime example of a capacitor would be monopolar scissors with an insulation layer placed through a metal cannula. The alternating current flowing through the scissors induces unintended stray current in any conductor in close proximity with the monopolar instrument. The magnitude of the current induced depends on the proximity and insulation of the two conductors and the amount and duration of voltage used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/31\">",
"       31",
"      </a>",
"      ]. Hybrid trocar sleeves are prone to induce capacitive coupling, since the plastic locking anchor prevents the capacitive current from dissipating in the abdominal wall, resulting in electrical current passing through nearby structures, such as bowel (",
"      <a class=\"graphic graphic_picture graphicRef63495 \" href=\"mobipreview.htm?16/1/16401\">",
"       picture 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insulation failure &ndash; Insulation failure results from breakdown of the insulation covering the shaft of the active electrode (",
"      <a class=\"graphic graphic_picture graphicRef81831 \" href=\"mobipreview.htm?2/34/2593\">",
"       picture 2",
"      </a>",
"      ). This can happen during the sterilization process or during the surgical procedure. These defects are not rare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/32\">",
"       32",
"      </a>",
"      ]. Up to 20 percent of reusable laparoscopic instruments may have an insulation failure due to defects developed during handling and cleaning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/33\">",
"       33",
"      </a>",
"      ]. The distal one-third of the laparoscopic instrument is the most common site of insulation failure. Insulation failure can also occur from inappropriate repeated use of disposable equipment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTERVENTIONS TO ENHANCE SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several safety mechanisms have been developed to minimize the potential risks of electrosurgery. Nevertheless, no safety mechanism will replace sound surgical judgment and proper use of surgical instruments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Return electrode monitoring system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A return electrode monitoring system monitors the resistance between the patient's body and the dispersion pad, interrupting the power in case the contact area",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the conductivity are reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/1\">",
"     1",
"    </a>",
"    ]. This helps to prevent patient injury at the site of the dispersion pad.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Active electrode monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active electrode monitoring prevents electrosurgical burns due to stray currents by adding a second layer of insulation and a conductive sheath to the surgical instrument. The system continuously monitors stray currents and automatically shuts off the ESU if the amount or character of the stray currents becomes abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/34\">",
"     34",
"    </a>",
"    ]. This is the only safety tool that effectively prevents electrical burns from capacitive coupling and insulation failure that occur during the surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Computer-controlled tissue feedback systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest the use of an ammeter as a safety tool, since this can result in overzealous use of energy and potential complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/19\">",
"     19",
"    </a>",
"    ]. However, computer-controlled tissue feedback systems can be useful safety tools, since they can automatically sense tissue resistance and adjust the output voltage accordingly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/25\">",
"     25",
"    </a>",
"    ]. This can result in decreased use of energy and decreased thermal spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Visual inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monopolar instruments can be visually inspected for insulation failure prior to surgery. However, microscopic insulation defects can be missed, and, because of high current density, can cause severe burns. Visual inspection also will not prevent insulation failure during surgery, and will not prevent capacitive coupling from occurring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Testing wands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special testing wands that can detect even microscopic insulation defects have been developed; however, they do not prevent insulation failure from occurring during surgery and will not prevent capacitive coupling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Body piercing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there have been no reported electrosurgical injuries in the literature in relation to body piercing, the general recommendation is to remove umbilical and labial body piercing prior to surgery, as well as other metal objects that are close to the surgical site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/36\">",
"     36",
"    </a>",
"    ]. Theoretically, faulty instrument insulation can allow current to go from the surgical instrument to the metal object causing a skin burn. It is not necessary to remove piercing or other metal jewelry distant from the operative site, since these objects are too far away from the active electrode to receive substantial electrical current.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255197510\">",
"    <span class=\"h1\">",
"     PREVENTION OF ELECTROSURGICAL INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid the electrosurgical injuries discussed above, we suggest the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/1,2,34\">",
"     1,2,34",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255197517\">",
"    <span class=\"h2\">",
"     Monopolar surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use lowest possible power setting",
"     </li>",
"     <li>",
"      Use a low voltage waveform (cut)",
"     </li>",
"     <li>",
"      Use brief, intermittent activation",
"     </li>",
"     <li>",
"      Do not activate in open circuit",
"     </li>",
"     <li>",
"      Do not activate in close proximity or direct contact with another instrument",
"     </li>",
"     <li>",
"      Use bipolar electrosurgery where appropriate",
"     </li>",
"     <li>",
"      Use an all-metal or all-plastic cannula system (not metal-plastic hybrids)",
"     </li>",
"     <li>",
"      Use a return electrode monitoring system",
"     </li>",
"     <li>",
"      Use active electrode monitoring to eliminate concerns regarding insulation failure and capacitive coupling during hysteroscopic and laparoscopic electrosurgical procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the desired tissue effect is not achieved at usual power settings, the surgeon should check all of the equipment, including removing excessive char on the electrode, before increasing the power setting to high levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255197525\">",
"    <span class=\"h2\">",
"     Bipolar surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Terminate current at the end of vapor phase",
"     </li>",
"     <li>",
"      Apply current in pulsatile fashion",
"     </li>",
"     <li>",
"      Avoid the use of an in-line ammeter",
"     </li>",
"     <li>",
"      Alternate between desiccation and incision",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18157871\">",
"    <span class=\"h1\">",
"     ELECTROSURGERY AND IMPLANTABLE DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardiac implantable electronic device (CIED) refers to any permanently implanted cardiac pacemaker, implantable cardioverter defibrillator (ICD) or cardiac resynchronization device, or ventricular assist device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/37\">",
"     37",
"    </a>",
"    ]. Incomplete evaluation of patients with CIEDs can lead to adverse outcomes (eg, inhibited CIED function, asystole) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other implantable devices that use electric current and which may be affected by the use of electrosurgery include neurologic or spinal cord stimulators, and gastric neurostimulators (Enterra Therapy) used to treat gastroparesis. Limiting an interaction with these devices is desirable, though the consequences of malfunction with these devices are not immediately life-threatening as with CIEDs.",
"   </p>",
"   <p>",
"    The nature of the implanted cardiac device and the patient&rsquo;s level of dependence upon it should be determined preoperatively, typically with the aid of the patient&rsquo;s cardiologist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link&amp;anchor=H46#H46\">",
"     \"Pacing system malfunction: Evaluation and management\", section on 'Pacing system evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In more urgent or emergent circumstances, the device can be identified by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtaining the manufacturer&rsquo;s identification card from the patient",
"     </li>",
"     <li>",
"      Chest radiography",
"     </li>",
"     <li>",
"      Supplemental resources such as a manufacturer&rsquo;s database, pacemaker clinic record",
"     </li>",
"     <li>",
"      Consultation with a cardiology or pacemaker service",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anesthesia, in general, does not directly influence CIED function. However, ultrasound-guided techniques are preferred if the block will be in the vicinity of an implanted CIED, rather than using nerve stimulation techniques for administering peripheral nerve block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of peripheral nerve blocks\", section on 'Ultrasound guidance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H827041480\">",
"    <span class=\"h2\">",
"     Potential for electromagnetic interference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromagnetic interference (EMI) with CIEDs can occur as a result of inadequate attention to the manner in which electrosurgery is used during the procedure.",
"   </p>",
"   <p>",
"    The potential for EMI depends upon the distance between the electrodes, the pathway of current, and the frequency of electrosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/41\">",
"     41",
"    </a>",
"    ]. For bipolar electrosurgery, current flows between the tips of the forceps; stray currents are minimal. The main limitation of bipolar electrosurgery is its inability to cut tissue; however, where cutting is needed, a scalpel or ultrasonic shears can be used.",
"   </p>",
"   <p>",
"    For surgical procedures in which bipolar electrosurgery or ultrasonic shears are not appropriate, monopolar electrosurgery is the typical choice. During monopolar electrosurgery, current travels between the active electrode (hand-held instrument) to the dispersion pad, the position of which depends upon the nature of the procedure and extent and location of skin exposed for preparation. Care must be taken to ensure proper positioning and placement of the return electrode such that the return current path does not travel near the CIED generator or leads.",
"   </p>",
"   <p>",
"    For procedures in which the path between the tip of the electrosurgery pen and the dispersion pad does not cross the CIED generator or leads, the risk of interference is low. However, there can be some diffusion of current because it does not travel in a direct straight line from instrument to pad. The further away the operative field is from the CIED, the better. For example, if surgery is confined to the pelvis or lower extremity and the return electrode is placed on the buttock, the potential of EMI to a CIED in the chest is low. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Monopolar electrosurgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H827041883\">",
"    <span class=\"h2\">",
"     Potential harmful effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects include damage to the device, inability of the device to deliver pacing or shocks, lead-tissue interface damage, changes in pacing behavior, electrical reset to the backup pacing mode, or inappropriate ICD therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse clinical outcomes include, but are not limited to, hypotension, tachyarrhythmia or bradyarrhythmia, myocardial tissue damage, and myocardial ischemia or infarction. Other related outcomes may include extended hospital stay, delay or cancellation of surgery, readmission to manage device malfunction, and additional hospital resource utilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H827041487\">",
"    <span class=\"h2\">",
"     Prevention of electromagnetic interference",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the planned procedure is likely to interfere with the function of the pacemaker in an individual who is highly dependent upon the device, alternative methods of cautery and hemostasis can be used including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar electrosurgery &ndash; Bipolar electrosurgery minimizes the electrical field affecting the pacing system by limiting current between the tips of the forceps. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Bipolar electrosurgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasonic dissector &ndash; For tissue dissection and hemostasis of moderate size vessels, the ultrasonic dissector is an alternative to electrosurgery. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Ultrasonic cutting and coagulating device'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Topical hemostatic agents &ndash; A variety of topical agents can be used to effect hemostasis of small vessels, minimizing the use of electrosurgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17769?source=see_link\">",
"       \"Overview of topical hemostatic agents used in the operating room\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H827041562\">",
"    <span class=\"h2\">",
"     Preparing for a potential interaction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with a CIED should be monitored with continuous electrocardiographic and peripheral pulse monitoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/39,42\">",
"       39,42",
"      </a>",
"      ]. The electrocardiographic signal will often display interference from EMI which can make detection of pacemaker malfunction difficult. Thus, peripheral perfusion, most commonly a pulse oximetry plethysmograph or invasive arterial waveform, should be monitored as well.",
"     </li>",
"     <li>",
"      Temporary pacing and defibrillation equipment should be immediately available before, during, and after the procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"       \"Temporary cardiac pacing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=see_link\">",
"       \"Basic principles and technique of cardioversion and defibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preoperative management of the CIED function may include reprogramming to an asynchronous pacing mode, disabling any special algorithms and suspending anti-tachyarrhythmia functions, if present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/39\">",
"       39",
"      </a>",
"      ]. The need for reprogramming should be determined by the anesthesiologist in conjunction with a cardiology service. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link&amp;anchor=H27#H27\">",
"       \"Pacing system malfunction: Evaluation and management\", section on 'Electromagnetic interference'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A magnet should be available in the operating room. Clinical magnets, when appropriately positioned over the CIED site, can change pacing to an asynchronous mode in pacemakers, and suspend tachycardia therapies in implantable cardiac defibrillators. However, responses of CIEDs to magnet application can be variable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/43\">",
"       43",
"      </a>",
"      ]. Magnets should not be routinely used over an implantable cardiac defibrillator (ICD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link&amp;anchor=H24#H24\">",
"       \"Pacing system malfunction: Evaluation and management\", section on 'Magnet application'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     EMERGING TECHNOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several developments in electrosurgical technology have been emerging in the last few years and include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tissue link floating ball",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Tissue link floating ball is a saline-cooled, high-density monopolar probe used for dissection and coagulation. The continuous flow of saline maintains the surface temperature below 100&ordm;C, which prevents tissue charring. Therefore, the device achieves a greater depth of tissue coagulation and hemostasis compared with electrosurgery without saline cooling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, smoke formation and tissue sticking are reduced. Surgical devices using this technology have been made for both open and laparoscopic surgery. The device has been used for hepatic and pulmonary resections with good preliminary results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], and may have a role in the resection of gynecologic cancers, myomectomy, and following ovarian cystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Bipolar vessel sealing devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bipolar vessel sealing system (LigaSure&trade;) applies a precise amount of bipolar energy and pressure to fuse collagen and elastin within the vessel walls. This results in a permanent seal that can withstand three times the normal systolic pressure, and seals vessels up to 7 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/47\">",
"     47",
"    </a>",
"    ]. The sealing is achieved with minimal sticking and charring; thermal spread to adjacent tissues is approximately 2 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/12\">",
"     12",
"    </a>",
"    ]. The generator for this device uses a feedback-controlled response system to ensure adequate tissue sealing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/47\">",
"     47",
"    </a>",
"    ]. The LigaSure&trade; system has been used successfully in a variety of procedures, such as vaginal hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/48\">",
"     48",
"    </a>",
"    ] and laparoscopic oncology surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/49\">",
"     49",
"    </a>",
"    ]. The LigaSure&trade; device has been used effectively in laparoscopic colectomy, hepatectomy, and even splenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The main disadvantage in using this system over standard bipolar technology is cost, especially since these devices are disposable. Nondisposable devices that use similar technology have been introduced with promising initial results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     PlasmaKinetic tissue management system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another system employing advanced bipolar technology is the PlasmaKinetic tissue management system. This system delivers pulsed bipolar energy through the instrument to the tissue, allowing intermittent tissue cooling, which limits lateral thermal spread and tissue sticking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/35\">",
"     35",
"    </a>",
"    ]. The system has an instrument identification feature that automatically detects the optimal settings for the specific instrument, as well as an impedance monitor with visual and audible tissue impedance indicators. The system has two different modes, the vapor-pulse coagulation mode and the PlasmaKinetic tissue-cutting mode. In the vapor-pulse mode, high energy is delivered to grasped tissue, creating vapor zones. The current then travels around the high-impedance vapor zones, following the path of least resistance. The vapor zones subsequently collapse, and with each new energy pulse more and more tissue between the instrument jaws is coagulated, ultimately resulting in uniform coagulation of tissue. The PlasmaKinetic tissue-cutting mode allows the surgeon to cut tissue using bipolar energy, which allows for simultaneous cutting and coagulation of tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     EnSeal&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;This system provides vessel sealing by combining a compression mechanism with thermal energy control in a bipolar sealing device. The instrument is capable of achieving seal strengths up to seven times the normal systolic pressures on vessels up to 7 mm with a typical thermal spread of approximately 1 mm. Although there have been few publications about this device in the medical literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], it is already in widespread use among surgeons.",
"   </p>",
"   <p>",
"    The compression mechanism applies uniform pressure along the full length of the instrument jaw, achieving compression forces similar to those of a linear stapler. Compression is combined with controlled energy delivery utilizing NanoPolar&trade; thermostats to reach collagen denaturation temperatures in seconds, which are maintained at approximately 100&ordm;C throughout the power delivery cycle. The device also has a cutting mechanism to allow one-step sealing and transection of vessels and soft tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ALTERNATIVE ENERGY SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two important alternative energy sources, the harmonic scalpel and lasers, will be discussed briefly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Ultrasonic cutting and coagulating device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultrasonic cutting and coagulating surgical device (eg, Harmonic Scalpel&reg;) converts ultrasonic energy into mechanical energy at the functional end of the instrument. A piezoelectric crystal in the handpiece generates vibration at the tip of the active blade at 55,500 times per second over a variable excursion of 50 to 100 micrometers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/57\">",
"     57",
"    </a>",
"    ]. This results in rupture of hydrogen bonds and produces heat, which leads to denaturation of proteins and, eventually, separation of tissue. These effects are reached at tissue temperatures of 60 to 80&ordm;C, resulting in coagulum formation without the desiccation and charring caused by temperatures of 80&ordm;C and higher associated with traditional electrosurgical methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The harmonic scalpel has been used successfully in a number of open and laparoscopic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The advantages of this technology include minimal thermal spread, decreased tissue charring and smoke formation when compared with traditional electrosurgical instruments, and no risk of electrical injury due to the absence of electrical current within the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/57,61\">",
"     57,61",
"    </a>",
"    ]. It is also a versatile instrument, allowing the surgeon to dissect, cut, and coagulate using one instrument.",
"   </p>",
"   <p>",
"    \"Clipless\" laparoscopic cholecystectomy refers to a procedure in which the cystic artery and duct are divided and sealed with the Harmonic Scalpel&reg;, which is also used to dissect the gallbladder from the liver bed. One randomized trial found shorter operative times and fewer gallbladder perforations performing a \"clipless\" laparoscopic cholecystectomy, compared with conventional laparoscopy with clips on the duct and artery and monopolar electrocautery to dissect the gallbladder from the liver bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/62\">",
"     62",
"    </a>",
"    ]. There were no bile leaks in the \"clipless\" group. \"Clipless\" laparoscopic cholecystectomy has also been used safely in patients with acutely inflamed gallbladders and in those with cirrhosis with good results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main disadvantages are: the limited ability to coagulate vessels larger than 3 to 5 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/65\">",
"     65",
"    </a>",
"    ], increased cost of disposable instruments, potential for extensive thermal spread at high energy levels (level 5) for more than five seconds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/14\">",
"     14",
"    </a>",
"    ], and the user-dependent nature of the instrument. The surgeon has to be able to modify surgical technique when using this instrument, depending on the tissue type and the wanted effect.",
"   </p>",
"   <p>",
"    The instrument has five levels, with most generators being preset to use level 3 for cutting and level 5 for coagulation. The difference between level settings is the blade excursion length, with longer excursion on higher levels. When the blade travels longer distances with each vibration, more heat is generated and the mechanical effect is more pronounced, resulting in faster separation of tissue and decreased coagulation ability. The amount of tissue tension is also of crucial importance, and inexperienced surgeons can develop an initial aversion to using this instrument, having placed too much tension on a vascular pedicle, allowing premature tissue separation and bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light Amplification and Stimulated Emission of Radiation (LASER) is a commonly used alternative to electrosurgery, and offers a precise application of energy without the inherent risks of lateral tissue damage and stray current associated with standard electrosurgery. Laser energy is generated when electrons jump from higher to lower energy levels during their circuits around the nucleus. The energy created induces molecular vibration and thermal energy upon contact with the target tissue.",
"   </p>",
"   <p>",
"    The laser consists of an energy source, a",
"    <span class=\"nowrap\">",
"     gating/focusing",
"    </span>",
"    mechanism and radiating medium. The type of medium (as an example, carbon dioxide [CO",
"    <sub>",
"     2",
"    </sub>",
"    ], argon, potassium-titanium-phosphate [KTP], neodymium:yttrium aluminum garnet [NdYAG]) determines the wavelength emitted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/66\">",
"     66",
"    </a>",
"    ]. The CO",
"    <sub>",
"     2",
"    </sub>",
"    laser passes from the generator through a series of mirrors to the target tissue, allowing the surgeon to change the spot size for a desired effect. The argon, KTP and NdYAG lasers use quartz fibers for delivery of the beam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although lasers are widely used in ophthalmologic and dermatologic surgery, their popularity in general and gynecologic surgery may have declined somewhat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/68\">",
"     68",
"    </a>",
"    ], possibly due to the advent of alternative energy sources. Some useful applications of laser energy in gynecologic surgery include cervical conization, laparoscopic excision of endometriosis, and treatment of vulvar intraepithelial neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37737/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In monopolar surgery, electrical current goes through the patient to complete the current cycle, while in bipolar surgery, the current only goes through the tissue in between the two electrodes of the instrument. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Monopolar versus bipolar'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cut mode on the electrosurgical unit generates a continuous, low-voltage current, concentrating the energy over a small area. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cutting and coagulation currents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The coagulation mode on the electrosurgical unit generates an interrupted, high-voltage current, dispersed over a large surface area. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cutting and coagulation currents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fulguration and vaporization are noncontact methods of monopolar electrosurgery, while",
"      <span class=\"nowrap\">",
"       desiccation/coagulation",
"      </span>",
"      is a direct contact method of monopolar electrosurgery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Desiccation, vaporization, and fulguration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaporization results from rapid heating in the cut mode with intense vibration and heat within the cells, which causes the cell to explode and form smoke (plume). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Desiccation, vaporization, and fulguration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fulguration is caused by an interrupted current (coagulation mode), causing slower tissue heating and less-focused tissue effect. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Desiccation, vaporization, and fulguration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cut mode is preferred when thermal spread is undesirable, such as when the electrosurgical device is in close proximity to vital structures. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The coagulation mode is better suited for fatty tissue and scar tissue, and when fulgurating a large surface area with superficial bleeding. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bipolar electrosurgery is ideal when dealing with vascular areas or large blood vessels, such as the uterine artery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Bipolar electrosurgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The disappearance of water vapor is a good guide for deciding when to stop the application of bipolar electrosurgical energy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A return electrode monitoring system and active electrode monitoring are important safety tools during monopolar electrosurgery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Interventions to enhance safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several modern alternatives to traditional electrosurgery, such as the LigaSure&trade;, EnSeal&reg; and the harmonic scalpel, can be valuable additions to a surgeon's armamentarium. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Emerging technology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/1\">",
"      Massarweh NN, Cosgriff N, Slakey DP. Electrosurgery: history, principles, and current and future uses. J Am Coll Surg 2006; 202:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/2\">",
"      Mayooran Z, Pearce S, Tsaltas J, et al. Ignorance of electrosurgery among obstetricians and gynaecologists. BJOG 2004; 111:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/3\">",
"      Tucker RD. Laparoscopic electrosurgical injuries: survey results and their implications. Surg Laparosc Endosc 1995; 5:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/4\">",
"      Tucker RD, Schmitt OH, Sievert CE, Silvis SE. Demodulated low frequency currents from electrosurgical procedures. Surg Gynecol Obstet 1984; 159:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/5\">",
"      Wu MP, Ou CS, Chen SL, et al. Complications and recommended practices for electrosurgery in laparoscopy. Am J Surg 2000; 179:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/6\">",
"      Redwine DB, Wright JT. Laparoscopic treatment of complete obliteration of the cul-de-sac associated with endometriosis: long-term follow-up of en bloc resection. Fertil Steril 2001; 76:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/7\">",
"      Lu S, Xiang J, Qing C, et al. Effect of necrotic tissue on progressive injury in deep partial thickness burn wounds. Chin Med J (Engl) 2002; 115:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/8\">",
"      Sutton PA, Awad S, Perkins AC, Lobo DN. Comparison of lateral thermal spread using monopolar and bipolar diathermy, the Harmonic Scalpel and the Ligasure. Br J Surg 2010; 97:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/9\">",
"      Matthews BD, Pratt BL, Backus CL, et al. Effectiveness of the ultrasonic coagulating shears, LigaSure vessel sealer, and surgical clip application in biliary surgery: a comparative analysis. Am Surg 2001; 67:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/10\">",
"      Landman J, Kerbl K, Rehman J, et al. Evaluation of a vessel sealing system, bipolar electrosurgery, harmonic scalpel, titanium clips, endoscopic gastrointestinal anastomosis vascular staples and sutures for arterial and venous ligation in a porcine model. J Urol 2003; 169:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/11\">",
"      Kinoshita T, Kanehira E, Omura K, et al. Experimental study on heat production by a 23.5-kHz ultrasonically activated device for endoscopic surgery. Surg Endosc 1999; 13:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/12\">",
"      Goldstein SL, Harold KL, Lentzner A, et al. Comparison of thermal spread after ureteral ligation with the Laparo-Sonic ultrasonic shears and the Ligasure system. J Laparoendosc Adv Surg Tech A 2002; 12:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/13\">",
"      Phillips CK, Hruby GW, Durak E, et al. Tissue response to surgical energy devices. Urology 2008; 71:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/14\">",
"      Emam TA, Cuschieri A. How safe is high-power ultrasonic dissection? Ann Surg 2003; 237:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/15\">",
"      Abstracts of the Global Congress of Minimally Invasive Gynecology, 34th Annual Meeting of the American Association of Gynecologic Laparoscopists, Chicago, Illinois, USA, November 9-12, 2005. J Minim Invasive Gynecol 2005; 12:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/16\">",
"      Campbell PA, Cresswell AB, Frank TG, Cuschieri A. Real-time thermography during energized vessel sealing and dissection. Surg Endosc 2003; 17:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/17\">",
"      Lamberton GR, Hsi RS, Jin DH, et al. Prospective comparison of four laparoscopic vessel ligation devices. J Endourol 2008; 22:2307.",
"     </a>",
"    </li>",
"    <li>",
"     Munro, M. Energy sources for operative laparoscopy. In: Diagnostic and Operative Gynecologic Laparoscopy, Gomel, V, Taylor, PJ (Eds), Mosby-Year Book, St Louis 1995. p. 26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/19\">",
"      Brill AI. Energy systems for operative laparoscopy. J Am Assoc Gynecol Laparosc 1998; 5:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/20\">",
"      LeBlanc KA. Laparoscopic incisional and ventral hernia repair: complications-how to avoid and handle. Hernia 2004; 8:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/21\">",
"      Sutton C. Hysteroscopic surgery. Best Pract Res Clin Obstet Gynaecol 2006; 20:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/22\">",
"      Vilos GA. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (Versapoint): a pilot study. Fertil Steril 1999; 72:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/23\">",
"      Berg A, Sandvik L, Langebrekke A, Istre O. A randomized trial comparing monopolar electrodes using glycine 1.5% with two different types of bipolar electrodes (TCRis, Versapoint) using saline, in hysteroscopic surgery. Fertil Steril 2009; 91:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/24\">",
"      Bradley LD. Complications in hysteroscopy: prevention, treatment and legal risk. Curr Opin Obstet Gynecol 2002; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/25\">",
"      Nduka CC, Super PA, Monson JR, Darzi AW. Cause and prevention of electrosurgical injuries in laparoscopy. J Am Coll Surg 1994; 179:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/26\">",
"      Hulka JF, Levy BS, Parker WH, Phillips JM. Laparoscopic-assisted vaginal hysterectomy: American Association of Gynecologic Laparoscopists' 1995 membership survey. J Am Assoc Gynecol Laparosc 1997; 4:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/27\">",
"      Peterson HB, Ory HW, Greenspan JR, Tyler CW Jr. Deaths associated with laparoscopic sterilization by unipolar electrocoagulating devices, 1978 and 1979. Am J Obstet Gynecol 1981; 139:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/28\">",
"      Krebs HB. Intestinal injury in gynecologic surgery: a ten-year experience. Am J Obstet Gynecol 1986; 155:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/29\">",
"      Humes DJ, Ahmed I, Lobo DN. The pedicle effect and direct coupling: delayed thermal injuries to the bile duct after laparoscopic cholecystectomy. Arch Surg 2010; 145:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/30\">",
"      Vilos GA, Newton DW, Odell RC, et al. Characterization and mitigation of stray radiofrequency currents during monopolar resectoscopic electrosurgery. J Minim Invasive Gynecol 2006; 13:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/31\">",
"      Vilos G, Latendresse K, Gan BS. Electrophysical properties of electrosurgery and capacitive induced current. Am J Surg 2001; 182:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/32\">",
"      Yazdani A, Krause H. Laparoscopic instrument insulation failure: the hidden hazard. J Minim Invasive Gynecol 2007; 14:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/33\">",
"      Montero PN, Robinson TN, Weaver JS, Stiegmann GV. Insulation failure in laparoscopic instruments. Surg Endosc 2010; 24:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/34\">",
"      Vancaillie TG. Active electrode monitoring. How to prevent unintentional thermal injury associated with monopolar electrosurgery at laparoscopy. Surg Endosc 1998; 12:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/35\">",
"      Presthus JB, Brooks PG, Kirchhof N. Vessel sealing using a pulsed bipolar system and open forceps. J Am Assoc Gynecol Laparosc 2003; 10:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/36\">",
"      Jacobs VR, Morrison JE Jr, Paepke S, Kiechle M. Body piercing affecting laparoscopy: perioperative precautions. J Am Assoc Gynecol Laparosc 2004; 11:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/37\">",
"      American Society of Anesthesiologists. Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators: an updated report by the american society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices. Anesthesiology 2011; 114:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/38\">",
"      Purday JP, Towey RM. Apparent pacemaker failure caused by activation of ventricular threshold test by a magnetic instrument mat during general anaesthesia. Br J Anaesth 1992; 69:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/39\">",
"      Bernstein AD, Irwin ME, Parsonnet V, et al. Report of the NASPE Policy Conference on antibradycardia pacemaker follow-up: effectiveness, needs, and resources. North American Society of Pacing and Electrophysiology. Pacing Clin Electrophysiol 1994; 17:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/40\">",
"      Manickam BP, Brull R. Implications of a permanent cardiac pacemaker in peripheral nerve blockade. Reg Anesth Pain Med 2009; 34:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/41\">",
"      Chauvin M, Crenner F, Brechenmacher C. Interaction between permanent cardiac pacing and electrocautery: the significance of electrode position. Pacing Clin Electrophysiol 1992; 15:2028.",
"     </a>",
"    </li>",
"    <li>",
"     American Society of Anesthesiologists: Standards for basic anesthetic monitoring. In ASA Standards, Guidelines and",
"Statements, American Society of Anesthesiologists Publication, October 5&ndash; 6, 1999",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/43\">",
"      Jacob S, Panaich SS, Maheshwari R, et al. Clinical applications of magnets on cardiac rhythm management devices. Europace 2011; 13:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/44\">",
"      Pearson, M, McClurken, M, Thompson, R. Saline enhanced thermal sealing of tissue. Potential for bloodless surgery. Min Invas Ther Allied Technol 2002; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/45\">",
"      Di Carlo I, Barbagallo F, Toro A, et al. Hepatic resections using a water-cooled, high-density, monopolar device: a new technology for safer surgery. J Gastrointest Surg 2004; 8:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/46\">",
"      Yim AP, Rendina EA, Hazelrigg SR, et al. A new technological approach to nonanatomical pulmonary resection: saline enhanced thermal sealing. Ann Thorac Surg 2002; 74:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/47\">",
"      Kennedy JS, Stranahan PL, Taylor KD, Chandler JG. High-burst-strength, feedback-controlled bipolar vessel sealing. Surg Endosc 1998; 12:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/48\">",
"      Levy B, Emery L. Randomized trial of suture versus electrosurgical bipolar vessel sealing in vaginal hysterectomy. Obstet Gynecol 2003; 102:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/49\">",
"      Dubuc-Lissoir J. Use of a new energy-based vessel ligation device during laparoscopic gynecologic oncologic surgery. Surg Endosc 2003; 17:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/50\">",
"      Rimonda R, Arezzo A, Garrone C, et al. Electrothermal bipolar vessel sealing system vs. harmonic scalpel in colorectal laparoscopic surgery: a prospective, randomized study. Dis Colon Rectum 2009; 52:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/51\">",
"      Ikeda M, Hasegawa K, Sano K, et al. The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg 2009; 250:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/52\">",
"      Romano F, Gelmini R, Caprotti R, et al. Laparoscopic splenectomy: ligasure versus EndoGIA: a comparative study. J Laparoendosc Adv Surg Tech A 2007; 17:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/53\">",
"      Richter S, Kollmar O, Schilling MK, et al. Efficacy and quality of vessel sealing: comparison of a reusable with a disposable device and effects of clamp surface geometry and structure. Surg Endosc 2006; 20:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/54\">",
"      Wang CJ, Yuen LT, Yen CF, et al. Comparison of the efficacy of the pulsed bipolar system and conventional bipolar electrosurgery in laparoscopically assisted vaginal hysterectomy. J Laparoendosc Adv Surg Tech A 2005; 15:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/55\">",
"      Sahin DA, Kusaslan R, Sahin O, et al. Comparison of Ligasure, SurgRx, and suture techniques in intra-abdominal adhesions that occur after liver resection in rats: an experimental study. Int Surg 2007; 92:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/56\">",
"      Sahin DA, Kusaslan R, Sahin O, et al. Histopathological effects of bipolar vessel sealing devices on liver parenchyma and comparison with suture method: an experimental study. Eur Surg Res 2007; 39:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/57\">",
"      McCarus SD. Physiologic mechanism of the ultrasonically activated scalpel. J Am Assoc Gynecol Laparosc 1996; 3:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/58\">",
"      Amaral JF. The experimental development of an ultrasonically activated scalpel for laparoscopic use. Surg Laparosc Endosc 1994; 4:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/59\">",
"      Gil-Moreno A, Puig O, P&eacute;rez-Benavente MA, et al. Total laparoscopic radical hysterectomy (type II-III) with pelvic lymphadenectomy in early invasive cervical cancer. J Minim Invasive Gynecol 2005; 12:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/60\">",
"      Ou CS, Harper A, Liu YH, Rowbotham R. Laparoscopic myomectomy technique. Use of colpotomy and the harmonic scalpel. J Reprod Med 2002; 47:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/61\">",
"      Amaral, JF, Chrostek, C. Depth of thermal injury: Ultrasonically activated scalpel vs electrosurgery. Surg Endosc 1995; 9:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/62\">",
"      Kandil T, El Nakeeb A, El Hefnawy E. Comparative study between clipless laparoscopic cholecystectomy by harmonic scalpel versus conventional method: a prospective randomized study. J Gastrointest Surg 2010; 14:323.",
"     </a>",
"    </li>",
"    <li>",
"     El Nakeeb, A, Askar, W, El Lithy, R, Farid, M. Clipless laparoscopic cholecystectomy using the harmonic scalpel for cirrhotic patients: a prospective randomized study. Surg Endosc 2010; Epub ahead of print.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/64\">",
"      Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for acute cholecystitis operated with harmonic scalpel. Surg Laparosc Endosc Percutan Tech 2009; 19:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/65\">",
"      Bubenik LJ, Hosgood G, Vasanjee SC. Bursting tension of medium and large canine arteries sealed with ultrasonic energy or suture ligation. Vet Surg 2005; 34:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/66\">",
"      Verdaasdonk RM, van Swol CF. Laser light delivery systems for medical applications. Phys Med Biol 1997; 42:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/67\">",
"      Singh S, Maxwell D. Tools of the trade. Best Pract Res Clin Obstet Gynaecol 2006; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/68\">",
"      Lanzafame RJ. Laser use and research in gastroenterology, gynecology, and general surgery: a status report. J Clin Laser Med Surg 2001; 19:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/69\">",
"      Ueda M, Ueki K, Kanemura M, et al. Diagnostic and therapeutic laser conization for cervical intraepithelial neoplasia. Gynecol Oncol 2006; 101:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/70\">",
"      Sutton CJ, Ewen SP, Jacobs SA, Whitelaw NL. Laser laparoscopic surgery in the treatment of ovarian endometriomas. J Am Assoc Gynecol Laparosc 1997; 4:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37737/abstract/71\">",
"      Penna C, Fallani MG, Fambrini M, et al. CO2 laser surgery for vulvar intraepithelial neoplasia. Excisional, destructive and combined techniques. J Reprod Med 2002; 47:913.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2890 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37737=[""].join("\n");
var outline_f36_54_37737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Monopolar versus bipolar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cutting and coagulation currents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Desiccation, vaporization, and fulguration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Time, power, tissue, and electrode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thermal spread",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Smoke plume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monopolar electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bipolar electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laparoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hysteroscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTERVENTIONS TO ENHANCE SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Return electrode monitoring system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Active electrode monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Computer-controlled tissue feedback systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Visual inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Testing wands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Body piercing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255197510\">",
"      PREVENTION OF ELECTROSURGICAL INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255197517\">",
"      Monopolar surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H255197525\">",
"      Bipolar surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18157871\">",
"      ELECTROSURGERY AND IMPLANTABLE DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H827041480\">",
"      Potential for electromagnetic interference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H827041883\">",
"      Potential harmful effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H827041487\">",
"      Prevention of electromagnetic interference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H827041562\">",
"      Preparing for a potential interaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      EMERGING TECHNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tissue link floating ball",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Bipolar vessel sealing devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PlasmaKinetic tissue management system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      EnSeal&reg;",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ALTERNATIVE ENERGY SOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Ultrasonic cutting and coagulating device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Laser",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2890\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2890|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/14/16610\" title=\"figure 1\">",
"      Basic effects of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/51/13119\" title=\"figure 2\">",
"      Monopolar electrosurgical instrument",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/30/34276\" title=\"figure 3\">",
"      Tissue damage in monopolar electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2890|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/1/16401\" title=\"picture 1\">",
"      Capacitive coupling in electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/34/2593\" title=\"picture 2\">",
"      Laparoscopic electocautery insulation failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14984?source=related_link\">",
"      Devices for dissection and hemostasis in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17769?source=related_link\">",
"      Overview of topical hemostatic agents used in the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=related_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_54_37738="Treatment of aneurysmal subarachnoid hemorrhage";
var content_f36_54_37738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of aneurysmal subarachnoid hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Robert J Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Christopher S Ogilvy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/54/37738/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/54/37738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid hemorrhage (SAH) is often a devastating event. Approximately 10 percent of patients die prior to reaching the hospital while only one-third will have a \"good result\" after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/1\">",
"     1",
"    </a>",
"    ]. Therapeutic advances have added to the armamentarium for treating this malignant process. A reduction of case-fatality rates from 1971 to 2002 in one study and from 1981 to 1986 and 2002 to 2008 in another study may reflect an improved approach to management over these time periods.",
"   </p>",
"   <p>",
"    The treatment of SAH is reviewed here. Other aspects of this illness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysmal SAH is associated with a high morbidity and mortality. Mortality within the first 30 days approaches 50 percent and is attributed largely to the effects of initial and recurrent bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important predictive factors for acute prognosis after SAH include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level of consciousness and neurologic grade on admission",
"     </li>",
"     <li>",
"      Patient age (inverse correlation)",
"     </li>",
"     <li>",
"      Amount of blood on initial head computed tomography (CT) scan (inverse correlation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperglycemia is also associated with a poor outcome after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. In addition, SAH appears to be a risk factor for infectious and noninfectious fever, which in turn is associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that contribute to an unfavorable outcome after SAH are cerebral infarction and symptomatic vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/4\">",
"     4",
"    </a>",
"    ]. Some, but not all, evidence suggests that anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    red blood cell transfusions may also be associated with a worse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/12-15\">",
"     12-15",
"    </a>",
"    ], as well as renal",
"    <span class=\"nowrap\">",
"     insufficiency/failure",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of grading systems are used in practice to standardize the clinical classification of patients with SAH based upon the initial neurologic examination. The grading system proposed by Hunt and Hess (",
"    <a class=\"graphic graphic_table graphicRef69179 \" href=\"mobipreview.htm?8/57/9115\">",
"     table 1",
"    </a>",
"    ) and that of the World Federation of Neurological Surgeons (WFNS) (",
"    <a class=\"graphic graphic_table graphicRef65468 \" href=\"mobipreview.htm?13/56/14219\">",
"     table 2",
"    </a>",
"    ) are among the most widely used. The WFNS system incorporates the Glasgow Coma scale (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 3",
"    </a>",
"    ) combined with the presence of motor deficit.",
"   </p>",
"   <p>",
"    The Fisher grade is an index of vasospasm risk based upon a CT-defined hemorrhage pattern (",
"    <a class=\"graphic graphic_table graphicRef81122 \" href=\"mobipreview.htm?8/36/8779\">",
"     table 4",
"    </a>",
"    ), and the Claassen grading system is a similar index of the risk of delayed cerebral ischemia due to vasospasm (",
"    <a class=\"graphic graphic_table graphicRef57558 \" href=\"mobipreview.htm?12/19/12603\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A system proposed by Ogilvy and Carter stratifies patients based upon age, Hunt and Hess grade, Fisher grade, and aneurysm size (",
"    <a class=\"graphic graphic_table graphicRef70705 \" href=\"mobipreview.htm?29/55/30587\">",
"     table 6",
"    </a>",
"    ). In addition to predicting outcome, this scale more accurately substratifies patients for therapy.",
"   </p>",
"   <p>",
"    Grading scales for subarachnoid hemorrhage are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/406?source=see_link\">",
"     \"Subarachnoid hemorrhage grading scales\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient presenting with aneurysmal subarachnoid hemorrhage (SAH) is admitted to an intensive care setting for constant hemodynamic monitoring. Patients are given stool softeners, kept at bedrest, and given analgesia to diminish hemodynamic fluctuations and lower the risk of rebleeding. Transcranial Doppler (TCD) ultrasonography measurements are taken and used as a baseline as the patient progresses through treatment; serial TCD is used to monitor for vasospasm. The institution of measures to prevent and treat vasospasm is of major importance. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Nimodipine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention of vasospasm'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of vasospasm'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Deep venous thrombosis (DVT) prophylaxis with pneumatic compression stockings is started prior to aneurysm treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/17\">",
"     17",
"    </a>",
"    ]. Subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    5000 units three times daily can be added for DVT prophylaxis once the aneurysm is treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antithrombotic discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few data, most experts favor reversal of all anticoagulation for acute SAH until the aneurysm is definitively repaired by surgery or coiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association issued in 2006 recommend that all anticoagulants and antiplatelet agents should be discontinued after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, the guidelines recommend that any anticoagulant effect should be reversed immediately with appropriate agents such as vitamin K, fresh frozen plasma, or unactivated prothrombin complex concentrate, which is also called factor IX complex. We use the therapeutic approach that is recommended for warfarin-associated intracerebral hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Initial treatment plan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    can be added for DVT prophylaxis once the aneurysm is treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intracranial pressure and blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SAH often develop increased intracranial pressure (ICP) that is usually due to acute hydrocephalus and reactive hyperemia after hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H21#H21\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Increased ICP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With increased ICP, cerebral perfusion may be impaired. Cerebral perfusion pressure (CPP) equals the mean arterial pressure (MAP) minus the ICP. Thus, increases in MAP may be the only means to maintain CPP at a level necessary to maintain perfusion. One study&rsquo;s results suggest that this CPP threshold may be 70 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/21\">",
"     21",
"    </a>",
"    ]. On the other hand, elevated blood pressure can worsen a SAH since the mechanical force across the plugged bleeding site is related to the difference between the systemic blood pressure and the cerebrospinal fluid (CSF) pressure.",
"   </p>",
"   <p>",
"    The optimal therapy of hypertension in SAH is not clear. While lowering blood pressure may decrease the risk of rebleeding, this benefit may be offset by an increased risk of infarction. The importance of these factors was illustrated in a report of 134 patients with subarachnoid hemorrhage, 80 of whom received antihypertensive therapy to lower the diastolic pressure below 100 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients given antihypertensive therapy had a lower incidence of rebleeding (15 versus 33 percent) that was offset by a higher incidence of infarction (43 versus 22 percent).",
"   </p>",
"   <p>",
"    We generally place a ventriculostomy in appropriate patients; this allows direct measurement of intracranial pressure and often drops systemic blood pressure into the normal range. In the absence of ICP measurement, antihypertensive therapy is often withheld unless there is a severe elevation in blood pressure because of concern about cerebral ischemia and the frequent compensatory nature of acute hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/23\">",
"     23",
"    </a>",
"    ]. The patient&rsquo;s cognitive status may be a useful guide; if the patient is alert, then CPP is adequate, and lowering the blood pressure may decrease the risk of rerupture; we typically keep the systolic blood pressure in such patients below 140 mmHg. In contrast, antihypertensive therapy is generally withheld in those with a severely impaired level of consciousness since the impairment may be due to a reduced CPP.",
"   </p>",
"   <p>",
"    The use of hypertonic saline has been evaluated in patients with elevated ICP related to traumatic brain injury and appears to lower ICP and may improve CPP (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35882?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of acute severe traumatic brain injury\", section on 'Osmotic therapy'",
"    </a>",
"    ). A small observational study in 16 patients with poor-grade SAH suggests that it may also be useful in this setting; but further study is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When blood pressure control is necessary, the use of vasodilators such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    should be",
"    <strong>",
"     avoided",
"    </strong>",
"    because of their propensity to increase cerebral blood volume and therefore intracranial pressure.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nimodipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    was initially used in patients with SAH to prevent vasospasm. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention of vasospasm'",
"    </a>",
"    below.) However, despite the vasodilatory effects of nimodipine on cerebral vessels, there is no convincing evidence that nimodipine affects the incidence of either angiographic or symptomatic vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. Nevertheless, nimodipine has been demonstrated to improve outcomes in SAH and is the standard of care in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/25-28,31-33\">",
"     25-28,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of seven randomized trials of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    administered for SAH noted the following benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       Nimodipine",
"      </a>",
"      treatment compared with placebo improved the odds of a good outcome after SAH by 1.86 (99% CI 1.07-3.25).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       Nimodipine",
"      </a>",
"      reduced the odds of deficit, mortality, or both attributed to vasospasm by 0.46, and it reduced the infarction rate on CT by 0.58 (99% CI 0.38-0.90).",
"     </li>",
"     <li>",
"      Overall mortality was slightly reduced in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       nimodipine",
"      </a>",
"      group, but the trend was not statistically significant.",
"     </li>",
"     <li>",
"      The treatment effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       nimodipine",
"      </a>",
"      in individual trials was positively correlated with the severity of SAH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 1998 systematic review found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    treatment compared with placebo was associated with a 24 percent relative risk reduction of poor outcome (95% CI 12-38) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/30\">",
"     30",
"    </a>",
"    ]. The number needed to treat (NNT) with nimodipine to prevent one poor outcome was 13 (95% CI 8-30). A similar conclusion was reached by a 2007 meta-analysis of calcium antagonists for aneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/34\">",
"     34",
"    </a>",
"    ], where the benefits of calcium antagonists depended largely on one large trial of nimodipine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     Nimodipine",
"    </a>",
"    is marketed as a cerebral selective drug. Nevertheless, blood pressure fluctuations are common after administration. Thus, blood pressure monitoring is essential to avoid hypotension and decreased cerebral perfusion pressure. Nimodipine can also temporarily reduce brain tissue pO2 in patients with poor grade SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/35\">",
"     35",
"    </a>",
"    ], although the clinical importance of this property is unknown.",
"   </p>",
"   <p>",
"    The mechanism of benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    in SAH is unknown. Putative mechanisms include neuroprotection via reduction of calcium-dependent excitotoxicity, diminished platelet aggregation, dilation of small arteries not visible on angiograms, inhibition of ischemia triggered by red blood cell products, or some combination of these actions.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     Nimodipine",
"    </a>",
"    is ideally administered within four days of SAH. The typical dose is 60 mg every four hours by mouth or nasogastric tube. Nimodipine must be given orally; inadvertent intravenous administration has been associated with serious adverse events, including death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physiologic derangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic derangements occur frequently in the acute phase of SAH and might worsen the diffuse brain injury. A cohort study of 413 patients identified four variables that were independently associated with increased risk of death or disability three months after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoxemia (arterio-alveolar gradient &gt;125 mmHg)",
"     </li>",
"     <li>",
"      Metabolic acidosis (serum bicarbonate &lt;20",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Hyperglycemia (serum glucose &gt;180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [10",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Cardiovascular instability (MAP of &lt;70 or &gt;130 mmHg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Correction of these physiologic derangements in patients with SAH is suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/17\">",
"     17",
"    </a>",
"    ], although no studies have confirmed the benefit of such treatments. One study found that the use of an aggressive hyperglycemia management protocol appeared to improve glycemic control and neurologic outcomes; however the use of a historical control group limits the validity of this study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Seizure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antiepileptic drugs (AEDs) to prevent seizures in patients with SAH has been a widely debated topic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/38\">",
"     38",
"    </a>",
"    ]. Many experts believe that seizure prophylaxis in the setting of an unsecured aneurysm is reasonable, given the relatively low risk associated with AED administration versus the potential deleterious effects of seizures on an already dysautoregulated brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/3,39\">",
"     3,39",
"    </a>",
"    ]. However, evidence from a large case series suggests that AED exposure may be associated with worse neurologic and cognitive outcome after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/40\">",
"     40",
"    </a>",
"    ]. Therefore, the use of AEDs for seizure prophylaxis after SAH should probably be minimized whenever possible.",
"   </p>",
"   <p>",
"    The decision to treat with antiepileptic agents can be based upon the distribution of blood on axial imaging studies. A lower impetus to start antiepileptic agents is warranted in the setting of perimesencephalic blood without cortical layering, since this pattern of hemorrhage is associated with a particularly good prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continuation of AED therapy may not be necessary in most patients after undergoing aneurysmal clipping following a SAH, especially those without acute seizures who present with a good grade (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Antiepileptic drug therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antifibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , epsilon",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ) have been investigated in the prevention of rebleeding after aneurysmal SAH. A meta-analysis of nine trials concluded that although antifibrinolytic treatment reduces the risk of rebleeding (odds ratio [OR] 0.55, 95% CI 0.42-0.71), it does not show any evidence of reducing poor outcome defined as death, vegetative state, or severe disability (OR 1.12, 95% CI 0.88-1.43) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In earlier trials this lack of overall benefit appeared to be due to an increased risk of cerebral ischemia in patients treated with antifibrinolytic agents.",
"   </p>",
"   <p>",
"    In one subsequently published randomized clinical trial involving 505 patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    was administered immediately after SAH diagnosis and discontinued when the aneurysm was occluded (all within 72 hours, 70 percent within 24 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/43\">",
"     43",
"    </a>",
"    ]. Rebleeding was lower in the treated group (2.4 versus 10.8 percent). However, there was no significant impact on clinical outcomes (mortality, Glasgow Outcome Score) at six months.",
"   </p>",
"   <p>",
"    There are ongoing studies investigating a potential role for other hemostatic agents (eg, the thrombin inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    ) in aneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy for cerebral injury remains controversial. There is some justification for using glucocorticoids in the setting of SAH because of their putative effects on cerebral edema, prevention of vasospasm, and delayed hydrocephalus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/39\">",
"     39",
"    </a>",
"    ]. However, limited evidence from available clinical trials supports neither a beneficial nor adverse effect of glucocorticoids for the treatment of aneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION OF VASOSPASM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant vasospasm occurs in approximately 20 to 30 percent of patients with aneurysmal SAH, and it is thought to be related to spasmogenic substances generated during the lysis of subarachnoid blood clots [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/46\">",
"     46",
"    </a>",
"    ]. It typically begins no earlier than day three after hemorrhage, reaching a peak at days seven to eight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H15#H15\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Vasospasm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vasospasm is manifested clinically by a decline in neurologic status including the onset of focal neurologic abnormalities. It is the leading cause of death and disability after aneurysm rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/46\">",
"     46",
"    </a>",
"    ]. Treatment of vasospasm can be difficult (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of vasospasm'",
"    </a>",
"    below). Thus, prevention is important.",
"   </p>",
"   <p>",
"    The theoretical concern that nicotine replacement therapy may be associated with increased vasospasm after aneurysmal subarachnoid hemorrhage was not substantiated in an observational study of 258 patients with SAH who were also active smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/47\">",
"     47",
"    </a>",
"    ]. Treatment was associated with similar incidence of angiographic vasospasm, a lower rate of clinical vasospasm and better Glasgow Outcome Scores on discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hyperdynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following aneurysmal occlusion, hyperdynamic therapy, including modest hemodilution, induced hypertension (with pressor agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    or dopamine), and hypervolemia (so-called \"triple-H\" therapy), has been used to try to prevent vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. A systematic review of triple-H therapy for prophylaxis of vasospasm found that there were few well-designed prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/50\">",
"     50",
"    </a>",
"    ]; the reviewers concluded that despite wide confidence intervals, the results from two studies did suggest some benefit of triple-H therapy on reduction of symptomatic vasospasm and mortality.",
"   </p>",
"   <p>",
"    A subsequent analysis identified only one truly randomized trial and one quasi-randomized trial of volume expansion therapy in patients with aneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/51\">",
"     51",
"    </a>",
"    ]. Both trials were small, and no beneficial effect of prophylactic volume expansion was found. A preliminary study suggested that use of sophisticated hemodynamic monitoring of cardiac output may improve the efficacy of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach may be more appropriately used in the treatment rather than the prevention of symptomatic vasospasm. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of vasospasm'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While the routine use of hypervolemic therapy remains of unproven benefit in the prophylactic treatment of patients with aneurysmal SAH, hypovolemia is a risk factor for ischemic complications and should be",
"    <strong>",
"     avoided",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other methods to prevent vasospasm may be used at the time of surgery in patients with SAH.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 28 patients who underwent surgery within 72 hours of the onset of severe SAH received a cisternal infusion of urokinase after aneurysm clipping in an effort to diminish clot size [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/54\">",
"       54",
"      </a>",
"      ]. No symptomatic vasospasm occurred in any patients, and the treatment was safe.",
"     </li>",
"     <li>",
"      A randomized trial of intrathecal urokinase infusion into the cisterna magna in patients with SAH who had been treated with coil embolization also showed a significant decrease in symptomatic vasospasm and a lower rate of permanent neurologic deficits but had no impact on mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early cisternal cerebrospinal fluid (CSF) washout during the operative repair may reduce the incidence of vasospasm and hydrocephalus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/56\">",
"       56",
"      </a>",
"      ]. CSF irrigation cannot be performed with endovascular therapy. However, the incidence of symptomatic vasospasm appears to be similar after treatment with surgery or coiling, despite the inability to perform CSF irrigation with coiling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pleiotropic effects of statin therapy appear promising for vasospasm prevention, based upon the potential to improve cerebral vasomotor reactivity by upregulating endothelial nitric oxide synthase, increase cerebral blood flow, and attenuate vasculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings from at least three small randomized placebo-controlled trials suggest that statin treatment is beneficial for preventing vasospasm and improving outcome after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. These trials randomly assigned patients to either statin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40 mg daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    80 mg daily) or placebo within 48 to 96 hours after aneurysmal SAH; treatment was continued for 14 to 21 days.",
"   </p>",
"   <p>",
"    A meta-analysis of these trials included a total of 158 patients; only three were receiving statins prior to SAH. Most patients received concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    . The investigators reported that statin treatment reduced the incidence of radiologically confirmed clinical vasospasm (RR 0.73), the incidence of delayed ischemic deficits (RR 0.38), and mortality (RR 0.22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the strength of this meta-analysis was limited by small numbers of patients and events. In addition, the included studies used different definitions of vasospasm, and the statistical test of heterogeneity for the primary outcome (incidence of vasospasm) was significant, suggesting that it may not be appropriate to combine the included studies for this outcome. A subsequently reported meta-analysis found no effect of statin therapy on the risk of transcranial Doppler vasospasm, delayed cerebral ischemia, poor neurologic outcome, or mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, larger placebo-controlled trials are still needed to confirm that statin treatment is effective therapy for SAH. Nevertheless, given the available data suggesting benefit and the relative safety of statins, we suggest initiating statin treatment within 48 hours of aneurysmal SAH and continuing until discharge from intensive care. In addition, we suggest continuing statin therapy after SAH for patients who were taking statins prior to SAH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents are under investigation for the prevention of vasospasm after SAH, including endothelin receptor antagonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    prolonged-release implants, and statins.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endothelin (ET) receptor antagonists - Endothelin 1 (ET1) is a 21 amino acid peptide that acts as a direct and potent vasoconstrictor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. The action of ET1 is mediated mainly through two major endothelin receptors, ET-A and ET-B. ET-A receptors are located on vascular smooth muscle cells where they mediate both vasoconstriction and smooth muscle cell proliferation. In comparison, ET-B receptors are found primarily on vascular endothelial cells and mediate vasodilation via the release of endothelium-derived nitric oxide. ET-B receptors are also located on vascular smooth muscle cells where they mediate vasoconstriction.",
"      <br/>",
"      <br/>",
"      The investigational drug clazosentan is a specific ET receptor antagonist that has a much higher affinity for the ET-A than the ET-B receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. Clazosentan therefore potently inhibits the ET-A receptor-mediated vasoconstriction effect of ET1 and minimally inhibits the ET-B receptor-mediated vasodilation.",
"      <br/>",
"      <br/>",
"      In a phase II randomized, double-blind, controlled trial of 413 patients with aneurysmal SAH, all doses of clazosentan (1, 5, and 15",
"      <span class=\"nowrap\">",
"       mg/hour)",
"      </span>",
"      significantly reduced the incidence of angiographically evident moderate or severe vasospasm in a dose-dependent manner compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/71\">",
"       71",
"      </a>",
"      ]. However, clazosentan did not improve morbidity and mortality. This trial, with the results of two other smaller trials (one of clazosentan and the other a mixed",
"      <span class=\"nowrap\">",
"       ET-A/B",
"      </span>",
"      antagonist TAK-044), were combined in a meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/72\">",
"       72",
"      </a>",
"      ]. Again, the results showed that treatment reduced delayed ischemic deficits and angiographic vasospasm but did not impact overall morbidity and mortality. Potential benefits of treatment may have been offset in part by an increase in adverse effects: pulmonary complications, hypotension, and anemia.",
"      <br/>",
"      <br/>",
"      Another trial is planned to determine whether clazosentan is effective for improving vasospasm-related outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      therapy has been proposed as a means to prevent vasospasm based upon its efficacy in preventing neurologic complications in pregnant women with eclampsia. A small study of 40 patients with SAH found a trend toward improved outcomes in patients treated with magnesium compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/74\">",
"       74",
"      </a>",
"      ], and a subsequent randomized controlled trial involving 283 patients with SAH found a reduced risk of delayed cerebral ischemia in those assigned to magnesium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/75\">",
"       75",
"      </a>",
"      ], but these differences were not statistically significant. A double-blind randomized trial in 327 patients with aneurysmal SAH showed no significant differences in clinical outcomes between patients treated with magnesium sulfate and those receiving placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/76\">",
"       76",
"      </a>",
"      ]. A post hoc analysis of this study found that higher mean plasma magnesium concentrations were actually associated with worse clinical outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/77\">",
"       77",
"      </a>",
"      ]. Another randomized study of intravenous magnesium sulfate in 110 patients with aneurysmal SAH found that treatment was associated with a reduced incidence of radiologic infarction but there was no difference in clinical outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"       Nicardipine",
"      </a>",
"      prolonged-release implants (NPRIs) are polymers that are loaded with nicardipine and implanted into the basal cisterns, in contact with the large arteries of the circle of Willis, thus permitting local delivery of constant high doses of nicardipine to the intracranial vessels. In a preliminary randomized controlled trial, implantation of NPRIs was associated with a significant reduction in angiographic vasospasm, and improved clinical outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF ANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After aneurysmal SAH, the patient is at substantial risk of rebleeding: 3 to 4 percent in the first 24 hours and 1 to 2 percent each day in the first month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/2\">",
"     2",
"    </a>",
"    ]. Rerupture is associated with a mortality that is estimated to be 70 percent. Aneurysm repair is the only effective treatment to prevent this occurrence. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Early rebleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgery has been the mainstay of therapy of intracranial aneurysms, however, endovascular techniques are becoming more widely used. In the future, gene therapy combined with endovascular techniques may offer improved results for aneurysm treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management of cerebral aneurysms is an effective and safe procedure with the evolution of microsurgical techniques in the hands of an experienced surgeon. Placement of a clip across the neck of the aneurysm remains the treatment of choice for most aneurysms (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68084 \" href=\"mobipreview.htm?27/1/27668\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Temporary vessel occlusion using cerebroprotective techniques such as hypothermia, induced hypertension, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , has greatly facilitated safe dissection near the aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/81\">",
"     81",
"    </a>",
"    ]. Temporary clip occlusion may be achieved via traditional extraluminal clip placement or with an intravascular balloon. Intraoperative angiography is a useful diagnostic adjunct to micro Doppler sonography in confirming parent vessel patency after clip occlusion.",
"   </p>",
"   <p>",
"    A protocol employing immediate ventriculostomy placement, aneurysm clipping (if intracranial pressure was less than or equal to 30 mmHg without an intracranial clot or less than or equal to 50 mmHg in the presence of a clot), and aggressive postoperative hypertensive, hypervolemic, and hemodilutional therapy was evaluated in 35 patients with poor-grade aneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/82\">",
"     82",
"    </a>",
"    ]. The outcome was reported as good in 19 patients (54 percent), fair in 4 (11 percent), and poor in 4 (11 percent); eight patients (23 percent) died. In contrast, 19 poor-grade patients who received no surgical treatment survived a mean of 32 hours with 100 percent mortality. This aggressive approach to therapy in patients with poor grade aneurysmal SAH was supported in another report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/83\">",
"     83",
"    </a>",
"    ]. It should be emphasized, however, that the data available reflects the experience of large cerebrovascular centers with abundant experience and support for the management of this exceedingly tenuous patient population.",
"   </p>",
"   <p>",
"    Operative risks associated with aneurysm treatment include new or worsened neurologic deficits caused by brain retraction, temporary arterial occlusion, and intraoperative hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. Procedure-related surgical complications occurred in 29 (20 percent) of 143 patients in a retrospective series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/87\">",
"     87",
"    </a>",
"    ], although functional outcome was good in 22 (76 percent) of those patients. Treatment at specialized neurosurgical centers performing high volumes of cerebral aneurysm procedures is associated with better outcome compared with treatment at lower volume centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite laboratory evidence of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/81\">",
"     81",
"    </a>",
"    ] and widespread use in clinical practice, intraoperative hypothermia does not appear to improve neurologic outcome after surgery for intracranial aneurysm clipping. A randomized clinical trial of 1001 patients with \"good grade\" SAH found no benefit on any outcome measure for patients randomly assigned to intraoperative hypothermia compared with those assigned to normothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Endovascular therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in biopolymers and image chain devices have allowed the intraluminal approach to cerebral aneurysms to emerge as a safe and often effective alternative to surgical clipping. The Guglielmi electrolytically detachable coil system was introduced in the early 1990s for the treatment of these lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/90\">",
"     90",
"    </a>",
"    ]. The platinum coil is inserted into the lumen of the aneurysm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80064 \" href=\"mobipreview.htm?27/43/28340\">",
"     image 2",
"    </a>",
"    ). A local thrombus then forms around the coils, obliterating the aneurysmal sac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/91\">",
"     91",
"    </a>",
"    ]. Aneurysms with broad necks, a low neck-to-fundus ratio, distal segment lesions, and a number of giant aneurysms are not amenable to endovascular therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/92\">",
"     92",
"    </a>",
"    ]; surgical therapy is preferred in these circumstances.",
"   </p>",
"   <p>",
"    Endovascular therapy compares favorably to surgery in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. As an example, a prospective, randomized study of 109 patients with acute (less than 72 hours) subarachnoid hemorrhage due to a ruptured aneurysm found that significantly better primary angiographic results occurred after surgery in patients with anterior cerebral artery aneurysm, but after endovascular therapy in patients with posterior circulation aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/95\">",
"     95",
"    </a>",
"    ]. Technique related mortality was lower in the endovascular therapy group (2 versus 4 percent). There was no difference in clinical outcome at three months between the two groups.",
"   </p>",
"   <p>",
"    Another prospective study found that clinical and neuropsychological outcomes were similar at one year in patients treated within 72 hours of an acute subarachnoid hemorrhage with either surgery or endovascular therapy; most aneurysms in both groups were in the anterior and middle cerebral artery circulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of coils will undoubtedly rise as the number of experienced interventionalists increases. Some have argued that coiling will gradually replace surgical clipping for nearly all aneurysmal treatment as the endovascular technology advances and that this transition has already occurred to a large extent in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/97\">",
"     97",
"    </a>",
"    ]. Questions remain, however, regarding the long-term efficacy of intraluminal occlusions. Most follow-up studies to this point are in the range of a few years; complete aneurysm obliteration rates are generally cited to be 80 percent or greater.",
"   </p>",
"   <p>",
"    Thromboembolism can complicate the endovascular coiling. In one series, this occurred in 12.5 percent of endovascularly-treated aneurysms; aneurysm size &gt;10mm and neck size &gt;4mm were risk factors for this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/98\">",
"     98",
"    </a>",
"    ]. While of unproven benefit, some combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiplatelet therapy is used in most centers to minimize sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/99\">",
"     99",
"    </a>",
"    ]. In one large series, 9.3 percent of patients experienced a thromboembolic event during coiling despite use of heparin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/100\">",
"     100",
"    </a>",
"    ]. Rescue treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    appeared safe and effective; no patients experienced a bleeding complication and 29 of 42 patients did not suffer a clinical or radiologic infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intraprocedural aneurysm rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysm rupture during surgical clipping or endovascular coil embolization is associated with an increased risk of poor outcome.",
"   </p>",
"   <p>",
"    In the CARAT study, intraprocedural aneurysmal rupture occurred in 15 percent of 1010 patients with aneurysmal SAH treated either with surgical clipping (711) or coil embolization (299) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/101\">",
"     101",
"    </a>",
"    ]. Periprocedural death or disability was more likely in those with this complication (34 versus 17 percent). Intraprocedural rupture was more frequent in those tripped with clipping than in those treated with coiling (19 versus 5 percent), but secondary mortality and morbidity was similar in both groups. Other studies have shown similar rates of intraprocedural rupture during endovascular coiling of 4 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/98,102\">",
"     98,102",
"    </a>",
"    ]. In one study, risks were higher for middle cerebral artery aneurysms and in patients with hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Timing and choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding the timing and choice of therapy in the treatment of a rupture intracranial aneurysm are ideally made by a team of experienced surgeons and endovascular practitioners. Factors important to consider include the neurologic grade and clinical status of the patient, the availability of expertise in surgical and endovascular techniques, as well as the anatomic characteristics of the aneurysm, including the location and the size of the aneurysm and its neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/2,103\">",
"     2,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of surgery following intracranial aneurysm rupture is an area of controversy. The potential benefits of early surgery (within 48 to 72 hours of the hemorrhage) include prevention of rebleeding and management of vasospasm. The usual methods of treating vasospasm (hypervolemia, induced hypertension, intraarterial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    , and balloon angioplasty) are dangerous in the presence of an untreated aneurysm. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Early rebleeding'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of vasospasm'",
"    </a>",
"    below.) On the other hand, early surgery may be more complicated than a procedure delayed for 10 to 14 days; the presence of cerebral edema (which may prevent brain retraction and relaxation) and clot around the aneurysm increases the technical difficulty of surgery. Early surgery may also be associated with an increased risk of ischemic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early aneurysm repair in patients with good grade aSAH (Hunt and Hess grades 1 to 3) (",
"    <a class=\"graphic graphic_table graphicRef69179 \" href=\"mobipreview.htm?8/57/9115\">",
"     table 1",
"    </a>",
"    ) is a generally accepted treatment with a satisfying outcome in the large majority of patients. Approximately 70 to 90 percent of patients have a good neurologic recovery, with a mortality rate of 1.7 percent to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/105\">",
"     105",
"    </a>",
"    ]. Limited clinical trial evidence suggests that early aneurysm surgery may be associated with a lower risk of rebleeding and better outcome than later surgery, but the results did not achieve statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/106\">",
"     106",
"    </a>",
"    ]. Observational studies, which are limited by selection bias, suggest that early intervention is associated with better outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of patients with good grade aSAH may do well, or even better, with endovascular coiling. In the International Subarachnoid Aneurysm Trial (ISAT), 2143 patients with ruptured intracranial aneurysms were randomly assigned to neurosurgical clipping or endovascular coiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Significantly fewer patients undergoing coiling were dependent or dead at one year compared with patients undergoing surgical clipping (23.5 versus 30.9 percent), with an absolute risk reduction of 7.4 percent (95% CI 3.6-11.2) favoring coiling. The main difference between the two treatment groups was in the category of \"significant restriction in lifestyle,\" not in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/110\">",
"     110",
"    </a>",
"    ]. Mortality rates at one year among patients assigned to endovascular and neurosurgical treatment were 8.0 percent (95% CI 6.4-9.8) and 9.9 percent (95% CI 8.2-11.9), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/109\">",
"     109",
"    </a>",
"    ]. The risk of post-treatment seizures was significantly lower in the endovascular group compared with the neurosurgery group (relative risk 0.52, 95% CI 0.37-0.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/109\">",
"     109",
"    </a>",
"    ]. Post-treatment rebleeding from the target aneurysm was more common in the endovascular therapy group than the surgical group during the first year (2.6 versus 1.0 percent). Few rebleeding events occurred in either treatment group after one year, but again were more common in the endovascular therapy group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/111\">",
"     111",
"    </a>",
"    ]. However, within eight years rebleeding rates become similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/112\">",
"     112",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44806?source=see_link\">",
"     \"Late recurrence of subarachnoid hemorrhage and intracranial aneurysms\"",
"    </a>",
"    ). In a 12-month assessment of patients in the ISAT trial, the prevalence of epilepsy and cognitive impairment were less common in patients treated by endovascular coiling than surgical clipping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients randomized in ISAT represented a selected subgroup in which 88 percent were of good clinical status, 90 percent of the target aneurysms were smaller than 10 mm in diameter, and 95 percent of aneurysms were in the anterior circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/109\">",
"     109",
"    </a>",
"    ]; the results can only be applied to patients that fit these general characteristics, which is a small percentage of patients presenting with SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/108\">",
"     108",
"    </a>",
"    ]. Nevertheless, for such patients, endovascular coiling should be considered if expertise to perform the procedure is available on an emergency basis.",
"   </p>",
"   <p>",
"    Early surgery in patients with Hunt and Hess grades IV and V aneurysms (",
"    <a class=\"graphic graphic_table graphicRef69179 \" href=\"mobipreview.htm?8/57/9115\">",
"     table 1",
"    </a>",
"    ) is difficult due to excessive cerebral edema, and the outlook for these patients has traditionally been dismal. Endovascular techniques also may offer a less invasive and often definitive mode of therapy for this group; the concerns regarding the increased difficulty of early surgery do not apply to intraluminal therapy. Although not substantiated by any large series, the use of intravascular embolization of aneurysms in the acute setting may facilitate aggressive medical management algorithms for proactive treatment of cerebral vasospasm (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of vasospasm'",
"    </a>",
"    below). Definitive surgical clipping can be performed later if the aneurysm is not completely obliterated. Some data suggest that aneurysm occlusion in such patients (particularly if associated with advanced age and medical comorbidity) may not improve their overall prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/114\">",
"     114",
"    </a>",
"    ]. Treatment decisions need to be individualized with consultation with family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Posttreatment management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are managed in the intensive care unit after aneurysm therapy. Continuous cardiodynamic and neurologic monitoring is critical. Postoperative angiography is used at the surgeons&rsquo; discretion. Patients should have monitoring and treatment for vasospasm as outlined. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention of vasospasm'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of vasospasm'",
"    </a>",
"    below.) Aggressive physical, occupational, and, when necessary, speech therapy evaluations should be obtained as soon as possible in order to assess long-term physical and cognitive requirements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of complications is an important aspect of SAH management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/17\">",
"     17",
"    </a>",
"    ]. However, complications still occur and must be treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment of vasospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     Nimodipine",
"    </a>",
"    treatment reduces poor outcome associated with vasospasm but does not prevent or treat the vasospasm itself (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention of vasospasm'",
"    </a>",
"    above). Aggressive therapy is often necessary when symptomatic vasospasm occurs.",
"   </p>",
"   <p>",
"    An important prognostic distinction must be made between angiographic vasospasm, which is seen in 30 to 70 percent of angiograms performed at day seven after SAH, and clinical or symptomatic vasospasm, which is seen in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/46,115,116\">",
"     46,115,116",
"    </a>",
"    ]. Symptomatic vasospasm (that associated with a clinical decline) portends a poorer prognosis and may not be identifiable on cerebral angiography; microperforator spasm defies the resolution of even state-of-the-art angiography. Isolated angiographic vasospasm traditionally has not been treated. However, angiography is increasingly being used to identify patients with symptomatic vasospasm who might benefit from therapies such as intraluminal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    , a smooth muscle relaxant, or angioplasty. In one series in which angiograms were performed systematically in 381 patients 9&plusmn;2 days after aneurysmal SAH, the presence and severity of vasospasm correlated with the presence of cerebral infarction on CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aggressive therapy of vasospasm can only be pursued after the aneurysm has been treated with surgery or intraluminal therapy. Following aneurysmal occlusion, hyperdynamic therapy, including modest hemodilution, induced hypertension (with pressor agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    or dopamine), and hypervolemia (so-called \"triple-H\" therapy), is instituted in an effort to raise the mean arterial pressure and thereby increase cerebral perfusion. Volume expansion is achieved via crystalloid or colloid solution dependent upon physician preference. While this treatment approach has not been evaluated in randomized clinical trials, in case series of patients with symptomatic vasospasm, hyperdynamic therapy has been associated with improved cerebral blood flow and reversal of ischemia in more than half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. The evidence for a benefit from hemodilution is weaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/2\">",
"     2",
"    </a>",
"    ]. This approach does not appear to be helpful as a prophylaxis against vasospasm. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention of vasospasm'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Refractory vasospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasospasm that persists despite triple-H therapy has been treated successfully in some cases by percutaneous intraarterial angioplasty or by the intraarterial administration of vasodilators.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of angioplasty found dramatic, moderate, and minimal or nonexistent clinical improvement after 12, 11, and 9 procedures, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vasodilators reported as effective for improving vasospasm in case series include intraarterial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/121\">",
"       121",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/122\">",
"       122",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"       papaverine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/123-125\">",
"       123-125",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       nimodipine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/126\">",
"       126",
"      </a>",
"      ], and intrathecal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/127\">",
"       127",
"      </a>",
"      ]. Intraarterial papaverine and angioplasty also may be used in combination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/124\">",
"       124",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite a lack of clinical trial evidence, balloon angioplasty has become the mainstay of treatment at many centers for symptomatic vasospasm that is refractory to aggressive medical therapy, particularly for focal vasospasm of larger vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. Diffuse vasospasm involving smaller arterial branches may be more amenable to IA infusion of vasodilators, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Cervical sympathetic block at the level of the superior cervical ganglion was studied in nine patients, six of whom were conscious prior to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/130\">",
"     130",
"    </a>",
"    ]. The six conscious patients all had complete resolution of symptoms; two of the three comatose patients had transient improvements, but all three eventually died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus is a common complication of SAH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H20#H20\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Hydrocephalus'",
"    </a>",
"    .) Although data are scant, surgical and endovascular treatments appear to be associated with comparable risks of developing shunt-dependent hydrocephalus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ventricular drain placement can improve the clinical grade of patients presenting with SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/2\">",
"     2",
"    </a>",
"    ]. Drainage should be considered for patients who have a deteriorating level of consciousness and for those in whom no improvement in hydrocephalus occurs within 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/132\">",
"     132",
"    </a>",
"    ]. External drainage of CSF is often complicated by ventriculitis, particularly when drainage is continued for more than three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/133\">",
"     133",
"    </a>",
"    ]. Although earlier reports suggested that the frequency of rebleeding was increased with external ventricular drainage for acute hydrocephalus after aneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/133,134\">",
"     133,134",
"    </a>",
"    ], these studies had methodologic limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/135\">",
"     135",
"    </a>",
"    ], and later reports have found no association of external drainage with the risk of rebleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for long term CSF diversion can be assessed on a subacute basis after appropriate treatment of the aneurysm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia following SAH may be due to inappropriate secretion of antidiuretic hormone (SIADH) or rarely, to cerebral salt-wasting; these are physiologically distinct and are treated differently.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebral salt-wasting is less common than SIADH in this setting and is characterized by volume depletion, which leads to the release of ADH. It is usually treated with infusions of isotonic saline. Restoration of euvolemia will suppress the release of ADH. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8567?source=see_link\">",
"       \"Cerebral salt-wasting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with SIADH are euvolemic. While therapy of asymptomatic hyponatremia in SIADH usually consists of water restriction, fluid restriction is not desirable in patients with SAH as it increases the risk of vasospasm-related ischemic injury. Thus, hyponatremia is treated with isotonic saline, or, if necessary, hypertonic saline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/137\">",
"       137",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hyperdynamic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=see_link\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A protocol for managing hyponatremia in this setting is presented in the Table (",
"      <a class=\"graphic graphic_table graphicRef65772 \" href=\"mobipreview.htm?37/26/38315\">",
"       table 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Early rebleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rebleeding is associated with a poor prognosis. In a prospective study involving 574 hospitalized patients admitted within 14 days of SAH, rebleeding was associated with a 12-fold reduction in the probability of survival with functional independence at three months (odds ratio 0.08, 95% CI 0.02-0.34) after correction for admission Hunt-Hess grade and aneurysm size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/138\">",
"     138",
"    </a>",
"    ]. In one case series, half of hemorrhage expansions were related to rerupture of the aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/139\">",
"     139",
"    </a>",
"    ]. Other mechanisms of hemorrhage expansion or rebleeding may be similar to those for intracerebral hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link&amp;anchor=H5#H5\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Hematoma growth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only aneurysm treatment is effective in preventing rebleeding. Various strategies short of surgery have been attempted to decrease the risk of rebleeding following SAH, including induced hypotension and antifibrinolytic therapy. Both of these strategies have proven unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/41,140\">",
"     41,140",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment of aneurysms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Antifibrinolytic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Rebleeding can occur after aneurysm treatment. In the CARAT study, 1000 patients treated with coil embolization or surgical clipping at high-volume centers in the United States were followed for a mean of four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/141\">",
"     141",
"    </a>",
"    ]. The risk of rerupture was associated with the degree of aneurysm occlusion after treatment, ranging from 1.1 percent in 760 patients with complete aneurysm occlusion, to 2.9 percent in 173 patients with 91 to 99 percent aneurysm occlusion, 5.9 percent in 51 patients with 70 to 90 percent occlusion, and 17.6 percent in 17 patients with &lt;70 percent occlusion. In contrast to the randomized ISAT trial, this study did not find that the risk of rerupture was greater after treatment with coil embolization than with surgical clipping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Timing and choice of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Antiepileptic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptic drugs are usually continued for approximately six months in patients who have experienced an acute seizure (within seven days) following SAH, although there are no strict guidelines. Agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    are typically used.",
"   </p>",
"   <p>",
"    The incidence of late epilepsy (more than two weeks after surgery) after surgical management of SAH is unclear. In a retrospective report of 472 patients with aneurysmal SAH who had undergone surgical clipping of the aneurysm between 1994 and 2000 and were followed for at least 12 months, late epilepsy occurred in only 23 (4.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/142\">",
"     142",
"    </a>",
"    ]. Patients presenting with a poor grade had a higher incidence of epilepsy (9.6 and 12.5 percent of those grades 3 and 4, respectively). This study excluded patients who had been treated endovascularly and those who had surgery occurring more than 21 days after the bleed.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Grading'",
"    </a>",
"    above.) In the ISAT trial, 25 of 612 patients had a diagnosis of epilepsy at a 12 month assessment; the rate was lower in patients treated with endovascular coiling, as compared to surgical clipping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that antiepileptic drug therapy may not be necessary after aneurysmal clipping following SAH in most patients, particularly in those who present with a good grade and who have not had early seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     LONG TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome after treatment of aneurysmal subarachnoid hemorrhage (SAH) is affected by potential brain injury from the SAH and subsequent complications, as well as by risks related to neurosurgery (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgery'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Survivors of aneurysmal SAH have an increased mortality rate compared to the general population (SMR 1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/111,143,144\">",
"     111,143,144",
"    </a>",
"    ]. In the ISAT, the risk of death at five years was lower in the endovascular therapy group than in the surgical group. The risk of nonfatal vascular events (stroke, myocardial infarction) is also increased (RR 1.5) in survivors of aneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Neurologic morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest that SAH survivors have high rates of memory, mood, and neurocognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/1,113,145-148\">",
"     1,113,145-148",
"    </a>",
"    ]. The largest prospective evaluation of neuropsychological function evaluated 873 survivors of SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/147\">",
"     147",
"    </a>",
"    ]. At three months after aneurysmal clipping, global impairment was present in approximately 20 percent of all patients and in 16 percent of those with the best preoperative condition. Detailed neuropsychological testing of patients following surgically treated SAH has commonly shown cognitive deficits, even among patients making an otherwise good neurologic recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/149\">",
"     149",
"    </a>",
"    ]. The importance of these neuropsychological deficits to long-term morbidity is controversial, but they are often permanent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/150\">",
"     150",
"    </a>",
"    ]. Depression, anxiety, and sleep disturbances are also common and contribute to decreased quality of life; these may be more amenable to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/148,151\">",
"     148,151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The location of the aneurysm responsible for SAH does not appear to influence cognitive outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/1\">",
"     1",
"    </a>",
"    ]. In the ISAT, the proportion of survivors who reached independent status were similar in those treated with endovascular therapy versus surgical clipping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/111\">",
"     111",
"    </a>",
"    ], however, among the group that was not otherwise disabled (mRS &gt;2) the proportion of those with cognitive impairment at 12 months was higher in those treated surgically than with endovascular coiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small proportion of SAH survivors develop epilepsy: less than 5 percent of patients treated surgically and a smaller percentage of those treated with endovascular coiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Antiepileptic drug therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Anosmia may complicate SAH. Studies suggest that this is a more frequent complication in patients who undergo go aneurysm clipping (one in three patients) than in those who undergo endovascular coiling (one in six patients), and that recovery is more likely in endovascularly treated patients as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. Intraventricular hemorrhage is a risk factor for this complication. Anosmia is a less frequent complication of nonaneurysmal perimesencephalic hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5413869\">",
"    <span class=\"h2\">",
"     Late rebleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who survive aneurysmal SAH have a small but enduring risk of recurrent SAH which can occur despite successful endovascular or surgical treatment of the ruptured aneurysm. Recurrent SAH may result from recurrence of the treated aneurysm, rupture of another pre-existing aneurysm in a patient with multiple aneurysms, and de novo aneurysm formation. The risk of these events and recommendations for monitoring and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44806?source=see_link\">",
"     \"Late recurrence of subarachnoid hemorrhage and intracranial aneurysms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Screening of family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-degree relatives of patients with SAH have a two- to five- fold increased risk of SAH compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/54/37738/abstract/155,156\">",
"     155,156",
"    </a>",
"    ]. It may be reasonable to screen some family members for the presence of cerebral aneurysm. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3767?source=see_link\">",
"     \"Screening for intracranial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28753187\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aneurysmal SAH is associated with a high morbidity and mortality. Mortality within the first 30 days approaches 50 percent and is attributed largely to the effects of initial and recurrent bleeding. The most important predictive factors for acute prognosis after SAH include: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Level of consciousness and neurologic grade on admission",
"     </li>",
"     <li>",
"      Patient age (inverse correlation)",
"     </li>",
"     <li>",
"      Amount of blood on initial head computed tomography (CT) scan (inverse correlation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with aneurysmal SAH are admitted to an intensive care setting for continuous hemodynamic and neurologic monitoring. Initial management includes bedrest, appropriate analgesia, prophylactic treatment for deep venous thrombosis with pneumatic compression stockings, and discontinuation of antithrombotics. Hypoxemia, metabolic acidosis, hyperglycemia, cardiovascular instability are common complications, worsen outcome and should be prevented and promptly treated. Antithrombotic therapy can be started or resumed after definitive treatment of the aneurysm. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A ventriculostomy is place in patients with elevated intracranial pressure (ICP) with acute hydrocephalus and allows measurement and treatment of elevated ICP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6009?source=see_link&amp;anchor=H15#H15\">",
"       \"Intraventricular hemorrhage\", section on 'External ventricular drain'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal therapy of hypertension in SAH is not clear. While lowering blood pressure may decrease the risk of rebleeding, this benefit may be offset by an increased risk of infarction. When blood pressure control is necessary, the use of vasodilators such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      should be avoided because of their propensity to increase cerebral blood volume and therefore intracranial pressure.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"       Labetalol",
"      </a>",
"      is preferred. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Intracranial pressure and blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       Nimodipine",
"      </a>",
"      (60 mg by mouth or nasogastric tube every four hours) has been demonstrated to improve neurologic outcomes in SAH. Treatment is started within four days of onset. The mechanism of benefit of nimodipine in SAH is unknown. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nimodipine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic antiepileptic drug (AED) therapy is not required in all patients, but may be considered in some with unsecured aneurysms and large concentrations of blood at the cortex. &nbsp;Seizures should be treated promptly. Continuation of AED therapy may not be necessary in patients without acute seizures after the aneurysm is secured. AEDs are usually continued for approximately six months in patients who have experienced an acute seizure (within seven days) following SAH. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Seizure prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Antiepileptic drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aneurysmal rebleeding is associated with a very high mortality. Surgical clipping and endovascular coiling are effective in preventing rebleeding and generally should be performed early. Both types of procedures are effective with acceptable complications rates. The choice of therapy is individualized under the guidance of experienced clinicians considering the available expertise, the anatomic characteristics of the aneurysm, and the neurologic and clinical status of the patient. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment of aneurysms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antifibrinolytic agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      , epsilon",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      ) to prevent rebleeding have not been shown to be overall effective in the management of patients with SAH. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antifibrinolytic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinically significant vasospasm complicates 20 to 30 percent of aneurysmal SAH and is associated with delayed cerebral ischemia and worse neurologic outcome: (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment of vasospasm'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypovolemia is a risk factor for ischemic complications and should be avoided.",
"     </li>",
"     <li>",
"      There is limited data to suggest that hyperdynamic therapy is of value in the prevention of symptomatic vasospasm but may be used to ameliorate documented vasospasm in a patient with a secured aneurysm. Hyperdynamic therapy employs modest hemodilution, induced hypertension with pressor agents and hypervolemia.",
"     </li>",
"     <li>",
"      Clinical vasospasm that persists despite triple H therapy may be treated by percutaneous intraarterial angioplasty or intraarterial administration of vasodilators. There is limited data supporting that their use improves clinical outcomes.",
"     </li>",
"     <li>",
"      Limited data suggests that statin therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      40 mg daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      80 mg daily) may reduce the incidence of vasospasm, delayed ischemic deficits and mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrocephalus is a common complication of SAH. Placement of a ventricular drain should be considered in patients with impaired level of consciousness and progressive or not improving hydrocephalus. Some patients may require placement of a permanent shunt. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Hydrocephalus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyponatremia is common after SAH usually due to SIADH. A protocol for managing hyponatremia in this setting is presented in the Table (",
"      <a class=\"graphic graphic_table graphicRef65772 \" href=\"mobipreview.htm?37/26/38315\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SAH survivors have high rates of memory, mood, and neurocognitive impairment. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Neurologic morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with aneurysmal SAH are at enduring risk of recurrent SAH. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44806?source=see_link\">",
"       \"Late recurrence of subarachnoid hemorrhage and intracranial aneurysms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      First-degree relatives of patients with SAH have a two- to five- fold increased risk of SAH compared with the general population. Screening of family members for the presence of cerebral aneurysm is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3767?source=see_link\">",
"       \"Screening for intracranial aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/1\">",
"      Tidswell P, Dias PS, Sagar HJ, et al. Cognitive outcome after aneurysm rupture: relationship to aneurysm site and perioperative complications. Neurology 1995; 45:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/2\">",
"      Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009; 40:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/3\">",
"      Hijdra A, van Gijn J, Nagelkerke NJ, et al. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke 1988; 19:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/4\">",
"      Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke 2007; 38:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/5\">",
"      Ko SB, Choi HA, Carpenter AM, et al. Quantitative analysis of hemorrhage volume for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Stroke 2011; 42:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/6\">",
"      Dorhout Mees SM, van Dijk GW, Algra A, et al. Glucose levels and outcome after subarachnoid hemorrhage. Neurology 2003; 61:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/7\">",
"      Frontera JA, Fernandez A, Claassen J, et al. Hyperglycemia after SAH: predictors, associated complications, and impact on outcome. Stroke 2006; 37:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/8\">",
"      Pasternak JJ, McGregor DG, Schroeder DR, et al. Hyperglycemia in patients undergoing cerebral aneurysm surgery: its association with long-term gross neurologic and neuropsychological function. Mayo Clin Proc 2008; 83:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/9\">",
"      Kruyt ND, Biessels GJ, de Haan RJ, et al. Hyperglycemia and clinical outcome in aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke 2009; 40:e424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/10\">",
"      Commichau C, Scarmeas N, Mayer SA. Risk factors for fever in the neurologic intensive care unit. Neurology 2003; 60:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/11\">",
"      Fernandez A, Schmidt JM, Claassen J, et al. Fever after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology 2007; 68:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/12\">",
"      Naidech AM, Drescher J, Ault ML, et al. Higher hemoglobin is associated with less cerebral infarction, poor outcome, and death after subarachnoid hemorrhage. Neurosurgery 2006; 59:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/13\">",
"      Naidech AM, Jovanovic B, Wartenberg KE, et al. Higher hemoglobin is associated with improved outcome after subarachnoid hemorrhage. Crit Care Med 2007; 35:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/14\">",
"      Oddo M, Milby A, Chen I, et al. Hemoglobin concentration and cerebral metabolism in patients with aneurysmal subarachnoid hemorrhage. Stroke 2009; 40:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/15\">",
"      Broessner G, Lackner P, Hoefer C, et al. Influence of red blood cell transfusion on mortality and long-term functional outcome in 292 patients with spontaneous subarachnoid hemorrhage. Crit Care Med 2009; 37:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/16\">",
"      Zacharia BE, Ducruet AF, Hickman ZL, et al. Renal dysfunction as an independent predictor of outcome after aneurysmal subarachnoid hemorrhage: a single-center cohort study. Stroke 2009; 40:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/17\">",
"      Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006; 354:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/18\">",
"      Le Roux PD, Winn HR. Management of the ruptured aneurysm. Neurosurg Clin N Am 1998; 9:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/19\">",
"      Bernardini GL, DeShaies EM. Critical care of intracerebral and subarachnoid hemorrhage. Curr Neurol Neurosci Rep 2001; 1:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/20\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/21\">",
"      Schmidt JM, Ko SB, Helbok R, et al. Cerebral perfusion pressure thresholds for brain tissue hypoxia and metabolic crisis after poor-grade subarachnoid hemorrhage. Stroke 2011; 42:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/22\">",
"      Wijdicks EF, Vermeulen M, Murray GD, et al. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1990; 92:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/23\">",
"      van Gijn J. Subarachnoid haemorrhage. Lancet 1992; 339:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/24\">",
"      Al-Rawi PG, Tseng MY, Richards HK, et al. Hypertonic saline in patients with poor-grade subarachnoid hemorrhage improves cerebral blood flow, brain tissue oxygen, and pH. Stroke 2010; 41:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/25\">",
"      Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983; 308:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/26\">",
"      Philippon J, Grob R, Dagreou F, et al. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien) 1986; 82:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/27\">",
"      Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988; 68:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/28\">",
"      Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989; 298:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/29\">",
"      Barker FG 2nd, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg 1996; 84:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/30\">",
"      Feigin VL, Rinkel GJ, Algra A, et al. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 1998; 50:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/31\">",
"      Mee E, Dorrance D, Lowe D, Neil-Dwyer G. Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. Neurosurgery 1988; 22:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/32\">",
"      Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 1988; 69:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/33\">",
"      Harders A, Kakarieka A, Braakman R. Traumatic subarachnoid hemorrhage and its treatment with nimodipine. German tSAH Study Group. J Neurosurg 1996; 85:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/34\">",
"      Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; :CD000277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/35\">",
"      Stiefel MF, Heuer GG, Abrahams JM, et al. The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage. J Neurosurg 2004; 101:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/36\">",
"      Claassen J, Vu A, Kreiter KT, et al. Effect of acute physiologic derangements on outcome after subarachnoid hemorrhage. Crit Care Med 2004; 32:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/37\">",
"      Latorre JG, Chou SH, Nogueira RG, et al. Effective glycemic control with aggressive hyperglycemia management is associated with improved outcome in aneurysmal subarachnoid hemorrhage. Stroke 2009; 40:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/38\">",
"      Naval NS, Stevens RD, Mirski MA, Bhardwaj A. Controversies in the management of aneurysmal subarachnoid hemorrhage. Crit Care Med 2006; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     Ruptured cerebral aneurysms: Perioperative management. In: Concepts in Neurosurgery, Ratcheson RA, Wirth FP (Eds), Williams &amp; Wilkins, Baltimore 1994. Vol 6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/40\">",
"      Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005; 36:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/41\">",
"      Roos YB, Rinkel GJ, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003; :CD001245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/42\">",
"      Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology 2000; 54:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/43\">",
"      Hillman J, Fridriksson S, Nilsson O, et al. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 2002; 97:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/44\">",
"      Sugawara T, Jadhav V, Ayer R, et al. Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. Stroke 2009; 40:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/45\">",
"      Feigin VL, Anderson N, Rinkel GJ, et al. Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage. Cochrane Database Syst Rev 2005; :CD004583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/46\">",
"      Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985; 16:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/47\">",
"      Carandang RA, Barton B, Rordorf GA, et al. Nicotine replacement therapy after subarachnoid hemorrhage is not associated with increased vasospasm. Stroke 2011; 42:3080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/48\">",
"      Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage : a randomized controlled trial. Stroke 2000; 31:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/49\">",
"      Egge A, Waterloo K, Sj&oslash;holm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery 2001; 49:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/50\">",
"      Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg 2003; 98:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/51\">",
"      Rinkel GJ, Feigin VL, Algra A, van Gijn J. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2004; :CD000483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/52\">",
"      Mutoh T, Kazumata K, Ishikawa T, Terasaka S. Performance of bedside transpulmonary thermodilution monitoring for goal-directed hemodynamic management after subarachnoid hemorrhage. Stroke 2009; 40:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/53\">",
"      Hoff R, Rinkel G, Verweij B, et al. Blood volume measurement to guide fluid therapy after aneurysmal subarachnoid hemorrhage: a prospective controlled study. Stroke 2009; 40:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/54\">",
"      Sasaki T, Kodama N, Kawakami M, et al. Urokinase cisternal irrigation therapy for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a study of urokinase concentration and the fibrinolytic system. Stroke 2000; 31:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/55\">",
"      Hamada J, Kai Y, Morioka M, et al. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a prospective randomized study. Stroke 2003; 34:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/56\">",
"      Auer LM, Mokry M. Disturbed cerebrospinal fluid circulation after subarachnoid hemorrhage and acute aneurysm surgery. Neurosurgery 1990; 26:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/57\">",
"      Goddard AJ, Raju PP, Gholkar A. Does the method of treatment of acutely ruptured intracranial aneurysms influence the incidence and duration of cerebral vasospasm and clinical outcome? J Neurol Neurosurg Psychiatry 2004; 75:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/58\">",
"      Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/59\">",
"      Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998; 95:8880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/60\">",
"      Sterzer P, Meintzschel F, R&ouml;sler A, et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001; 32:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/61\">",
"      McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002; 33:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/62\">",
"      Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005; 36:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/63\">",
"      Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005; 36:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/64\">",
"      Chou SH, Smith EE, Badjatia N, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke 2008; 39:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/65\">",
"      Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke 2008; 39:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/66\">",
"      Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2010; 41:e47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/67\">",
"      Levin ER. Endothelins. N Engl J Med 1995; 333:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/68\">",
"      Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 1998; 43:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/69\">",
"      Vatter H, Zimmermann M, Tesanovic V, et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg 2005; 102:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/70\">",
"      Vatter H, Zimmermann M, Tesanovic V, et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation. J Neurosurg 2005; 102:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/71\">",
"      Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008; 39:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/72\">",
"      Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis. Stroke 2009; 40:3403.",
"     </a>",
"    </li>",
"    <li>",
"     Clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage treated by surgical clipping (CONSCIOUS-2). file://clinicaltrials.gov/ct2/show/NCT00558311?term=vasospasm&amp;rank=8 (Accessed on January 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/74\">",
"      Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 96:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/75\">",
"      van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005; 36:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/76\">",
"      Wong GK, Poon WS, Chan MT, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke 2010; 41:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/77\">",
"      Wong GK, Poon WS, Chan MT, et al. Plasma magnesium concentrations and clinical outcomes in aneurysmal subarachnoid hemorrhage patients: post hoc analysis of intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage trial. Stroke 2010; 41:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/78\">",
"      Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med 2010; 38:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/79\">",
"      Barth M, Capelle HH, Weidauer S, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke 2007; 38:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/80\">",
"      Ribourtout E, Raymond J. Gene therapy and endovascular treatment of intracranial aneurysms. Stroke 2004; 35:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/81\">",
"      Ogilvy CS, Chu D, Kaplan S. Mild hypothermia, hypertension, and mannitol are protective against infarction during experimental intracranial temporary vessel occlusion. Neurosurgery 1996; 38:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/82\">",
"      Bailes JE, Spetzler RF, Hadley MN, Baldwin HZ. Management morbidity and mortality of poor-grade aneurysm patients. J Neurosurg 1990; 72:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/83\">",
"      Rordorf G, Ogilvy CS, Gress DR, et al. Patients in poor neurological condition after subarachnoid hemorrhage: early management and long-term outcome. Acta Neurochir (Wien) 1997; 139:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/84\">",
"      Andrews RJ, Bringas JR. A review of brain retraction and recommendations for minimizing intraoperative brain injury. Neurosurgery 1993; 33:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/85\">",
"      Samson D, Batjer HH, Bowman G, et al. A clinical study of the parameters and effects of temporary arterial occlusion in the management of intracranial aneurysms. Neurosurgery 1994; 34:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/86\">",
"      Fridriksson S, S&auml;veland H, Jakobsson KE, et al. Intraoperative complications in aneurysm surgery: a prospective national study. J Neurosurg 2002; 96:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/87\">",
"      McLaughlin N, Bojanowski MW. Early surgery-related complications after aneurysm clip placement: an analysis of causes and patient outcomes. J Neurosurg 2004; 101:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/88\">",
"      Berman MF, Solomon RA, Mayer SA, et al. Impact of hospital-related factors on outcome after treatment of cerebral aneurysms. Stroke 2003; 34:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/89\">",
"      Todd MM, Hindman BJ, Clarke WR, et al. Mild intraoperative hypothermia during surgery for intracranial aneurysm. N Engl J Med 2005; 352:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/90\">",
"      Dovey Z, Misra M, Thornton J, et al. Guglielmi detachable coiling for intracranial aneurysms: the story so far. Arch Neurol 2001; 58:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/91\">",
"      Guglielmi G, Vi&ntilde;uela F, Sepetka I, Macellari V. Electrothrombosis of saccular aneurysms via endovascular approach. Part 1: Electrochemical basis, technique, and experimental results. J Neurosurg 1991; 75:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/92\">",
"      Fernandez Zubillaga A, Guglielmi G, Vi&ntilde;uela F, Duckwiler GR. Endovascular occlusion of intracranial aneurysms with electrically detachable coils: correlation of aneurysm neck size and treatment results. AJNR Am J Neuroradiol 1994; 15:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/93\">",
"      Pouratian N, Oskouian RJ Jr, Jensen ME, et al. Endovascular management of unruptured intracranial aneurysms. J Neurol Neurosurg Psychiatry 2006; 77:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/94\">",
"      Qureshi AI, Janardhan V, Hanel RA, Lanzino G. Comparison of endovascular and surgical treatments for intracranial aneurysms: an evidence-based review. Lancet Neurol 2007; 6:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/95\">",
"      Vanninen R, Koivisto T, Saari T, et al. Ruptured intracranial aneurysms: acute endovascular treatment with electrolytically detachable coils--a prospective randomized study. Radiology 1999; 211:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/96\">",
"      Koivisto T, Vanninen R, Hurskainen H, et al. Outcomes of early endovascular versus surgical treatment of ruptured cerebral aneurysms. A prospective randomized study. Stroke 2000; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/97\">",
"      Maurice-Williams RS. Aneurysm surgery after the International Subarachnoid Aneurysm Trial (ISAT). J Neurol Neurosurg Psychiatry 2004; 75:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/98\">",
"      Pierot L, Cognard C, Anxionnat R, et al. Ruptured intracranial aneurysms: factors affecting the rate and outcome of endovascular treatment complications in a series of 782 patients (CLARITY study). Radiology 2010; 256:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/99\">",
"      van den Bergh WM, Kerr RS, Algra A, et al. Effect of antiplatelet therapy for endovascular coiling in aneurysmal subarachnoid hemorrhage. Stroke 2009; 40:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/100\">",
"      Ries T, Siemonsen S, Grzyska U, et al. Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature. Stroke 2009; 40:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/101\">",
"      Elijovich L, Higashida RT, Lawton MT, et al. Predictors and outcomes of intraprocedural rupture in patients treated for ruptured intracranial aneurysms: the CARAT study. Stroke 2008; 39:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/102\">",
"      Renowden SA, Benes V, Bradley M, Molyneux AJ. Detachable coil embolisation of ruptured intracranial aneurysms: a single center study, a decade experience. Clin Neurol Neurosurg 2009; 111:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/103\">",
"      Sherif C, Gruber A, Dorfer C, et al. Ruptured carotid artery aneurysms of the ophthalmic (C6) segment: clinical and angiographic long term follow-up of a multidisciplinary management strategy. J Neurol Neurosurg Psychiatry 2009; 80:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/104\">",
"      Brilstra EH, Rinkel GJ, Algra A, van Gijn J. Rebleeding, secondary ischemia, and timing of operation in patients with subarachnoid hemorrhage. Neurology 2000; 55:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/105\">",
"      Le Roux PD, Elliott JP, Downey L, et al. Improved outcome after rupture of anterior circulation aneurysms: a retrospective 10-year review of 224 good-grade patients. J Neurosurg 1995; 83:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/106\">",
"      Whitfield PC, Kirkpatrick PJ. Timing of surgery for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2001; :CD001697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/107\">",
"      Phillips TJ, Dowling RJ, Yan B, et al. Does treatment of ruptured intracranial aneurysms within 24 hours improve clinical outcome? Stroke 2011; 42:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/108\">",
"      Molyneux A, Kerr R, Stratton I, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002; 360:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/109\">",
"      Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005; 366:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/110\">",
"      Nichols DA, Brown RD Jr, Meyer FB. Coils or clips in subarachnoid haemorrhage? Lancet 2002; 360:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/111\">",
"      Molyneux AJ, Kerr RS, Birks J, et al. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. Lancet Neurol 2009; 8:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/112\">",
"      Schaafsma JD, Sprengers ME, van Rooij WJ, et al. Long-term recurrent subarachnoid hemorrhage after adequate coiling versus clipping of ruptured intracranial aneurysms. Stroke 2009; 40:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/113\">",
"      Scott RB, Eccles F, Molyneux AJ, et al. Improved cognitive outcomes with endovascular coiling of ruptured intracranial aneurysms: neuropsychological outcomes from the International Subarachnoid Aneurysm Trial (ISAT). Stroke 2010; 41:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/114\">",
"      Koffijberg H, Buskens E, Rinkel GJ. Aneurysm occlusion in elderly patients with aneurysmal subarachnoid haemorrhage: a cost-utility analysis. J Neurol Neurosurg Psychiatry 2011; 82:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/115\">",
"      Frontera JA, Fernandez A, Schmidt JM, et al. Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke 2009; 40:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/116\">",
"      Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 2011; 42:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/117\">",
"      Crowley RW, Medel R, Dumont AS, et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke 2011; 42:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/118\">",
"      Darby JM, Yonas H, Marks EC, et al. Acute cerebral blood flow response to dopamine-induced hypertension after subarachnoid hemorrhage. J Neurosurg 1994; 80:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/119\">",
"      Muizelaar JP, Becker DP. Induced hypertension for the treatment of cerebral ischemia after subarachnoid hemorrhage. Direct effect on cerebral blood flow. Surg Neurol 1986; 25:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/120\">",
"      Bejjani GK, Bank WO, Olan WJ, Sekhar LN. The efficacy and safety of angioplasty for cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 1998; 42:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/121\">",
"      Badjatia N, Topcuoglu MA, Pryor JC, et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 2004; 25:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/122\">",
"      Fraticelli AT, Cholley BP, Losser MR, et al. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2008; 39:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/123\">",
"      Firlik KS, Kaufmann AM, Firlik AD, et al. Intra-arterial papaverine for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Surg Neurol 1999; 51:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/124\">",
"      Numaguchi Y, Zoarski GH. Intra-arterial papaverine treatment for cerebral vasospasm: our experience and review of the literature. Neurol Med Chir (Tokyo) 1998; 38:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/125\">",
"      Kassell NF, Helm G, Simmons N, et al. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg 1992; 77:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/126\">",
"      Hui C, Lau KP. Efficacy of intra-arterial nimodipine in the treatment of cerebral vasospasm complicating subarachnoid haemorrhage. Clin Radiol 2005; 60:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/127\">",
"      Thomas JE, Rosenwasser RH, Armonda RA, et al. Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke 1999; 30:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/128\">",
"      Rabinstein AA, Wijdicks EF. Cerebral Vasospasm in Subarachnoid Hemorrhage. Curr Treat Options Neurol 2005; 7:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/129\">",
"      Polin RS, Coenen VA, Hansen CA, et al. Efficacy of transluminal angioplasty for the management of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 2000; 92:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/130\">",
"      Treggiari MM, Romand JA, Martin JB, et al. Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage. Stroke 2003; 34:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/131\">",
"      Dehdashti AR, Rilliet B, Rufenacht DA, de Tribolet N. Shunt-dependent hydrocephalus after rupture of intracranial aneurysms: a prospective study of the influence of treatment modality. J Neurosurg 2004; 101:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/132\">",
"      Suarez-Rivera O. Acute hydrocephalus after subarachnoid hemorrhage. Surg Neurol 1998; 49:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/133\">",
"      Hasan D, Vermeulen M, Wijdicks EF, et al. Management problems in acute hydrocephalus after subarachnoid hemorrhage. Stroke 1989; 20:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/134\">",
"      Par&eacute; L, Delfino R, Leblanc R. The relationship of ventricular drainage to aneurysmal rebleeding. J Neurosurg 1992; 76:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/135\">",
"      Fountas KN, Kapsalaki EZ, Machinis T, et al. Review of the literature regarding the relationship of rebleeding and external ventricular drainage in patients with subarachnoid hemorrhage of aneurysmal origin. Neurosurg Rev 2006; 29:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/136\">",
"      Hellingman CA, van den Bergh WM, Beijer IS, et al. Risk of rebleeding after treatment of acute hydrocephalus in patients with aneurysmal subarachnoid hemorrhage. Stroke 2007; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/137\">",
"      Woo CH, Rao VA, Sheridan W, Flint AC. Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia. Neurocrit Care 2009; 11:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/138\">",
"      Naidech AM, Janjua N, Kreiter KT, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Arch Neurol 2005; 62:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/139\">",
"      van Asch CJ, Oudendijk JF, Rinkel GJ, Klijn CJ. Early intracerebral hematoma expansion after aneurysmal rupture. Stroke 2010; 41:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/140\">",
"      Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke 1988; 19:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/141\">",
"      Johnston SC, Dowd CF, Higashida RT, et al. Predictors of rehemorrhage after treatment of ruptured intracranial aneurysms: the Cerebral Aneurysm Rerupture After Treatment (CARAT) study. Stroke 2008; 39:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/142\">",
"      Buczacki SJ, Kirkpatrick PJ, Seeley HM, Hutchinson PJ. Late epilepsy following open surgery for aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2004; 75:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/143\">",
"      Wermer MJ, Greebe P, Algra A, Rinkel GJ. Long-term mortality and vascular event risk after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2009; 80:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/144\">",
"      Nieuwkamp DJ, Algra A, Blomqvist P, et al. Excess mortality and cardiovascular events in patients surviving subarachnoid hemorrhage: a nationwide study in Sweden. Stroke 2011; 42:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/145\">",
"      Mayer SA, Kreiter KT, Copeland D, et al. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology 2002; 59:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/146\">",
"      Hackett ML, Anderson CS. Health outcomes 1 year after subarachnoid hemorrhage: An international population-based study. The Australian Cooperative Research on Subarachnoid Hemorrhage Study Group. Neurology 2000; 55:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/147\">",
"      Anderson SW, Todd MM, Hindman BJ, et al. Effects of intraoperative hypothermia on neuropsychological outcomes after intracranial aneurysm surgery. Ann Neurol 2006; 60:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/148\">",
"      Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke 2010; 41:e519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/149\">",
"      Ljunggren B, Sonesson B, S&auml;veland H, Brandt L. Cognitive impairment and adjustment in patients without neurological deficits after aneurysmal SAH and early operation. J Neurosurg 1985; 62:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/150\">",
"      Stenhouse LM, Knight RG, Longmore BE, Bishara SN. Long-term cognitive deficits in patients after surgery on aneurysms of the anterior communicating artery. J Neurol Neurosurg Psychiatry 1991; 54:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/151\">",
"      Visser-Meily JM, Rhebergen ML, Rinkel GJ, et al. Long-term health-related quality of life after aneurysmal subarachnoid hemorrhage: relationship with psychological symptoms and personality characteristics. Stroke 2009; 40:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/152\">",
"      Wermer MJ, Donswijk M, Greebe P, et al. Anosmia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2007; 61:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/153\">",
"      Bor AS, Niemansburg SL, Wermer MJ, Rinkel GJ. Anosmia after coiling of ruptured aneurysms: prevalence, prognosis, and risk factors. Stroke 2009; 40:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/154\">",
"      Greebe P, Rinkel GJ, Algra A. Anosmia after perimesencephalic nonaneurysmal hemorrhage. Stroke 2009; 40:2885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/155\">",
"      Gaist D, Vaeth M, Tsiropoulos I, et al. Risk of subarachnoid haemorrhage in first degree relatives of patients with subarachnoid haemorrhage: follow up study based on national registries in Denmark. BMJ 2000; 320:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/54/37738/abstract/156\">",
"      Bor AS, Rinkel GJ, Adami J, et al. Risk of subarachnoid haemorrhage according to number of affected relatives: a population based case-control study. Brain 2008; 131:2662.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1127 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37738=[""].join("\n");
var outline_f36_54_37738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28753187\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Grading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antithrombotic discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intracranial pressure and blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nimodipine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physiologic derangements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Seizure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antifibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION OF VASOSPASM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hyperdynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF ANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Endovascular therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intraprocedural aneurysm rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Timing and choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Posttreatment management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment of vasospasm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Refractory vasospasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Early rebleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Antiepileptic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      LONG TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Neurologic morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5413869\">",
"      Late rebleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Screening of family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28753187\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1127\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1127|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/1/27668\" title=\"diagnostic image 1\">",
"      Angiogram clipped basilar aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/43/28340\" title=\"diagnostic image 2\">",
"      Angiogram coiled cerebral aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1127|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/57/9115\" title=\"table 1\">",
"      Hunt and Hess grading system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/56/14219\" title=\"table 2\">",
"      WFNS SAH grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 3\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/36/8779\" title=\"table 4\">",
"      Fisher SAH CT grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/19/12603\" title=\"table 5\">",
"      Claassen SAH CT grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/55/30587\" title=\"table 6\">",
"      Ogilvy Carter grading system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/26/38315\" title=\"table 7\">",
"      Treatment of hyponatremia in SAH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8567?source=related_link\">",
"      Cerebral salt-wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6009?source=related_link\">",
"      Intraventricular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44806?source=related_link\">",
"      Late recurrence of subarachnoid hemorrhage and intracranial aneurysms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35882?source=related_link\">",
"      Management of acute severe traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3767?source=related_link\">",
"      Screening for intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/406?source=related_link\">",
"      Subarachnoid hemorrhage grading scales",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_54_37739="Causes of acromegaly";
var content_f36_54_37739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of acromegaly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary GH excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GH-cell adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed GH-cell and PRL-cell adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mammosomatotroph-cell adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plurihormonal adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GH-cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Familial syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple endocrine neoplasia-I (GH-cell adenoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Familial acromegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        McCune-Albright syndrome (rarely-adenoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carney's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        GH excess (ectopic or iatrogenic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic islet-cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        GHRH excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Central ectopic (&lt;1 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypothalamic hamartoma, choristoma, ganglioneuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Peripheral ectopic (1 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchial carcinoid, pancreatic islet-cell tumor, small cell lung cancer, adrenal adenoma, medullary thyroid carcinoma, pheochromocytoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Melmed S. Acromegaly. N Engl J Med 1990; 322:966.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37739=[""].join("\n");
var outline_f36_54_37739=null;
var title_f36_54_37740="Rates of cutaneous drug reactions";
var content_f36_54_37740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rates of cutaneous reactions to drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate (percent) of allergic cutaneous reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        1.2-5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        2.1-3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semisynthetic penicillins",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin G",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cephalosporins",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoroquinolones",
"       </td>",
"       <td>",
"        0.1-1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furosemide",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoclopramide",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heparin sodium",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrazepam",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diazepam",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maprotiline",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escitalopram",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic/tetracyclic antidepressants",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SSRIs",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SSRIs: selective serotonin reuptake inhibitors.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.",
"      </li>",
"      <li>",
"       van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51:703.",
"      </li>",
"      <li>",
"       Kulthanan K, Chularojanamontri L, Manapajon A, et al. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 2011; 22:155.",
"      </li>",
"      <li>",
"       Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, et al. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 2009; 70:1258.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37740=[""].join("\n");
var outline_f36_54_37740=null;
var title_f36_54_37741="WHO MEC for potential drug interactions";
var content_f36_54_37741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: Drug interactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       COC",
"      </td>",
"      <td class=\"subtitle1\">",
"       CIC",
"      </td>",
"      <td class=\"subtitle1\">",
"       P/R",
"      </td>",
"      <td class=\"subtitle1\">",
"       POP",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        DMPA",
"       </p>",
"       <p>",
"        NET-EN",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        LNG/ETG",
"       </p>",
"       <p>",
"        Implants",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cu-IUD",
"      </td>",
"      <td class=\"subtitle1\">",
"       LNG-IUD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\" rowspan=\"1\">",
"       Drugs which affect liver enzymes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rifampicin or rifabutin",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       <p>",
"        DMPA 1",
"       </p>",
"       <p>",
"        NET-EN 2",
"       </p>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       <p>",
"        DMPA 1",
"       </p>",
"       <p>",
"        NET-EN 2",
"       </p>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lamotrigine",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\" rowspan=\"1\">",
"       Antimicrobials (excluding rifampicin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Broad spectrum antibiotics",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Antifungals and Antiparasites",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Antiretroviral therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nucleoside reverse transcriptase inhibitors",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       <p>",
"        DMPA 1",
"       </p>",
"       <p>",
"        NET-EN 1",
"       </p>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       <p>",
"        Initiation: 2/3",
"       </p>",
"       <p>",
"        Continuation: 2",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Initiation: 2/3",
"       </p>",
"       <p>",
"        Continuation: 2",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Non-nucleoside reverse transcriptase inhibitors",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       <p>",
"        DMPA 1",
"       </p>",
"       <p>",
"        NET-EN 2",
"       </p>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       <p>",
"        Initiation: 2/3",
"       </p>",
"       <p>",
"        Continuation: 2",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Initiation: 2/3",
"       </p>",
"       <p>",
"        Continuation: 2",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ritonavir-boosted protease inhibitors",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       <p>",
"        DMPA 1",
"       </p>",
"       <p>",
"        NET-EN 2",
"       </p>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       <p>",
"        Initiation: 2/3",
"       </p>",
"       <p>",
"        Continuation: 2",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Initiation: 2/3",
"       </p>",
"       <p>",
"        Continuation: 2",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    WHO comments: Although the interaction of rifampicin or rifabutin with POPs, NET-EN and LNG/ETG implants is not harmful to women, it is likely to reduce the effectiveness of POPs, NET-EN and LNG/ETG implants. Use of other contraceptives should be encouraged for women who are long-term users of any of these drugs.Whether increasing the hormone dose of POPs alleviates this concern remains unclear.",
"    <br>",
"     Use of DMPA is a Category 1 because its effectiveness is not decreased by the use of rifampicin or rifabutin.",
"     <div class=\"footnotes\">",
"      1: A condition for which there is no restriction for the use of the contraceptive method.",
"      <br>",
"       2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"       <br>",
"        3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"        <br>",
"         4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"         <br>",
"          COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Medical Eligibility Criteria for Contraceptive Use - 3rd Ed. Available at: file://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy;2006 World Health Organization. Revised from: Medical Eligibility Criteria for Contraceptive Use, 2008 update. Available at: file://www.who.int/reproductive-health/publications/mec/.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37741=[""].join("\n");
var outline_f36_54_37741=null;
var title_f36_54_37742="Double pigtail ureteral stent";
var content_f36_54_37742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Double pigtail ureteral stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ureteral stents are hollow tubes with multiple sideholes. The curls of the double pigtail stent are positioned in the renal pelvis proximally and bladder distally to limit stent migration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37742=[""].join("\n");
var outline_f36_54_37742=null;
var title_f36_54_37743="Grass STIT trial";
var content_f36_54_37743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Daily averaged grass pollen counts, scoring of symptoms, and scoring of rescue medication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 606px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    P value presented for the comparison of the two treatment groups tested by ANOVA with the score as response variable, treatment group as fixed effect, and pollen region as random effect. Reduction was calculated as ((Active - Placebo)/Placebo) x 100.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dahl, R, Kapp, A, Colombo, G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_54_37743=[""].join("\n");
var outline_f36_54_37743=null;
